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PREFACE 
 
Oxidative stress has been associated with a number of notorious diseases including 
Parkinson’s disease, cancer, and it exerts its effect on cellular machineries primarily via 
thiols which are very sensitive to oxidation due to their chemical nature. Thiol-based 
redox modulation of cellular functions is an emerging field of study and there are 
numerous examples of proteins whose activity has been shown to be under the control of 
cellular redox status. Transcriptional regulators are key targets of reactive oxygen species 
(ROS) under oxidative stress conditions due to the capability of transcription regulators 
to control the expression of various genes involved in redox processes. The last decade 
has witnessed the identification of many transcriptional regulators whose activity is 
controlled by ROS.  
 
The aim of this research was to gain knowledge on redox-modulation of two 
transcriptional regulators; CprK (Section I) and Rev-erbβ (Section II). Recognition of the 
molecular mechanism underlying the redox regulation and function of these 
transcriptional regulators is the main focus of this thesis. We focused primarily on the 
following three issues: 1) The identification of the redox-active cysteines, 2) 
determination of the type of modifications of the redox-sensitive cysteines upon 
oxidation and, 3) unraveling the downstream effects of oxidation of redox-active 
cysteines on the cellular function of these proteins. This thesis is composed of 7 chapters. 
The general introduction (chapter 1) describes our current understanding of thiol based 
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redox modulation of transcriptional regulators.  Chapter 2 provides an introduction and 
prior knowledge about a bacterial transcriptional activator, CprK. Chapter 3 is a copy of 
the publication by Gupta N et al (Gupta N and Ragsdale SW. Dual roles of an essential 
cysteine residue in activity of a redox-regulated bacterial transcriptional activator. J Biol 
Chem. 2008 Oct 17;283(42):28721-8). In this chapter, Steve Ragsdale and I designed the 
experiments, interpreted the results and wrote the manuscript, and I performed the 
experiments. Chapter 4 is an introduction to the eukaryotic transcription regulator, Rev-
erb, which is emerging as a key controller of many cellular functions. The contents of 
chapter 5 were published in the following paper: Gupta, N., and Ragsdale, SW. 2011. 
Thiol-disulfide redox dependence of heme binding and heme ligand switching in the 
nuclear hormone receptor, Rev-erbβ. J. Biol. Chem. 286(6):4392-403. Epub 2010 Dec 1. 
In this chapter, both authors contributed to the research design, data analysis and writing. 
I performed the experiments.Chapter 6 reports on the analysis of redox-dependent gas 
binding to Rev-erbβ. Chapter 7 describes ongoing work and potential future directions for 
the project. 
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ABSTRACT 
 
THIOL-BASED REDOX MODULATION OF TRANSCRIPTIONAL 
REGULATORS; CprK AND Rev-erbβ 
 
By 
Nirupama Gupta 
 
Chair: Stephen W Ragsdale 
 
 
Thiol-based redox regulation of both prokaryotic and eukaryotic systems plays an 
important role in modulating cellular functions such as gene expression. Transcriptional 
factors play an important role in these modulations and exert redox-dependent activity 
through highly conserved cysteine residues in them. This thesis illustrates thiol-disulfide 
redox regulation of two such transcriptional regulators: CprK and Rev-erbβ. 
 
CprK is a positive transcriptional regulator from a prokaryotic organism, 
Desulfitobacterium dehalogenans. CprK has been shown to contain a thiol/disulfide 
redox switch that undergoes reversible inactivation upon oxidation. We have 
demonstrated that a disulfide bond, formed between Cys11 and Cys200 in vivo, is 
responsible for oxidative inactivation of CprK. Moreover, we have shown that Cys11 is 
also required for binding DNA and that Cys11 mutants are unable to bind DNA due to a
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change in their tertiary structures. Therefore, Cys11 plays dual roles in maintaining the 
normal activity of CprK and its redox inactivation. 
 
Rev-erbβ is a human nuclear receptor and downregulates the expression of target genes in 
the presence of heme. Our studies with the ligand binding domain of Rev-erbβ (Rev-erbβ 
LBD) have revealed that its affinity for heme is controlled by a thiol-disulfide redox-
switch, where the oxidized LBD exhibits 5-fold lower affinity for heme than the reduced 
LBD.  Oxidation of the protein also triggers a ligand switch in which the reduced Rev-
erbβ LBD binds heme via Cys 384/His568 while the oxidized protein coordinates heme 
primarily via His/neutral residue ligand pair. 
 
Gas binding analyses with the heme-Rev-erbβ LBD complexes show a dependence of 
binding on the redox status of the heme and the protein. The binding constants for CO 
and H2S are low and below their physiological concentrations.  In contrast, NO shows 
very low binding affinities for heme-Rev-erbβ LBD complexes. 
  
Currently, we are characterizing full-length hRev-erbβ and our preliminary results 
corroborate our earlier findings on the redox-regulation of heme binding and heme ligand 
switching in the isolated LBD.  In addition, full-length hRev-erbβ shows redox regulation 
of DNA binding.  
 
Overall, these findings indicate a potential role for the thiol-disulfide redox-switch in 
Rev-erbβ in responding to changes in redox poise in the cell under oxidative stress. 
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Chapter 1 
 
GENERAL INTRODUCTION: TRANSCRIPTIONAL REGULATORS AND 
THEIR REDOX REGULATION 
 
1.1 Transcriptional regulators 
Transcription is the process of generating a complementary RNA copy of a DNA 
sequence, via RNA polymerase (12). The process of transcription is highly regulated to 
fulfil the dynamic demands of the cell for meeting its metabolic needs and in responding 
to its environment. Transcription is partly controlled by transcriptional regulators alone or 
in complex with other proteins that can either promote (as an activator) or block (as a 
repressor) the recruitment of RNA polymerase to promoters or enhancers of specific 
target genes (11, 16, 20). 
 
Transcriptional regulators are essential for gene regulation and found in all living 
organisms (28). Transcription regulators may control gene expression by various 
mechanisms (7), including but not limited to the following ones that are pertinent to this 
dissertation. One mechanism is to stabilize or inhibit the binding of RNA polymerase to a 
promoter or enhancer DNA sequence. Another mode of action is to directly catalyze the 
acetylation or deacetylation of histones or recruit enzymes to perform the same actions. 
For example, histone acetylation occurs via histone acetyltransferase (HAT) activity. 
  2 
 
 Acetylation weakens the association of histones with DNA making the gene more 
accessible and thus upregulating expression. On the other hand, deacetylation of histones 
is caused by histone deacetylase (HDAC) activity, which enhances DNA-histone 
association, resulting in decreased accessibility of DNA and down-regulation of 
transcription (18). A third mechanism of regulation is via recruitment of co-activators or 
co-repressors to the site of transcription, adding another level of complexity to 
modulation of gene expression (31). Transcriptional regulators themselves are also 
subject to regulation at the transcriptional, translational and posttranslational levels. 
Examples include NF-кB and p53, key transcriptional regulators. NF-кB is inducible by 
serum, growth factors and cytokines at the transcriptional level and is regulated by 
association/dissociation of IкB at posttranslational level. p53 is regulated at the 
posttranslational level via phosphorylation/dephosphorylation. Additionally, at the 
posttranslational level, oxidation of cysteine(s) has also been shown to affect the function 
of many transcriptional regulators (19, 25, 27) and this thesis focuses on two such thiol-
based redox-regulated transcriptional regulators. 
 
1.2 Thiol-based redox modulation of transcriptional regulators 
1.2.1 Thiol-based redox modulation 
Oxygen is the terminal electron acceptor for all aerobic organisms; however, the 
incomplete reduction of oxygen results in generation of reactive oxygen species (ROS). 
ROS are continuously generated as a natural byproduct from the leakage of the 
respiratory chain in mitochondria and have important roles in cell signaling and 
homeostasis. However, under conditions of environmental stress (e.g. exposure to toxins, 
heavy metals, UV-radiation, heat shock) or during infection and inflammation, the levels 
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of ROS can increase dramatically and can cause deleterious effects (23, 24). When 
production of ROS supersedes the antioxidant capacity of the cell, it causes oxidative 
stress.  The beneficial effects of ROS in host defense during microbial infection, in 
wound healing and in the redox signaling have been well documented (3, 10, 29). 
However, ROS are implicated in varieties of diseases including cancers, cardiovascular 
(heart attack, stroke), neurodegenerative (Alzheimer’s and Parkinson’s disease) and 
autoimmune diseases (1, 4, 16).  Because ROS can damage cellular proteins, nucleic 
acids and lipids, cells have evolved various mechanisms to eliminate ROS. Cells have 
several antioxidant enzymatic systems such as superoxide dismutases, catalases, 
glutathione peroxidases or small molecule antioxidants such as ascorbic acid, tocopherol, 
uric acid and glutathione that play important role in detoxifying ROS. Superoxide 
dismutase ameliorates the damaging effects of superoxide by converting it into hydrogen 
peroxide. Catalase converts the hydrogen peroxide into oxygen and water (2). 
Glutathione peroxidase, a selenoprotein, also reduces hydrogen peroxide to water in a 
redox dependent manner. This process also involves glutathione (GSH), which upon 
reaction with ROS is converted to disulfide state (GSSG) (9).    
 
ROS, as mentioned above, can damage vital molecules in cells including proteins, nucleic 
acids and lipids. The effect of ROS on nucleic acid damage and lipid oxidation is beyond 
the scope of this thesis and only protein modifications during oxidative stress are 
described here. In general, proteins carrying cysteine and methionine residues are targets 
of oxidants stress. Being electron rich and polarizable, sulfur, present in both cysteine and 
methionine, is sensitive to various oxidants. This thesis focuses only on cysteine (thiol) 
oxidation in proteins. The sulfhydryl group (-SH) in cysteine is sensitive to ROS and 
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(Figure 1) is oxidized to cysteine sulfenic acid (Cys-SOH) by a 2-electron oxidation. 
However, Cys-SOH is generally a short-lived, intermediate and can form intra- or inter- 
molecular disulfides. Sulfenic acid can also form  a  S-thiolated adduct with low 
molecular weight (LMW) thiols such as GSH or can form  thiosulfinate (4) with other 
sulfenic acids. Overoxidation of cysteines may result in reversible cysteine modification 
forming sulfinic (-SO2H) or irreversible cysteine modification forming sulfonic (-SO3H) 
acids. Re-reduction of these thiols can occur either by LMW-thiols, by glutaredoxin 
(Grx), or by thioredoxin (Trx) (24).  
 
 Oxidation of cysteine residues in proteins can result in changes in their structure or in 
their cellular localization, or redox properties.  These changes can affect the function of 
redox-sensitive cellular proteins. For example, thiol oxidation can change a protein’s 
ligand binding affinity [e.g. glucocorticoid receptor (17)], modify the DNA binding 
affinity of a DNA binding protein [e.g. OhrR (21)] or alter the activity of an enzyme [e.g. 
GapDH (32)]. These functional changes following thiol modification by ROS allow 
proteins to act as redox-sensors. In most instances, these thiol modifications in the protein 
during redox sensing are reversible and contribute to thiol-based switches (1, 6). Thiol-
based switches can be defined as proteins whose function can be reversibly modulated by 
the oxidation state of redox-active cysteine(s)  
 
  5 
 
 
 
Figure 1.1: Cysteine modifications via ROS. Cysteines are reversibly oxidized by ROS 
from R-SH to R–SOH (sulfenic acid) (1). Sulfenic acid (1) is unstable and can form intra- 
or inter- molecular disulfides (2). Sulfenic acid can also make an s-thiolated adduct with 
low molecular weight thiols such as GSH (2). On the other side sulfenic acid can also be 
converted to a cyclic sulfenylamide (3) with a polypeptide backbone amide or 
thiosulfinate (4) with other sulfenic acid. Re-reduction of these thiols can occur either by 
low molecular weight (LMW)-thiols (5), or by glutaredoxin (Grx) (6), or by thioredoxin 
(Trx) (7).  Overoxidation results in irreversible modification of cysteines forming sulfinic 
(8) and sulfonic (9) acids. This figure has been modified from Roos and Messeens, 2001, 
Free Radical Biology & Medicine (23). 
 
 
1.2.2 Thiol-based redox switches 
Thiol-based redox switches are present both in prokaryotes and eukaryotes. These 
switches play a protective role in the detoxification of ROS limiting the deleterious 
effects of oxidative stress. This regulation is often controlled by transcriptional regulators 
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via their redox-sensitive cysteines (1). These redox-sensitive transcriptional regulators 
have received a lot of attention in the last decade because of the growing interest in the 
area of free radicals and oxidative stress. Furthermore, it has been shown that the 
development and progression of many human diseases are linked to redox-sensitive 
transcriptional regulators (8). For example, redox-sensitive transcription factors such as 
NFкB and AP-1 are prime targets for chemoprevention with anti-inflammatory and 
antioxidative phytochemicals (26). OxyR was the first transcriptional regulator 
discovered to have the ability to sense ROS (2). Since then, many transcriptional 
regulators have been studied in prokaryotes (such as OxyR, OhrR, MerR and others) and 
in eukaryotes such as Yap1, Keap1/Nrf2 and others, which show thiol-based redox 
regulation. Some of these redox regulated transcription regulators are described below to 
facilitate a better understanding of thiol-based redox modulation of transcriptional 
regulators.  
 
OxyR belongs to the LysR family of DNA binding proteins and positively regulates the 
expression of a large peroxide inducible-regulon. OxyR from E. coli gets activated in 
response to peroxide stress via an intramolecular disulfide bond between two conserved 
cysteines; Cys199 and Cys208. Cys199 first forms a sulfenic acid, which then undergoes 
reaction with Cys208, thus forming a disulfide. Then, the activated oxidized form of 
OxyR binds as a tetramer to promoters and activates the transcription of target genes (4, 
13).  
 
Another prokaryotic transcriptional regulator, OhrR, is a repressor that senses organic 
hydroperoxide and other ROS. Unlike OxyR, OhrR from Xanthomonas campestris 
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becomes inactivated upon oxidation, thus derepressing target genes. During oxidative 
stress, Cys22 is oxidized to sulfenic acid followed by formation of an intermolecular 
disulfide with Cys12. The disulfide interferes with DNA binding, thus allowing the 
transcription of target genes (21). OhrR from Bacillus subtilis also causes the 
derepression of target genes via oxidation of cysteine. However, the exact mechanism of 
oxidative inactivation in the B. subtilis OhrR is not known. A conserved cysteine, Cys15, 
is required for redox sensing and has been demonstrated to form the sulfenic acid in vitro. 
However, the sulfenic acid form of Ohr is still active and further modification is required 
for oxidative inactivation to occur, which has not been identified yet (15). 
 
Yap1p is one of the best characterized eukaryotic thiol-based redox switches. Yap1 
activates the expression of ~100 genes in response to ROS. The target genes include 
thioredoxin, GSH biosynthetic enzymes, glutathione reductase and others, which have 
conspicuous roles in thiol homeostasis (14). Yap1 has two cysteine rich domains (CRD) 
at the N-and C-termini that contain redox-sensitive cysteines. Under normal 
circumstances Yap1 is exported to the cytoplasm via a nuclear export receptor (Crm1), 
which binds to the CRD at the C-terminus. When peroxide stress occurs, Cys36 of 
glutathione peroxidase is oxidized and interacts with Cys598, one of the redox-sensitive 
cysteines in the C-terminal CRD. Further thiol-disulfide exchange reactions subsequently 
lead to disulfide formation between Cys303-Cys598 and Cys310-Cys629. These 
disulfides induce a conformational change in Yap1 that brings the N- and C-termini close 
together. This change in conformation restricts Crm1 binding to Yap1 and causes nuclear 
accumulation of Yap1, which leads to enhanced expression of target genes (1, 30). 
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Nrf2, another eukaryotic transcriptional regulator, plays a significant role in the 
activation of genes that contain an antioxidant response element (ARE), such as heme 
oxygenase-1, glutathione-S-transferase, catalase and others. The redox-sensitive Keap1 
protein usually remains associated with Nrf2 and targets it for ubiquitin-dependent 
proteosomal degradation. Keap1 contains more than 25 Cys residues including redox-
sensitive Cys151, Cys236 and Cys613. Keap1 also has Cys residues, such as Cys273 and 
Cys288, which coordinate Zn. Upon oxidation of Keap1, an intermolecular disulfide 
bond between two Cys151 residues and an intramolecular disulfide bond between 
Cys236 and Cys613 are formed.  Upon oxidation of Cys273 and Cys288 Zn is released.  
Apparently a disulfide bond is not formed between Cys 273 and Cys 288 and their 
oxidation prodcuts are not known. Oxidation of these cysteines causes conformational 
changes in Keap1 and results in release of Nrf2 and its subsequent nuclear accumulation 
(22).  
 
Cysteines, due to their facile redox-chemistry (5), play a key role in thiol-based redox 
switches, in responding to oxidative stress as described above (8). Redox-regulation of 
two similar systems is described in this thesis: (1) Section I describes, CprK, which is a 
prokaryotic transcriptional regulator, and (2) Rev-erbβ, a human transcriptional regulator 
has been described in Section II. CprK is a prokaryotic transcriptional regulator and is 
involved in the process of dehalorespiration. In the presence of ortho-haloaromatic 
compounds, which are recalcitrant to degrade in nature, CprK gets activated and induces 
expression of the genes involved in biodegradation of these compounds. We have 
identified the oxidative modification of redox-active cysteines in CprK and have 
characterized the dual role of one of the redox-active cysteines, Cys11 in the structure 
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and activity of CprK. Rev-erbβ, on the other hand, is a human transcriptional repressor 
and is implicated in different cellular processes such as circadian rhythm, metabolism, 
growth and inflammation. In this study, we have identified redox-active cysteines in Rev-
erbβ and studied their oxidative modification. We have found that the function of Rev-
erbβ is redox regulated and have elucidated the mechanism of redox modulation of Rev-
erbβ in vitro. Discovery of Rev-erbβ as a redox-switch opens the doors to elucidating its 
role in several redox sensitive cellular processes. 
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SECTION I 
Chapter 2 
CprK, A TRANSCRIPTIONAL REGULATOR OF DEHALORESPIRATION 
 
2.1 Halogenated organic compounds and their biodegradation 
2.1.1 Halogenated organic compounds 
One of the largest groups of xenobiotics, halogenated organic compounds, are  
continuously released in the atmosphere by plants, marine animals, bacteria, fungi, 
mammals and other natural processes (10). Natural production of these halogenated 
organic compounds has been a vital part of our ecosystem, but anthropogenic 
accumulation (industrial and agricultural) of these compounds, in the last century, has 
resulted in significant environmental contamination (22). These compounds are widely 
used in industrial applications because of their specific chemical and physical properties, 
such as excellent dielectric properties, stability to oxidation, flame resistance and relative 
inertness (14).  
 
The halogenated organic compounds have hazardous effects on human health and have 
been implicated in different types of cancers, reproductive disorders in males and 
females, birth defects, infant mortality, cardiovascular problems, muscle dysfunction, 
liver damage and others (2). To safeguard human health and the environment from these
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harmful chemicals that are persistent in the environment as persistent organic pollutants 
(POPs), the Stockholm Convention treaty was signed in 2001. POPs are toxic 
halogenated organic compounds and are comprised of three groups: (1) industrial 
chemical products such as PCBs, (2) combustion and by-products including dioxins, and 
(3) pesticides such as DDT. The list of POPs initially started with twelve halogenated 
organic compounds (the “dirty dozen”), but since May 2009, 9 more POPs which might 
have devastating effects on the environment and effect on human health such as cancer 
and diminished intelligence, have been added to the list. Interestingly, 16 of these POPs 
are chlorinated organic compounds (Stockholm Convention on POPs, United Nations 
Environment Program, 2001).  
 
2.1.2. Remediation strategies and biodegradation 
Halogenated organic compounds are present as pollutants in the air, soil, underground 
water and sediments. These compounds are persistent in nature and thus require aided 
degradation. There are various physiochemical treatments available for soil remediation, 
such as thermal cleaning or extraction of the contaminants by adsorption on activated 
carbon preceded by evaporation (33). Unfortunately, all these processes are not only 
costly and inadequate, but also cause damage to soil (23). Providentially, some microbes 
can remove the halogen groups from these compounds, otherwise a very difficult process, 
and make the compound easier to degrade further in the environment.In fact, 
bioremediation of soil is emerging as a viable alternate for soil-cleanup. Microorganisms 
can degrade halogenated organic compounds by the following mechanisms (9). 
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1. Oxidative dehalogenation: This process is catalyzed via mono-and di-oxygenases in 
co-metabolic or metabolic reactions. Halogenated organic compounds are used as a 
carbon/oxidizable electron source (9, 28). 
2. Dehydrohalogenation: In the process of dehydrohalogenation, the halogen is 
removed in the form of the acid (e.g. HCl) from the halogenated organic compounds 
by dehydrohalogenases (9). 
3. Substitutive dehalogenation: Dehalogenation of halogenated organic compounds is 
largely mediated by hydrolytic dehalogenases (halidohydrolases), but thiolytic 
dehalogenation is also possible with the help of glutathione-S-transferase. 
Additionally, dehalogenation via intramolecular substitution takes place via 
halohydrin halogen-halide lyases (9). 
4. Dehalogenation by methyl transfer: Dehalogenation via this mechanism involves 
transfer of a methyl group from the substrate to tetrahydrofolate in some strictly 
anaerobic bacteria and is also called fermentative dehalogenation (9, 11). 
5. Reductive dehalogenation: Reductive dehalogenation is an important process in the 
biodegradation of halogenated aliphatic and aromatic compounds and might occur in 
three different ways that are described in section 2.2 (9, 25, 34). 
 
Halogenated organic compounds, especially halogenated aromatic compounds, such as 
polychlorinated biphenyls (PCBs), are relevant to section I of this thesis and are also 
known to be toxic for human health (35). Due to the presence of the halogen group in the 
benzene ring, the water solubility of these molecules is reduced and molecules are 
hydrophobic innature. Therefore, these halogenated aromatic compounds when released 
into the environment, eventually settle into sediments (humic acid) or form sludges (oil-
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water mixtures) on the bottom of rivers, lakes and oceans (36). Mechanical disturbance 
by wind and rain help these compounds enter into the food chain. These compounds, 
being lipophilic in nature, eventually accumulate in the fatty tissue of living animals 
including human beings and are distributed at higher concentration at the top of the food 
chain (36). 
 
Halogenated aromatic compounds, in general, are stable in the environment due to their 
long half lives (35). Their biodegradation mainly depends on the aerobic oxidative and 
anaerobic reductive dehalogenation. The aerobic oxidative dehalogenation of halogenated 
aromatic compounds has been extensively studied, though this mechanism is feasible 
only for lightly halogenated organic compounds.Heavily halogenated organic compounds 
are resistant to oxygen-aided degradation, because the electronegative nature of halogens 
inhibits oxygen attack on the carbon backbone (12, 38). Moreover, in many cases, only 
the top few millimeters of sediments are aerobic and the remaining sediments where 
halogenated aromatic compounds primarily reside are anaerobic. Therefore their 
degradation mostly depends on reductive dehalogenation via anaerobic bacterial flora that 
will be described in detail in section 2.2 (36). 
 
2.2 Reductive dehalogenation 
Microbial reductive dehalogenation, which is an anaerobic process in most instances, is a 
critical step in the metabolism of highly halogenated organic compounds including PCBs. 
The reductive dehalogenation mechanism involves removal of the halogen substituent 
with concurrent addition of electrons to the molecule. This process can take place either 
via replacement of a halogen with a hydrogen atom (hydrogenolysis) or via elimination 
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of two halogens from adjacent carbon atoms, leaving behind a double bond (vicinal 
reduction). Both processes require an electron donor and release the halogen atom as a 
halide ion (20). Overall, three different kinds of microbial reductive dehalogenation have 
been described in Nature (36). 
1. Co-metabolic reductive dehalogenation: Abiotic or co-metabolic reductive 
dehalogenation has been proposed to be catalyzed mostly by metal ion-containing, 
heat-stable tetrapyrroles or enzymes using the same as cofactors (25). This process is 
common among methanogenic, acetogenic, sulfate reducing and iron-reducing 
bacteria with no benefit to the organism. Haloalkanes are the most common substrate 
for this kind of reductive dehalogenation reaction. 
2. Reductive dehalogenation linked to carbon metabolism: Reductive dehalogenation 
is not confined to strictly anaerobic bacteria. For example, some phototropic bacteria, 
such as Rhodospirillum rubrum, a facultative anaerobe, grow phototropically on C2 
and C3 halocarboxylic acids in the absence of oxygen. Reductive dehalogenation is 
followed by assimilation of the carboxylic acids. 
3. Metabolic dehaloganation/dehalorespiration: The metabolic dehalogenation 
reaction is also known by other names such as halorepiration, dehalorespiration or 
halidogenesis. This process connects the reductive dehalogenation reaction to 
microbial growth by specific bio-catalysts (25). The reductive dehalogenation process 
is a two-electron transfer reaction that releases the halogen as a halogenide ion and 
replaces the halogen with hydrogen.  
 
Among the three processes described above, dehalorespiration is most relevant to this 
chapter and will be discussed further. Dehalorespiration is mainly performed by 
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anaerobic bacteria that use halogenated organic compounds as electron acceptors. 
Halogenated organic compounds are excellent electron acceptors because the standard 
redox potential for most of the R-Cl/R-H couples falls between +250 and +600 mV (8). 
The high redox-potential of the R-Cl/R-H couples ensures that reductive dehalogenation 
is a thermodynamically favorable reaction (ΔG ≈ -130 to -180 kJ/mol per chlorine 
removal), which in turn enables the microbes to couple reductive dehalogenation to their 
growth (25). 
 
2.3 Microbial dehalorespiration 
Isolation and characterization of Desulfomonile tiedjei pioneered the field of microbial 
dehalorespiration because this anaerobic bacterium was first demonstrated to couple the 
reductive dehalogenation of 3-chlorobenzoate to energy conservation (Figure 2.1) (7). In 
this process, the carbon-halogen bond is cleaved during reductive dehalogenation by a 
specific dehalogenase, which uses halogenated organic compounds as a substrate and 
transfers electrons to a respiratory chain for energy generation (Figure 2.1).  
 
 
Figure 2.1: Hypothesis for 
coupling between reductive 
dehalogenation and energy 
generation in D. tiedjei. Hydrogen 
acts as an electron donor and 3-
chlorobenzoate serves as an 
electron acceptor in the respiratory 
chain under anaerobic conditions 
and results in the generation of 
ATP. This figure is based on 
Fantroussi et al. 1998 (8). 
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Since then, many dehalorespirating bacteria have been described, including D. 
dehalogenans (Figure 2.2). The CprK protein described in this thesis is from D. 
dehalogenans. 
 
2.4 Dehalorespiration in Desulfitobacterium dehalogenans 
 Desulfitobacterium spp. is a species of anaerobic bacteria that belongs to the low G+C 
Gram positive branch of the dehalorespiring bacteria (Figure 2.2), which comprises a 
major group of isolates. Most of the Desulfitobacterium strains were initially collected 
from a site contaminated with anthropogenic halogenated aromatic compounds. 
Interestingly, the entire Desulfitobacterium genera can utilise a broad spectrum of 
substrates for dehalogenation (29).  
 
2.4.1 Desulfitobacterium dehalogenans 
Desulfitobacterium dehalogenans was first isolated from methanogenic lake sediments in 
North America and is the first characterized dehalorespirating desulfitobacterium. The 
organism was found to be resistant to microaerophilic conditions (30). D. dehalogenans 
can only use ortho-haloaromatic compounds (described in the earlier part of this chapter) 
as a substrate for dehalorespiration (Figure 2.3). A commonly studied substrate on which 
this bacterium can grow is 3-chloro-4-hydroxyphenylacetate (CHPA). The optimum pH 
for growth is 7.5, and the doubling time for the bacterium is around 3.5 hours at 37 °C. D. 
dehalogenans can grow utilizing pyruvate, lactate, formate or hydrogen as electron 
donors and CHPA as an electron acceptor. However, there is no electron transport 
coupled phosphorylation when the bacterium is grown on lactate+CHPA or 
pyruvate+CHPA. Nevertheless, formate and hydrogen, when used as electron donors for 
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dehalorespiration, establish a proton motive force that can be used for ATP generation. 
The bacterium can also use sulfite, thiosulfate, fumarate, nitrate and CO2 as alternate 
electron acceptors (Figure 2.3) (30, 31).  
 
Desulfitobacterium  dehalogenans (JW/IU-DCI) 
          
           Phylum: Firmicutes, Class: Clostridia,  
           Order: Clostridiales, Family: Peptococcaceae. 
 
Figure 2.3: Classification and growth properties of D. dehalogenans. CHPA, 3-
chloro-4hydroxyphenylacetic acid; DCP, dichlorophenol; TCP, trichlorophenol; TeCP, 
tetrachlorophenol; PCP, petachlorophenol; PCBs, polychlorobiphenyls; AQDS, 
anthraquinone-2,6-disulfonate (humic acid analogue) (17, 21, 29, 30, 37). 
 
The observation that D. dehalogenans can use CHPA in the presence of other energy-
yielding terminal electron acceptors has strengthened the argument that chlorinated 
phenols can competitively serve as alternative electron acceptors for D. dehalogenans and 
that reductive dehalogenation of these compounds leads to energy release, apparently 
through electron transport coupled phosphorylation (18, 26).  
 
D. dehalogenans can dehalogenate a variety of haloaromatic compounds, including 
pentachlorophenol, tetrachlorophenols, trichlorophenols, dichlorophenols, bromophenols 
at ortho position, hydroxyl-polychlorinated biphenyls, along with CHPA (Figure 2.3). It 
is unable to dehalogenate most fluorophenols and monochlorophenols with the exception 
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of CHPA in which the chlorine is present ortho to the hydroxyl group (19, 29, 30, 37). 
The ortho-chlorophenol reductive (o-CP) dehalogenase from D. dehalogenans is a 
membrane-associated enzyme that mediates electron transfer from donor to the 
halogenated substrate. The enzyme contains one [4Fe-4S] cluster, one [3Fe-4S] and one 
cobalamin per monomer (32). The gene encoding o-CP dehalogenase, cprA, is present in 
the cpr (chlorophenol reduction) gene cluster. 
 
2.4.2 Role of cpr gene cluster in dehalorespiration 
The cpr gene cluster in D. dehalogenans encodes proteins involved in the 
dehalorespiration process and consists of a total of 8 genes: cprT, cprK, cprZ, cprE, cprB, 
cprA, cprC and cprD, organized into four transcription units (Figure 2.4). All the cpr 
genes, except cprAB, are expressed constitutively. CprB and cprA are transcribed 
together. CprB has been predicted to encode an integral membrane protein that might 
serve as a membrane anchor for CprA. CprA encodes the o-CP dehalogenase pre-protein 
containing an amino terminal twin arginine (RR) signal sequence (S/TRRXFLK), which 
is a common feature of the reductive dehalogenases and is thought to play a role in the 
maturation and translocation of periplasmic proteins (32). 
 
CprC and cprD are constitutively transcribed as bicistronic transcripts. CprC contains six 
transmembrane helices and has similarities with membrane-bound NosR/NirI regulators, 
while the cprD gene product is similar to GroEL-type chaperones. CprK, cprZ, cprE are 
transcribed as a tricistronic message (cprKZE). CprE potentially encodes a GroEL-type 
chaperone similar to cprD, while cprZ has no similarity to any known protein. CprK 
encodes a transcriptional regulatory protein that is responsible for the transcription of all 
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of the transcripts in the gene cluster and is the focus of section I of this thesis. CprT is 
transcribed in the opposite direction from all other genes in the cluster. CprT encodes a 
protein that is similar to a trigger factor peptidyl prolyl isomerase, and is considered to be 
involved in protein folding (27). 
 
 
Figure 2.4: Gene organization and putative CprK-dependent promoter regions in 
the cpr gene cluster of D. dehalogenans. Arrows indicate the direction of transcription 
of each of the four transcription units. Functions/putative functions are indicated below or 
above of each gene. 
 
 
 
Figure 2.5 provides an overall picture of the roles of the cpr gene cluster in expression 
and maturation of CprA in D. dehalogenans. CprC, CprD, CprE and CprT are proposed 
be involved in protein folding and maturation of CprA. CprK regulates the expression of 
CprA; while CprB probably anchors CprA into the membrane.  
 
2.5 CprK: a transcriptional regulator of dehalorespiration 
CprK is a transcriptional regulator of the cpr gene cluster that encodes proteins involved 
in the degradation of aromatic compounds (e.g. CHPA) and belongs to the CRP-FNR 
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(cAMP Receptor Protein-Fumarate Nitrate reduction Regulatory protein) superfamily of 
transcriptional regulators. 
 
Figure 2.5: Model for the roles of cpr gene cluster products in expression and 
maturation of CprA. HK: histidine kinase with response regulator (ReRe). TAT: twin 
arginine specific complex. Me: metal ion that may be involved in the control of gene 
expression and is incorporated in mature reductive dehalogenase (CprA). CprA could be 
outside or inside of the cytoplasmic membrane. This figure is modified from Villemur et 
al., 2006 (34).          
 
 
2.5.1 Characteristics of CRP-FNR family: CRP-FNR is a very large family of 
transcriptional regulators with over 1200 family members. All members of this family are 
DNA binding proteins that predominantly act as activators of transcription, but negative 
regulation has also been observed by some of the members. Members of this family 
respond to a broad spectrum of intracellular and exogenous signals such as cAMP,  
anoxia, oxidative and nitrosative stress, nitric oxide, CO, 2-oxoglutarate and temperature. 
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CRP, one of the main members, is involved in amino acid and sugar metabolism, 
transport processes, protein folding, pilus synthesis and toxin production (15). 
Transcriptional regulators of this family are characterized by the presence of an N-
terminal effector binding domain and a C-terminally located helix-turn-helix (HTH) 
motif for DNA binding (16). It is believed that the HTH domain is one of the most 
ancient, conserved features of the transcription regulators (16) and was probably already 
present in the last universal common ancestor (1).  
 
 
A.                                                 B.                                       C.                  
Figure 2.6: The HTH domain. Salient structural features of a simple HTH domain (A), 
wHTH domain of the CRP-like group (B) and DNA binding domain of CprK (C). This 
figure was created in CHIMERA using the PDB Ids of the above described proteins; A-
1k78, B-1cgp, and C-2h6c. 
 
The basic HTH domain is comprised of three α-helices as shown in Figure 2.6.A. 
Sequence and structural analysis reveals that the loop between the first and second 
helices can accommodate insertions, but a sharp turn between the second and third 
helices, a characteristic feature of the HTH domain, has never been found to have 
insertions. The third helix, known as the recognition helix, forms the principal DNA-
protein interface by inserting itself into the major groove of the DNA (3, 4). One of the 
N
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modifications of the HTH domain, the winged HTH (wHTH) domain, usually contains a 
C-terminal β-strand hairpin extension that is called the wing (3, 5). Further modifications 
in the basic wHTH motif are possible. One of the subsets of the wHTH forms a CRP-like 
group (Figure 2.6.B), which is actually a four-stranded version of the wHTH domain. 
Along with the C-terminal β-hairpin, this group also has another β-hairpin in the linker 
region between the first and second helices of the HTH domain. The DNA binding 
domain of CprK falls in the same category (Figure 2.6.C). 
 
2.5.2 Characteristics of CprK 
2.5.2.1 Sequence and structure: This thesis focuses on CprK from D. dehalogenans. 
CprK is a newly identified member of the CRP-FNR family of transcriptional regulators 
(27). CprK shows low sequence similarity (30-40%) with CRP and FNR, but has a 
characteristic wHTH domain and an N-terminal cAMP-like effector binding domain, 
which places CprK in the CRP-FNR family of transcriptional regulators. Its wHTH motif 
is very small but has a significant number of conserved residues (Figure 2.7). On the 
other hand, the effector binding domain, the largest domain of the protein, has very few 
residues that are conserved with CRP and FNR (Figure 2.7). The diversity in the effector 
binding domain likely accounts for the recognition of different effector molecules among 
the family members.  
 
Most members of this family have only 1 or 2 cysteine residues with the exception of 
FNR, which has five cysteine residues and CprK that  has five cysteine residues (Cys11, 
Cys105, Cys111, Cys161 and Cys200) (Figure 2.7). The presence of a higher number of 
cysteine residues suggests a possible functional importance for the protein; for example, 
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the four cysteine residues conserved at the N-terminus of FNR are involved in ligation of 
an 4Fe-4S cluster (6). The CprK sequence does not contain the N-terminal conserved 
cysteines found in FNR. This is consistent with the finding that CprK does not contain a 
metal cluster, which is also supported by the lack of absorption in the 350 nm to 420 nm 
region (24). Interestingly, most of the cysteine residues in CprK are involved in redox 
regulation of the protein as described in Chapter 3. 
 
 
Figure 2.8: Crystal structures of CprK. Crystal structures of reduced (A) and oxidized 
(B) CprK from D. dehalogenans and D. hafniense respectively. 
 
The crystal structures of reduced CprK (D. dehalogenans) in the absence of CHPA (PDB 
ID: 2h6b) and of the oxidized protein (D. hafniense) with CHPA (PDB ID: 2h6c) have 
been solved at 2.9 Å and 2.2 Å resolution, respectively and both are dimers (13). Similar 
to CooA, the DNA binding domains are swapped between the two monomers in the 
crystal structures of CprK (Figure 2.8). The N-terminal effector-binding domain has 
CHPA bound to it. The C-helix that connects the DNA and effector-binding domains also 
DNA binding 
domain 
Effector binding 
domain 
CHPA
C-helix
B. A. 
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provides the interface for dimerization (Figure 2.8). A significant difference in the three-
dimensional arrangement of the DNA binding domain was observed in the reduced 
versus the oxidized proteins. In the oxidized protein, the DNA binding domain is at an 
approximately 110° angle from the C-helix, while in the reduced protein, the DNA 
binding domain is placed approximately parallel to the C-helix. 
 
2.5.2.2 Intrinsic and biophysical properties: CprK is a cytoplasmic protein and is 232 
amino acids long. The fulllength protein, described in this thesis, was expressed in E. coli 
cells with a C-terminal 6X-His tag. The pI of CprK is 5.74 and its molecular weight is 
26.65 kDa; however, the molecular weight of 6x His-tagged CprK is 27,947.1+/- 2.7 Da, 
as analyzed by mass spectrometry analysis, which is in agreement with the predicted 
amino acid sequence (24).  
  
2.5.2.3. DNA binding properties: CprK was characterized in 2004 as the first 
transcriptional regulator of dehalorespiration. Some of the experimentally demonstrated 
DNA binding properties of CprK (28) are as follows. CprK has been shown to bind DNA 
in the presence of CHPA. DNA footprinting analysis revealed that CprK protected a 14 
bp pseudopalindromic sequence as shown in Figure 2.9.A. This sequence is similar to the 
consensus sequences recognized by CRP and FNR (Figure 2.9).  
 
However, a electrophoretic mobility shift assay (EMSA) showed that a minimum of 32 
bp  are required for a gel shift in the in vitro assay, thereby extending the DNA length by  
few more residues on both sides of the 14 bp protected region (AGA TAA AAG TTA 
ATA CGC ACT AAT ACT TGT GT). The approximate Kd for CprK for DNA is 190 ± 
30 nM as determined in EMSA studies (24). However, the binding analysis done under 
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the same conditions by the anisotropy method indicated much lower Kd value; 14 ± 3 nM 
(Gupta and Ragsdale, University of Michigan, unpublished data). 
 
 
 
               
 
Figure 2.9: DNA binding sequence of CprK. A. CprK binding site in the cprB 
promoter region, as determined by DNase1 footprinting analysis. B. A comparison of the 
CRP and FNR binding sites on DNA with the CprK binding site (24).  
 
 
 
2.5.2.4. Effector binding properties: The effector molecule for CprK from D. 
dehalogenans is CHPA and is required for CprK to bind DNA. Many other effector 
molecules, such as 3-chlorophenylacetate, 4-hydroxyphenylacetate, 3-chloro-4-
hydroxybenzoate, 3-chlorobenzoate, 3, 5-dichloro-4-hydroxy benzoate and 2, 4-
dichlorobenzoate, were also tested by EMSA for binding to CprK. However, no 
significant binding or mobility shift was observed (24). This suggests that the chlorine 
group and the hydroxyl group are important for specific interactions between CHPA and 
CprK. 
 
AAGTTAATACGCACTAATACTTGTGTATGTATTCCTTATTACAATGTACCCGTA
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by CprK 
-41.5 -10 +1 
Transcription 
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-156 +37 
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Chapter 3 
 
DUAL ROLES OF AN ESSENTIAL CYSTEINE RESIDUE IN  ACTIVITY OF A 
REDOX REGULATED BACTERIAL TRANSCRIPTIONAL ACTIVATOR 
 
 
 
The content of this chapter has been published in J Biol Chem. 2008 Oct 
17;283(42):28721-8: Gupta N and Ragsdale SW. “Dual roles of an essential cysteine 
residue in activity of a redox-regulated bacterial transcriptional activator”. 
 
 
 
 
 
Acknowledgement 
The work was partly supported by NSF Grant GM 39451 to SWR and some of the 
instrumentation used in early parts of this study was purchased with funds from an NIH 
grant (1P20RR17675) to help support the Biophysics Core Instrumentation Core of the 
Redox Biology Center at the University of Nebraska. The costs of publication of this 
article were defrayed in part by the payment of page charges. This article must therefore 
be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to 
indicate this fact. We are enormously indebted to Dr. Ari Gafni for providing advice and 
for letting us use his CD instrument, to Dr. Joseph A. Schauerte and Kathleen Wisser for 
assistance with CD experiments, and Dr. Bruce Palfrey for letting us use his 
spectrofluorometer and for helpful discussions.  
 
 
 
 
 
  35 
 
3.1 Abstract 
CprK from Desulfitobacterium dehalogenans is the first characterized transcriptional 
regulator of anaerobic dehalorespiration and is controlled at two levels: redox and 
effector binding. Redox regulation of CprK occurs through a thiol/disulfide redox switch, 
which includes two classes of cysteine residues. Under oxidizing conditions, Cys11 and 
Cys200 form an intermolecular disulfide bond, while Cys105 and Cys111 form an 
intramolecular disulfide in vitro. Here, we report that Cys11 is involved in redox 
inactivation in vivo. Upon replacement of Cys11 with serine, alanine, or aspartate, CprK 
loses its DNA binding activity. C11A is unstable; circular dichroism studies demonstrate 
that the stability and overall secondary structures of CprK and the C11S and C11D 
variants are similar. Furthermore, effector binding remains intact in the C11S and C11D 
variants. Nevertheless, fluorescence spectroscopic results reveal that the tertiary 
structures of the C11S and C11D variants differ from that of the wild type protein. Thus, 
Cys11 plays a dual role in its involvement in a redox switching mechanism and in 
maintaining the correct tertiary structure that promotes DNA binding.  
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3.2 Introduction 
Desulfitobacterium dehalogenans, one of the most extensively studied reductive 
dehalogenating bacteria, was identified thirteen years ago (32). It is an anaerobic, gram 
positive bacterium with low G+C content (33). D. dehalogenans can use 3-chloro-4-
hydroxyphenylacetate (CHPA) and several other chlorinated aromatic compounds, 
including polychlorinated biphenyls, as electron acceptors (36, 37) in an energy yielding 
process called dehalorespiration (27, 32). In the absence of chlorinated aromatics, this 
organism can also utilize sulfite, thiosulfate, fumarate and nitrite as electron acceptors 
(32).   
 
 
Figure 3.1: CprK and dehalorespiration. In presence of CHPA (3-chloro-4-
hydroxyphenylacetate), CprK becomes activated upon binding of CHPA. Activated CprK 
induces the expression of genes in the cpr gene cluster including cprA. cprA encodes for 
the dehalogenase enzyme that exploits CHPA as substrate and catalyzes the 
dehalogenation of CHPA. This process of dehalogenation generates ATP for the cell.  
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Genes that encode proteins involved in dehalorespiration are present within the cpr gene 
cluster. The cpr gene cluster contains eight genes, cprT, cprK, cprZ, cprE, cprB, cprA, 
cprC, and cprD, which are located in five transcriptional units (cprK, cprT, cprZE, and 
cprBA or cprBACD) controlled by three promoters (28). CprK is constitutively expressed 
at low levels and acts as a transcriptional regulator for the cpr gene cluster (21). Induction 
of the cprA gene results in production of the dehalogenase enzyme, which catalyzes the 
reductive dehalogenation of chlorinated aromatic compounds (Figure 3.1). 
 
CprK has a C-terminal winged helix-turn-helix (wHTH) DNA binding motif (1) and an 
N-terminal effector binding motif. CHPA binds to the effector domain in CprK, which 
triggers a conformational change (8) that promotes the interaction of CprK with a nearly 
palindromic DNA sequence called a “dehalobox” (2) that is located in the promoter 
regions of the cprT, cprZ, and cprB genes in the cpr gene cluster (21).  The effector 
(CHPA) can bind to CprK in both the reduced and oxidized states, but the protein must 
be in the reduced state to bind DNA (13, 20). Thus, dehalorespiration is regulated at the 
transcriptional level by effector binding and by the redox state of the protein. As shown 
in Figure 3.2, transcription occurs only under reducing conditions and when the effector 
is present.  
 
CprK from D. dehalogenans has five cysteine residues: Cys11, Cys105, Cys111, Cys161 
and Cys200. All cysteines except Cys161 are redox-sensitive and are involved in redox 
regulation of CprK. Upon oxidation, CprK loses DNA binding activity (21) due to the 
formation of an inter-molecular disulfide bond between Cys11 and Cys200 and/or an 
intra-molecular disulfide bond between Cys105 and Cys111 as our lab reported 
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previously (20). Based on the crystal structures of oxidized D. hafniense CprK1 and 
reduced D. dehalogenans CprK, an inactive state is stabilized by linkage of the effector 
domain to the DNA binding domain by the intermolecular disulfide bond. In addition, 
mass spectrometric studies reveal that several regions of the structure exhibit enhanced 
dynamics upon reduction (13).  
 
Figure 3.2: Regulation of CprK. CprK can exist in a thiol-oxidized state, containing an 
intermolecular disulfide linkage between Cys11 and Cys200 and an intramolecular 
disulfide linkage between Cys105 and Cys111, or a thiol-reduced state, in which all these 
Cys residues are in the thiol(ate) form. Oxidized and reduced CprK bind the effector 
(CHPA) with similar affinity. The oxidized state of CprK has low affinity for DNA; 
while the reduced form with effector binds DNA with high affinity and positively 
regulates expression of the cpr gene cluster. The products of this gene cluster are 
involved in catalysis of dehalorespiration (8). 
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The physiological relevance of the disulfide bond between Cys11 and Cys200 in redox 
regulation has been questioned (2). Here, we show that the intermolecular disulfide bond 
between Cys11 and Cys200 is observed in vivo upon exposure of E. coli cells 
overexpressing CprK to oxidative stress conditions. We also show that replacement of 
Cys11 with Ser or Asp results in a stable but inactive protein. The results of fluorescence 
spectroscopic studies and electrophoretic mobility shift assays (EMSA) reveal that the 
C11D and C11S variants can still bind effector with high affinity, but are unable to bind 
DNA. Changes in the fluorescence spectrum of the variants reveal that the loss of DNA 
binding activity in the Cys11 variants is related to a change in the tertiary structure of the 
protein. Thus, Cys11 plays a dual role in maintaining the correct structure for DNA 
binding and in redox regulation of CprK.  
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3.3 Experimental procedures 
3.3.1 Cloning, overexpression, and purification of CprK: DNA isolation and 
manipulation were performed by standard techniques (23). Plasmid DNA was purified 
with a QIAprep spin miniprep kit (Qiagen, Valencia, CA). Construction of the 
overexpression plasmid and purification of CprK were described previously (21). 
 
3.3.2 Site-directed mutagenesis of CprK: Cys11 was substituted with alanine, serine, 
and aspartate residues by performing site-directed mutagenesis according to the 
QuikChange protocol from Stratagene (La Jolla, CA). The pQE60:cprK plasmid was the 
template for PCR and the primers were purchased from Integrated DNA Technologies. 
The DNA sequences of all PCR-generated DNA fragments were confirmed using dye 
terminator chemistry and automated sequencing of both DNA strands with a 
Beckman/Coulter CEQ2000XL 8-capillary DNA sequencer at the Genomics Core 
Research Facility (University of Nebraska, Lincoln, NE).  
 
3.3.3 Construction of strains for lacZ reporter assays: To measure in vivo activity of 
CprK, a two-plasmid reporter system was constructed, in which an arabinose-inducible 
cprK gene on one plasmid and a cpr promoter-lacZ fusion on another plasmid were 
cotransformed into an ara- E. coli strain. Wild type (WT) CprK was cloned into the 
pBAD-Myc-HisA expression vector (Invitrogen, Carlsbad, California), generating 
pBAD/Myc/HisA::cprK. To express the native protein lacking the His-tag, the native stop 
codon was included before the sequence that encodes the His-tag. Cys11 variants were 
generated by site-directed mutagenesis in the same construct. A cpr promoter-lacZ fusion 
was generated by cloning the promoter region of cprB into the EcoRI cloning site of 
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pRS551 (26) to yield pRS551::PcprB, which was used to transform the ara– E. coli strain 
LMG194 (Invitrogen, Carlsbad, California). Then, the pBAD/Myc/HisA::cprK construct 
and the corresponding C11A, C11S, and C11D variants were  transformed into the 
LMG194 cells containing pRS551::PcprB to generate the two-plasmid reporter system. 
The pBAD system provides tight control of CprK expression (6), and the E. coli strain 
provides a background that lacks dehalorespiration genes.  
 
3.3.4 Assay of in vivo activity of CprK: Promoter activity was measured in vivo by the 
β-galactosidase assay. Overnight cultures were grown aerobically at 37 °C in RM 
medium plus 50 µM CHPA, 0.2 % arabinose, 100 µg/ml ampicillin, and 34 µg/ml 
chloramphenicol. When required, diamide (1 mM final concentration) was added to the 
culture at an O.D.600≈0.2. Growth was stopped during the exponential phase by placing 
the cultures on ice when the O.D.600 reached 0.4 to 0.6. After 20 min, 500 µl of Z buffer 
(60 mM Na2HPO4.7H2O, 40 mM NaH2PO4.H2O, 10 mM KCl, 1 mM MgSO4, and 50 
mM β-mercaptoethanol, pH 7.0), 50 ml of 0.1% SDS, and 2 drops of chloroform were 
added to 500 µl of culture and the solution was incubated at 28 °C for at least 5 min when 
200 µl of 4 mg/ml O-nitrophenyl-β-D-galactoside (ONPG) (final concentration, 0.8 
mg/ml) was added. The reaction was stopped by adding 500 µl of 1 M Na2CO3 when the 
reaction mixture began to turn yellow, and the time of reaction was recorded.  The 
absorbances at 420 nm and 550 nm were then measured to calculate the promoter activity 
in Miller Units as described (12). Each reaction was performed in quadruplicate. 
 
3.3.5 In vivo intermolecular disulfide bond detection: E. coli strains containing the 
cprK gene were grown in LB media at 37 °C.  At an A600 nm of ~0.6, a 0.5 ml sample was 
  42 
 
centrifuged and the cell pellet was immediately frozen in liquid nitrogen. Diamide (1 
mM, final) was added to the rest of the culture and 0.5 ml samples were collected from 
the culture after 5, 10, 30 and 60 min, centrifuged, and frozen as just described. Next day, 
non-reducing loading buffer (60 mM Tris-Cl, pH 6.8, 1% SDS, 10% glycerol, 0.01% 
bromophenol blue) was added to the cell pellets at varying volumes to provide samples 
with equal final  cell density (based on the absorbance at 600 nm). Finally, 10 µl of each 
sample was loaded on a 15% SDS-PAGE gel and immunoblotted with an anti-CprK 
antibody. After electrophoresis, proteins were transferred to a PVDF membrane, which 
was first incubated with primary rabbit anti-CprK antibody (Cocalico Biologicals Inc., 
Reamstown PA) that had been purified by chromatography on a CprK-actigel ALD 
superflow affinity column (Sterogene Bioseparations Inc., Carlsbad, CA). The membrane 
was then treated with secondary antibody (goat anti-rabbit IgG conjugated to horseradish-
peroxidase, Sigma-Aldrich), and the presence of CprK was detected by 
chemiluminescence, using the protocol recommended by the manufacturer (Sigma-
Aldrich). 
 
3.3.6 Electrophoretic mobility shift assay (EMSA): EMSAs were performed as 
described (21) with increasing amounts of IRDye 700 labeled oligonucleotides (LI-COR, 
Inc, Lincoln). Data were analyzed by infrared imaging with an ODYSSEY infrared 
imager (LI-COR). 
 
3.3.7 Liquid chromatography mass spectrometry (LCMS) analysis: The intact protein 
was analyzed at the Mass Spectrometry Core Facility (University of Nebraska, Lincoln) 
by an LC-MS/MS system comprised of a Shimadzu (SCL-10A) HPLC system, a 4000 
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Qtrap (ABS) mass spectrometry system, and a turbo ion-spray source probe.  Protein 
samples (20 ml) were loaded onto a Micro-Tech Scientific C18 column (1.0 (ID) x 50 mm 
(length), 5 µm (particle size)) by a PE 200 Autosampler and eluted at a flow rate of 100 
µl/min at room temperature with a gradient of 0.3% formic acid in H2O (Solvent A) and 
0.3% formic acid in acetonitrile (Solvent B).  The percentage of Solvent B was increased 
linearly from 10-70% over a 5 min elution time. The data were acquired and processed 
with Analyst 1.4.1 software. Data was acquired in the Q1 (quadrupole one) positive ion 
mode as the mass range (m/z) of 850-1150 amu (atomic mass units) was scanned in 4 sec.  
The total run time for each sample was 20 min.  The molecular mass of the protein was 
calculated by analyzing several multiply charged peaks with the Bayesian Protein 
Reconstruct option in Bioanalyst 1.4.1 software.   
 
3.3.8 Intrinsic fluorescence quenching and circular dichroism (CD) analysis: For the 
CHPA binding assay shown in Fig. 3.6, 180 to 500 nM CprK was analyzed by 
fluorescence spectroscopy with a Shimadzu RF-530 1 PC Spectrofluorophotometer 
(Columbia, MD) at room temperature as described (20, 37). All fluorescence data were 
corrected for the inner filter effect (10). The intrinsic tryptophan fluorescence spectra of 
wild-type CprK, C11S, and C11D variants shown in Fig. 3.9 were recorded on an OLIS 
RSM1000F (OLIS, Inc., Bogart, GA).  
 
Binding of CHPA to CprK causes quenching of intrinsic tryptophan fluorescence of 
CprK. Dissociation constants were calculated by fitting the fluorescence quenching data 
to Equation 1 or 2, where Kd represents the dissociation constant for the ligand (L, 
CHPA), [L] is the total ligand concentration, [P] equals the total protein concentration, 
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ΔF is the observed fluorescence quenching, F0 equals the initial fluorescence, and ΔFmax 
is the maximum quenching that would be observed at infinite ligand concentrations. 
These equations assume a single binding site on CprK for CHPA. The [L] in Equation 1, 
which describes a standard one-site binding isotherm, should be free ligand, and because 
the free ligand concentration is unknown, we assumed that the free and total ligand 
concentrations are equal. However, when the [L] is in the range of the Kd, the fraction of 
bound ligand becomes significant; therefore, the data were also fit to quadratic Equation 
2, which accounts for ligand depletion at low CHPA concentrations. We also estimated 
the free ligand concentration by subtracting bound ligand ([P] * ∆F/Fmax] from [L], and 
fit this data to Equation 1. 
 
ΔF = (ΔFmax * L)/([L] + Kd)   (1) 
 
 (2) 
 
The different one-site treatments gave similar dissociation constants, while a two-site 
model [ΔF = (ΔFmax * L)/([L] + Kd1) + (ΔFmax * L)/([L] + Kd2)] gave a Kd1 in the low 
nanomolar range with high errors and a Kd2 that was similar to the Kd value obtained 
from the one-site model. The R2 values were also slightly better for the one-site model. 
Thus, we conclude that binding of CHPA to CprK follows a one-site binding model. 
 
CD measurements were performed at 4 °C with a JASCO J-715 instrument (Jasco Inc., 
MD). Spectra were scanned from 260 to 190 nm at a speed of 50 nm/min with a data 
pitch of 1 nm. Forty scans at a 2 sec response time and a 5 nm bandwidth were averaged 
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for each sample. For secondary structure analysis, experiments were performed in a 0.1 
mm path length cell with 0.7 mg/ml CprK in 10 mM potassium phosphate buffer, pH 7.5. 
The melting temperature of CprK was determined by measuring the CD spectrum of 0.2 
mg/ml protein (in 50 mM Tris, 300 mM NaCl, pH-7.5) over a temperature range of 20 °C 
to 80 °C in a 1 mm path length cell. Data were obtained in millidegrees and converted 
into molar ellipticity by JASCO software. The Continll program (22) within the CDpro 
software (29) was used for secondary structure analysis. 
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3.4 RESULTS 
3.4.1 Evidence for in vivo disulfide bond formation between Cys11 and Cys200  
 E. coli strains overexpressing CprK were grown in the presence or absence of diamide 
and samples were collected at 1, 5, 10, 30 and 60 min. Samples were prepared for non-
reducing SDS-PAGE analysis followed by Western blot analysis to identify the 
oligomeric state of CprK, omitting DTT, as described in the Experimental Procedures 
section. When cells were treated in the absence of oxidant, CprK was predominantly in 
the monomeric state (Figure 3.3.A, lane 1). However, when the cells were treated with 1 
mM diamide, CprK was rapidly converted from the monomeric to the dimeric form 
(lanes 2 to 6). Dimer formation was also observed when cells were treated with hydrogen 
peroxide (Figure 3.3.B). 
 
Treatment of the C11S variant with diamide did not result in dimer formation (Figure 
3.3.C). Similarly, the C200S variant remained predominantly in the monomeric state after 
treatment with diamide (Figure 3.3.D), with a small proportion of the dimeric form, as 
was observed in earlier in vitro experiments (20). Another band in the 15-20 kDa region 
appeared in the C200S variant, which might reflect a degradation product. In summary, 
these results indicate that in vivo Cys11 and Cys200 exist as the free thiol(ates) under 
normal growth conditions, and that they form an intermolecular disulfide bond when 
exposed to oxidants.  
 
Mass spectrometric analyses of the purified Cys11 variants revealed that the C11S and 
C11D variants are full-length proteins just like the wild-type CprK (Figure 3.4), with the 
only observed differences being due to the site-directed amino acid replacements. 
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Figure 3.3: In vivo Cys11-Cys200 disulfide bond formation upon treatment of cells 
with oxidants. Exposure of cells containing wild-type CprK to (A) 1 mM DA or (B) 1 
mM hydrogen peroxide or after treatment of (C) the C11S variant and (D) the C200S 
variant to 1 mM DA followed by separation on non reducing SDS-PAGE and Western 
blot analysis. The membranes were immunoblotted with anti-CprK antibody and stained 
as described in experimental procedures. 
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Figure 3.4: Parent ion analysis of CprK by mass spectrometry. Mass spectrometric 
analyses confirmed that CprK and variants are full-length proteins, with wild-type CprK 
(A) showing a mass of 28026.0 Da, C11S (B) of 28015.0 Da, and C11D (C) of 28040.0 
Da. 
 
 
3.4.2 Substitution of Cys11 with Ser/Asp inactivates CprK  
 
To analyze the role of Cys11, in vivo β-galactosidase and in vitro DNA binding assays 
were performed with the C11S and C11D variants. Attempts to purify the C11A variant 
failed, whereas the C11D and C11S variants could be purified at levels of 10-20 mg/liter 
of culture. EMSA assays were performed on the wild-type and variant forms of CprK in 
the presence of effector. Neither the C11S nor C11D variants showed any mobility shift 
of pcprB (Figure 3.5.A and 3.5.B). 
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Figure 3.5: Loss of in vitro DNA binding activity of Cys11 variants. (A) EMSA 
experiments after incubation of wild-type CprK (lanes 1-4) or C11S (lanes 5-7) with 
DNA in the presence of DA (lane 2, 5), or DTT (lanes 3, 6) or DTT+DA (lanes 4, 7). (B) 
EMSA experiments comparing wild-type CprK with C11D. Lane 2 has wild-type CprK 
with 50 mM DTT. Lanes 3 and 4 have the C11D variant with 50 mM DTT and 5 mM DA 
respectively. Lane 1 in (A) or (B) is a control that lacks protein. 
 
Similarly, in vivo analysis by the cprB promoter-lacZ fusion assay demonstrated that the 
C11S, C11A and C11D variants were severely compromised in DNA binding, with 2-3% 
β-galactosidase activity of the wild-type protein (Figure 3.6). Diamide-treated wild-type 
CprK showed 10% activity, indicating that oxidative stress inactivates CprK in vivo and 
  50 
 
that the reducing conditions within the cell compete with diamide oxidation to restore the 
active protein. Diamide treatment of C11A, C11S, and C11D variants further decreased 
the DNA binding activity to background levels. Because formation of the Cys11-Cys200 
disulfide bond is prevented in these variants, the additional decrease in activity could 
result from oxidation of Cys105 and Cys111 to form an intramolecular disulfide bond. 
 
Figure 3.6:  In vivo DNA binding activity of Cys11 variants.  E. coli strains expressing 
wild-type CprK or the Cys11 variants were incubated with no (filled bar) or 1 mM DA 
(open bar) and promoter activity was measured by the β-galactosidase assay as described 
under experimental procedures. Activity is expressed as percentage of Miller units 
exhibited by the variant compared to that of wild-type CprK. Data are shown as mean ± 
SD and are representative of three separate experiments, each performed in 
quadruplicate. 
 
3.4.3 Loss of DNA binding activity but unimpaired effector binding of the Cys11 
variants  
 
In order to determine if inactivity of the C11S and C11D variants is due to loss of 
effector or of DNA binding, effector binding affinity was measured by intrinsic 
tryptophan fluorescence (Figure 3.7).   
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Figure 3.7: Effector binding affinity of WT and the Cys11 variants. Fluorescence 
intensities for the oxidized (right) and reduced (left) wild-type (), C11D ({), and C11S 
() variants were measured, as described previously (8). The dashed and solid lines 
represent the fits to one-site binding models according to Eqs. 1 and 2, respectively, as 
described in experimental procedures. The effector concentration is given in µM units.  
 
As shown in Table 3.1 and Figure 3.7, the oxidized and reduced states of CprK, as well 
as the Cys11 variants bind CHPA with high affinity, and the data for the wild-type and 
Cys11 variant proteins are virtually superimposable. The binding data for the wild-type 
protein and the Cys11 mutants, best fit to a single binding site model. The ranges of Kd 
values are 0.29-0.49 µM and 0.34-0.68, for the oxidized and reduced proteins. In fact, 
composite fits that include all the data for wild-type and mutants (oxidized or reduced) 
give standard deviations that are similar to those for the individual fits. In addition, 
similar Kd values are obtained by fitting the data to the standard binding isotherm given 
in Equation 1 (dashed line, Fig. 3.7) as with the more rigorous quadratic Equation 2 (solid 
line) that takes ligand depletion at low CHPA concentrations into account. Therefore, 
based on the composite fits, the Kd value for CHPA of the oxidized and reduced states of 
CprK are between 0.3 µM and 0.5 µM.  
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Protein Redox State Kd (µM)1 
WT Reduced 0.52 ± 0.18 
 Oxidized 0.49 ± 0.16 
C11D Reduced 0.68 ± 0.11 
 Oxidized 0.31 ± 0.14 
C11S Reduced 0.34 ± 0.11 
 Oxidized 0.29 ± 0.11 
Combined2 Reduced 0.50 ± 0.09 
 Oxidized 0.30 ± 0.09 
 
Table 3.1: Dissociation constants for the complex between CprK (and variants) and 
CHPA. 1These values were calculated by fits to Equation 2, which accounts for ligand 
depletion at low concentrations of CHPA. 2These values were obtained by fitting the 
combined data sets for WT, C11S, and C11D. 
 
Because the CprK variants with substitutions at Cys11 retain high affinity for CHPA, the 
inactivity of these variants was presumed to result from loss of DNA binding ability. We 
compared the affinity of the Cys11 variants for DNA to that of the wild type protein by 
performing EMSA at increasing DNA concentrations. The C11S variant requires greater 
than 50-fold more DNA to obtain the same amount of CprK-DNA complex as with the 
wild-type protein (Figure 3.8). Thus, only marginal activity is observed when the thiol of 
Cys11 is replaced by a hydroxide (in C11S). With the C11D variant (data not shown), no 
gel shift was observed even at 500 nM DNA, indicating either that the negative charge or 
the increased steric bulk of Asp at residue 11 strongly inhibits DNA binding. Thus, 
CprK’s promoter binding activity appears to require the Cys11 thiol(ate) functionality. 
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Figure 3.8: Effect of increasing DNA concentration on DNA binding activity of 
C11S.  Wild-type CprK (lane1 to 3) and the C11S variant (lanes 5-7) were incubated with 
10 nM to 500 nM DNA containing the cpr promoter. Lane 4 was a control that lacked 
protein.  
 
3.4.4 Loss of DNA binding activity may reflect a change in tertiary structure of 
CprK 
Although the first 18 amino acid residues were disordered and not seen in the crystal 
structure of the reduced protein, the structure of oxidized CprK reveals Cys11 to be 
positioned near the DNA binding domain (Figure 3.9) (8). To explore the reason behind 
the loss of DNA binding activity of the Cys11 variants, fluorescence spectroscopy and 
circular dichroism experiments were performed. We expected to detect the changes, if 
any, in the tertiary structure, secondary structure or thermal stability of variants. 
 
To determine if loss of DNA binding activity in the Cys11 variants is associated with a 
change in the structure of CprK, intrinsic tryptophan fluorescence spectra were recorded 
of oxidized and DTT-reduced CprK and of the Cys11 variants (Figure  3.10).  
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Figure 3.9: Cys11 in the crystal structure of oxidized CprK. The crystal structure of 
oxidized D. hafniense CprK (A), focusing on the helix-turn-helix DNA binding domain 
(B). Cys11 and other residues (Cys200) predicted to be in the recognition helix, based on 
the structure of the CRP-DNA complex (8), and are colored according to element. This 
figure was generated from PDB ID: 2h6b in CHIMERA. 
 
As observed earlier, reduction of CprK leads to quenching of intrinsic tryptophan 
fluorescence (20), indicating that the single Trp at position 106 becomes more solvent 
exposed upon reduction (Figure 3.10.A & B). The fluorescence spectra of the DTT-
reduced forms of C11S and C11D coincide, with a significantly lower intensity than that 
of the reduced wild-type protein (Figure 3.10.B). These results indicate that the tertiary 
structures of the reduced Cys11 variants (at least in the region of Trp106) are different 
from that of wild-type CprK. 
 
The fluorescence spectrum of the oxidized C11S variant is similar to that of the reduced 
state of wild-type CprK (Figure 3.10.A), indicating that Trp106 in C11S is already rather 
solvent exposed in the oxidized protein. The fluorescence spectrum of oxidized C11D is 
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similar to that of oxidized wild-type CprK (Figure 3.10.A), while reduction of C11D 
leads to a marked (~40%) quenching of fluorescence (Figure 3.10.B).  
 
Figure 3.10: Intrinsic fluorescence spectrum of CprK. Spectra were recorded for wild-
type CprK, C11S and C11D in 50 mM Tris-HCl, 300 mM NaCl pH 7.5 (A), or the same 
buffer containing 50 mM DTT (B). Data presented here are representative of three 
different experiments. 
 
Based on CD analysis, substitutions at Cys11 cause only marginal changes in secondary 
structure (Figure 3.11 and Table 3.2), which are within or near the error limits of the 
experiment. Table 3.2 shows the results obtained from the secondary structure analysis 
for wild type CprK and the Cys11 variants. The normalized root-mean-squared deviation 
values for all of the fits are below 0.1, which indicates that the experimental data are well 
fit by parameters calculated by the Continll program. 
 
Stabilities of the Cys11 variants in the oxidized state were also measured by recording the 
CD spectrum at 222 nm in the temperature range between 20 °C and 80 °C (Figure 3.12). 
The actual melting temperature (Tm) could not be accurately determined as the thermal 
unfolding curves were irreversible. The wild-type protein gave an approximate Tm of 54 
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°C, while the variants exhibited transitions at slightly lower temperatures, indicating that 
they have similar or only slightly decreased, stability.  
 
Figure 3.11: Circular dichroism analysis. Superimposed CD spectra of WT, C11S and 
C11D variants. Data presented here are representative of three independent experiments. 
Samples were prepared in 10 mM potassium phosphate buffer, pH 7.5.  
 
 
Protein α-helix β-sheet Turn Unordered NRMSD
WT 0.421 0.167 0.154 0.258 0.018 
C11S 0.409 (2.8 %) 0.159 (4.8 %) 0.150 (2.6 %) 0.281 0.026 
C11D 0.415 (1.4 %) 0.139 (16.7%) 0.159 (3.2 %) 0.296 0.028 
X-ray 0.42 0.26 - - - 
 
Table 3.2:  Secondary structure analysis of wild-type CprK and variants. Secondary 
structure fractions are shown here as analyzed by the Continll program (CDPro software) 
in comparison with the secondary structure fractions based on the X-ray structure (PDB 
entry 2h6b) of wild-type CprK. Variation from the secondary structure content of wild-
type is given in parentheses after the measured secondary structure contents of variants.  
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Figure 3.12: Stability of wild-type CprK and Cys11 variants. Melting curves of wild-
type and variant proteins were obtained by recording the CD at 222 nm from 20 °C to 80 
°C in a buffer containing 50 mM Tris, 300 mM NaCl, and pH 7.5.  
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3.5 Discussion 
Upon binding its effector (CHPA), CprK induces the expression of genes involved in the 
use of chlorinated aromatic compounds as electron acceptors. Besides providing energy 
for the microbe, dehalorespiration helps to rid the environment of xenobiotics (like 
polychlorinated biphenyls) that constitute a significant health risk. Previous in vitro 
studies indicate that CprK contains two thiol/disulfide redox switches that regulate 
transcriptional activity of CprK: one involving Cys11 and Cys200 that, in the oxidized 
state, forms an intermolecular disulfide linkage and another involving Cys105 and 
Cys111 that forms an intramolecular disulfide bond (20). 
 
Redox regulation of CprK activity has been proposed to prevent expression of CprA 
under oxidative conditions (21). CprA catalyzes reductive dehalogenation through a 
mechanism involving oxygen-sensitive iron-sulfur clusters and the low valent Co(I) state 
of cobalamin (9). Here we describe further studies indicating that the intermolecular 
thiol/disulfide switch is formed in the E. coli cytoplasm under oxidative stress conditions. 
Exposure of D. dehalogenans to such oxidative conditions would likely occur commonly 
in this microaerophile, as it does in the facultative anaerobe E. coli. Since it would be 
wasteful to produce CprA under oxidative conditions, it would be advantageous for the 
cells to exert redox control of transcription of the cpr gene cluster.  
 
Thus, as shown in Figure 3.2, CprK is proposed to exert a two-tier mode of regulation of 
dehalorespiration involving a redox switch at one level and an effector-binding switch at 
another level. The studies described here also provide evidence that Cys11 plays a dual 
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role in transcriptional activation: as part of the intermolecular redox switch and in 
maintaining an optimal structure of CprK’s DNA binding domain. 
 
Formation of either the intramolecular or the intermolecular disulfide bond appears to be 
sufficient to inhibit transcriptional activation, since variants containing substitutions at 
Cys105, Cys111, or Cys200 (or Cys161, which does not appear play a redox role) retain 
redox-sensitivity and bind DNA and effector with affinities similar to those of the wild-
type protein (data not shown). Thus, formation of either the intramolecular or the 
intermolecular disulfide bond appears to reversibly inactivate CprK. Surprisingly, as 
shown in this paper, substitution of Cys11 with Ala, Ser, or Asp results in a protein that is 
unable to activate transcription in vivo or to bind the cpr promoter DNA in vitro, even 
under reducing conditions and at saturating concentrations of effector. Thus, beyond its 
involvement in the intermolecular redox switch, Cys11 plays an additional role in 
transcriptional activation. These results differ from studies in which C11S of the related 
CprK1 from D. hafniense was shown to retain DNA binding activity (2). Based on DNA 
sequence and mass spectrometric analysis, we are certain that the only mutation in these 
variants is at Cys11 and the redox inactivity is observed in forms of CprK containing (in 
vitro) and lacking (in vivo) the His-tag sequence. Thus, it is difficult to harmonize our 
results with those described earlier (2), except to suggest that CprK1 in D. hafniense may 
exhibit different redox properties than CprK from D. dehalogenans. For example, Cys105 
is absent in D. hafniense.  
 
As shown in Figure 3.9, Cys11 (in the oxidized protein) is very close to the recognition 
helix of the wHTH DNA binding domain in CprK that binds to the dehalobox promoter 
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sequence. Furthermore, binding of DNA protects the recognition helix (a 14-amino acid 
peptide including residues 182-196) from limited proteolysis (13). Although Cys11 is not 
observed in the structure of the reduced protein, reduction of CprK increases the overall 
structural dynamics of CprK in the region of Cys11 (13). Other regions that were shown 
to undergo local changes upon effector binding include the long C-helix that connects the 
DNA and effector binding domains and Arg152, which is in a proposed hinge region that 
may transmit the effector-binding signal to the DNA binding domain.  
 
By comparing the activities of CprK variants with Ala, Ser, or Asp substitution at Cys11, 
we expected to be able to determine whether Cys11 is involved in hydrophobic, H-
bonding, or ionic interactions that are important for transcriptional activation. However, 
all three variants share similarly low abilities to activate transcription (Figure 3.6). 
Although the C11A variant could not be purified for in vitro studies, C11S, C11D, and 
wild-type CprK are all stable proteins that can be purified in large quantities and studied 
by various biochemical methods. As with the wild-type protein, both oxidized and 
reduced states of the C11S and C11D variants have a single high affinity (0.3-0.7 µM) 
binding site for the effector (Figure 3.7) Similarly, the crystal structure revealed a single 
CHPA molecule bound at the effector binding site of CprK (8). A single site binding 
model was used to fit the effector binding data for the related CprK from D. hafniense 
(8). In summary, our results indicate that Cys11 does not play a major role in effector 
binding.  
 
Upon replacing Cys11 with serine, the DNA binding activity of CprK decreases more 
than 50-fold (Figure 3.8). Because the thiol and hydroxyl groups in the side chains of Cys 
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and Ser are similar in size and H-bonding ability, a H-bonding interaction(s) involving 
the neutral thiol of Cys11 does not explain the importance of this residue in 
transcriptional activation. Some redox-active thiols have unusually low pKa values; thus, 
to test the hypothesis that Cys11 may function as an ionized thiolate, the DNA binding 
activity of the C11D variant was tested. Although C11D retains high effector binding 
capacity, it exhibits no detectable DNA binding (Figure 3.7). These results suggest that 
the thiol(ate) function of Cys11 plays a crucial and very specific role in DNA binding.  
 
Based on studies of a related transcriptional activator (CprK1) from D. hafniense and two 
variants (C11S and C200S), the disulfide bond between Cys11 and Cys200 in redox 
regulation was concluded to lack physiological relevance (2). Gabor et al. hypothesized 
that, if the Cys11-Cys200 disulfide bond was important in vivo, replacement of either 
Cys11 or Cys200 with serine would result in a redox-insensitive active state of CprK. 
Since, in aerobically grown E. coli, the level of transcriptional activation mediated by the 
C11S variant was similar to that of wild-type CprK1, it was concluded that the Cys11-
Cys200 disulfide bond was not present in the cytoplasm of aerobically cultivated E. coli 
cells. However, the results described here clearly demonstrate the formation of the 
Cys11-Cys200 disulfide bond under oxidative stress conditions in the cytoplasm of E. 
coli, with an ambient redox potential of ~-250 mV (18, 31), which is similar to the redox 
potential of the ox/red couple for glutathione (i.e., between -240 (25) and -263 mV (15), 
the major redox buffer in most cells. Although the redox potentials for the intramolecular 
and intermolecular thiol/disulfide switches in CprK have not yet been determined, the 
redox potential of disulfide bonds in proteins vary over a wide range (-122 mV to -470 
mV) (18). Thus, we suggest that transcriptional control by CprK is subject to 
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thiol/disulfide regulation, like a number of processes in prokaryotes and eukaryotes, 
including transcriptional regulation by OxyR(3), glutathione biosynthesis (34), cell cycle 
progression (24), heme binding by heme oxygenase-2 (39), iron metabolism by FurS 
(17), DNA binding by NF- kB (16), and thioredoxin/thioredoxin reductase-dependent 
reactions (30, 40). 
 
Crystallographic (7) and site-directed mutagenesis (5) studies of bovine papillomavirus-1 
E2 demonstrated that Cys340 is required for transcriptional activation through 
interactions between its sulfhydryl group and two bases in its target DNA. Like CprK, the 
E2 protein is subject to redox regulation, with its transcriptional activity lost upon 
oxidation (14). Similar results were obtained with NF-kB, where it loses DNA binding 
activity upon alkylation of a Cys residue in the DNA binding domain (11).  
 
Fluorescence spectroscopic results demonstrate that the tertiary structures of the Cys11 
variants are different from that of wild-type CprK, in both the reduced and oxidized 
states. Furthermore, the thiol/disulfide transition in CprK results in a substantial change 
in conformation, especially affecting the DNA binding domain, as observed in the crystal 
structures of the oxidized and reduced proteins (8), by limited proteolysis studies (13), 
and by fluorescence spectroscopy (Figure 3.10). An important structural role for Cys11 is 
also supported by the observations that the C11A variant cannot be purified and that the 
C11S and C11D variants are slightly less stable than the wild-type protein. Functional 
and structural roles for cysteine have been demonstrated in various proteins (4, 19, 35, 
38) where cysteine plays a role in activity, in maintaining an active dimer, and in thermal 
stability. In the case of CprK, perhaps the charged Asp, being larger than the cysteine 
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residue, interferes with protein-DNA interactions by either direct stereoelectronic effects 
or by indirect effects on protein packing near the recognition helix. However, the position 
of Cys11 in active reduced CprK is not known (8). It is hoped that further structural 
studies will lead to a better understanding of the nature of interactions involving Cys11 
that promote DNA binding. 
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SECTION II 
Chapter 4 
 
Rev-erbβ, A TRANSCRIPTIONAL REGULATOR OF CIRCADIAN RHYTHM, 
GROWTH AND METABOLISM 
 
4.1 Nuclear receptors  
Transcription initiation in eukaryotes requires a group of proteins that assemble into a 
large complex that includes RNA polymerase, general transcription factors (TFIIA-H), 
coactivators, chromatin remodelers, histone acetylases, histone deactetylases, kinases and 
methylases. These proteins are important for transcription, however, regulation of 
transcription (activation or repression) and the choice of specific initiation sites i.e. genes 
for transcription are controlled by transcription factors. One of the largest groups of 
transcription factors in animals is represented by nuclear receptors. The nuclear receptor 
superfamily includes related but diverse arrays of transcription factors, which are capable 
of exerting transcriptional regulation in the nucleus in response to various intracellular 
and extracellular signals (36, 72). There are 48 nuclear receptors encoded in human 
genome; however, only 27 of them have known endogenous ligands. The remaining 21 
belong to the category of orphan nuclear receptors (6, 74). The widespread relevance of 
nuclear receptors/orphan nuclear receptors to almost all aspects of human 
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physiology, including metabolism, homeostasis, development and disease, has made 
them promising pharmacological targets (36, 41). In fact, almost 15% of current drugs 
target nuclear receptors (48), which make them the third largest target for the 
pharmaceutical industry after G protein coupled receptors and kinases (51). 
 
Nuclear receptors have two defining structural and functional features; first an N-terminal 
(sometimes, centrally located) conserved zinc finger DNA-binding domain (DBD) and 
second, a ligand binding domain (LBD) located at the C-terminus. The complete domain 
organization of a nuclear receptor is described in figure 4.1. The N-terminal domain is 
also called the hypervariable or A/B domain, which contains transcriptional activation 
function which is independent of ligand, and is termed as AF-1 (64). The sequence and 
length of the   A/B domain is highly variable among nuclear receptors.  
 
 
Figure 4.1:  General domain organization of nuclear receptors. Nuclear receptors, in 
general, have five domains (A/B, C, D, E and F) as depicted in the figure. 
 
Moreover, the A/B domain is the most frequent site of alternative splicing and contains a 
variety of kinase recognition sequences. DBD (or C domain) is the most conserved 
domain with two zinc fingers. It recognizes the hexanucleotide response element in the 
target promoter of nuclear receptors. The first Zn- finger contains the proximal-/P-box, an 
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alpha helix, which is responsible for specific recognition of the core half site of the 
response element. The second Zn-finger is comprised of the distal or D-box, which is also 
an α-helix. The D-box can mediate receptor dimerization, which is an important function 
because most nuclear receptors bind to their responsive elements as homodimers (e.g. 
GR, ER) or heterodimers (e.g. TR, RAR). However, NGF1-B, ROR are the example of 
some nuclear receptors which bind to their target as monomers. The response elements 
for nuclear receptors may be direct repeats (DRx, AGGTCA-Nx-AGGTCA, where N is 
any nucleotide and acts as spacer; x could be any number of residues from 0-10), everted 
repeats (ERx, ACTGGA-Nx-AGGTCA) or inverted repeats (IRx, AGGTCA-
Nx_ACTGGA). The DBD is followed by a flexible hinge region, called domain D that 
has a poorly defined function. The second characteristic domain of nuclear receptors is 
the LBD (domain E), which is preceded by domain D and is moderately conserved. This 
domain has an interior hydrophobic pocket for ligand binding and also contains ligand-
regulated transcriptional activation function-2 (AF-2). This function is mainly attributed 
to the 12th helix present on the extreme C-terminus of the domain that helps in co-
activator/co-repressor recruitment. Coactivators/corepressors interact with LBD via 
hydrohphobic interaction mediated by a helical LXXLL motif in co-activators/co-
repressors. Moreover, the LBD along with the DBD can provide an interface for 
dimerization (41). The F domain, which is present at the C-terminus of nuclear receptors, 
has no confirmed function and has variable length among nuclear receptors (3, 29, 57). 
 
Rev-erbβ and Rev-erbα are heme-regulated nuclear receptors that control the expression 
of a number of important target genes involved in metabolism and circadian rhythm. 
They are unique members of the superfamily of nuclear receptors because they: i) use 
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heme as a ligand that helps in recruiting corepressor and, ii) lack the 12th helix in the 
ligand binding domain responsible for AF-2. Although this thesis focuses on human Rev-
erbβ, both Rev-erbβ and Rev-erbα are discussed in this chapter, because they appear to 
have overlapping functional properties. 
 
4.2 Occurrence and expression profile 
Rev-erbα (also known as EAR1 or THRA1 or THRAL or ear-1 or hRev) and Rev-erbβ 
(also known as BD73 or EAR-1R or RVR) are the only two members of the Rev-erb 
group (Group D) and belong to thyroid hormone receptor-like subfamily of nuclear 
receptors (Nuclear receptors nomenclature committee, 1999). The gene encoding Rev-
erbβ is located on chromosome-3, while Rev-erbα is encoded by a gene present on 
chromosome-17 in humans (72). 
 
Rev-erbβ, and Rev-erbα, are conserved among vertebrates and extensively expressed 
during development and in adult life. Both, Rev-erbβ and Rev-erbα are known to be 
present at moderate levels in most human tissues, and have a high expression in 
metabolically active tissues such as liver, adipose tissue, skeletal muscle, and brain (8, 
18, 20, 33, 43, 50). In particular, in mouse, Rev-erbα (97.4 % sequence identity to 
human) exhibits elevated expression in testis and skeletal muscles, while Rev-erbβ shows 
higher expression in the central nervous system. Thus, the wide expression of Rev-erbβ 
and Rev-erbα, in different tissues and different developmental phases of life, indicates 
broad roles of these factors in cell proliferation and physiology (6). 
 
Moreover, Rev-erbs are clock-controlled genes and show a circadian pattern of 
expression, with peak levels in the middle of the day (16, 65). This circadian pattern of 
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expression can be attributed to their role in circadian circuitry, described later in this 
chapter. 
 
4.3 Isoforms 
The rev-erbα gene encodes two splice variants in human and rat. The larger isoform 
encodes a 614-amino acid protein, while the second isoform encodes 508 amino acids.   
Transcription initiation from an internal promoter generates the shorter isoform.  The two 
isoforms differ only in their N-terminal A/B domain (56). 
 
Rev-erbβ also exists in two different isoforms in human; Rev-erbβ1 and Rev-erbβ2, 
which are 579 and 504 amino acids long respectively. Rat is also reported to have two 
isoforms of Rev-erbβ (578 and 383 amino acids long) that may originate by alternate 
splicing.  (20, 54).  
 
4.4 Domain organization  
Rev-erbs have domain organizations that are atypical of nuclear receptors.. They have an 
N-terminal variable domain (A/B region), followed by a highly conserved DNA binding 
domain (DBD, C region), a hinge region (D region) and a C-terminal ligand binding 
domain (E region). Rev-erbs lack the F domain, which is not uncommon among nuclear 
receptors. Sequence identity between Rev-erbα and β is very high in the DBD (98%) and 
moderate in the LBD (74%). The major differences between Rev-erbs occur in the N-
terminal domain (29% sequence identity) and in the hinge region (31% sequence identity) 
(18) (Figure 4.2).  
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Overall, the A/B domains of Rev-erbs are serine rich (Figure 4.3), which is a site for 
posttranslational modification by GSK3β (described later). The DBD has two C4-type 
zinc fingers, which are characterized by four cysteines coordinating one zinc molecule 
with no further sequence similarity. The nuclear localization signal (NLS) of Rev-erbs is 
located within the DBD, which is unusual in the nuclear receptor family (11). 
 
4.5 Mechanism of action:  
Nuclear receptors can repress or activate transcription of target genes via different 
mechanisms. Three basic mechanisms of transcriptional regulation have been described 
and are as follows: Type I nuclear receptors reside in the cytoplasm and translocate into 
the nucleus after dissociation from heat shock proteins and dimerization following ligand 
binding. In the nucleus they bind to their promoter consisting of inverted repeats and 
enhance transcription of their target genes. Examples of this class of nuclear receptors 
includes androgen receptors, estrogen receptors etc. In contrast, type II receptors are 
retained in the nucleus irrespective of the occupancy of the ligand binding domain and, 
bind as heterodimers to their promoters. In general, co-repressors bind to these types of 
unliganded nuclear receptors and convey a repressive signal to the transcription 
assembly. Then, once the ligand is bound to the ligand binding domain, conformational 
changes occur in the nuclear receptor, which in turn release the co-repressor and recruits 
the co-activator. Representative of this class of nuclear receptors are retinoic acid 
receptor and retinoid X receptor. Type III class of nuclear receptors are constitutive 
transcriptional activators and act in a ligand-independent manner. They bind to their 
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response elements as monomers and are categorized as orphan nuclear receptors whose 
endogenous ligands are unknown such as SF-1 (31, 39, 70).  
 
Rev-erbs belong to the type II category of nuclear receptors and are constitutively bound 
to their responsive elements (RevREs; Rev-erb-responsive elements, see section 4.6.1 for 
detail), after translocation from the cytoplasm to the nucleus (68). However, unlike type 
II nuclear receptors, Rev-erbs recruit co-repressor (NCoR) upon liagnd (heme) binding to 
the LBD. They are unable to repress the target genes unless heme is bound to their LBD 
(44, 68). Upon binding of heme, Rev-erb recruits nuclear co-repressor (NCoR) and, in 
turn, NCoR recruits histone deacetylase (HDAC3 for Rev-erbα and HDAC1 for Rev-
erbβ) that results in transcriptional silencing of target genes (47) (Figure 4.3). 
 
Figure 4.3: Transcriptional repression mechanism of Rev-erbs. This figure is based 
on Burris T P, 2008. Mol Endocrinol (10). 
 
Rev-erbs are dominant transcriptional repressors and they suppress trans-activation 
mediated by retinoid related orphan receptors (RORs). Both Rev-erbs and RORs compete 
for the same DNA binding site and modulate expression of the same target genes such as 
  76 
 
Bmal1 (1, 23, 28). However, both Rev-erbs and RORs show a circadian pattern of 
expression with a 180º phase difference (10). 
 
Not much information is available about the mechanism of derepression of Rev-erb target 
genes. Two independent studies have revealed the role of Tip60α and ZNHIT-1 in 
derepression of Rev-erbβ mediated repression. Tip60α and ZNHIT-1 are both recruited to 
the apoCIII promoter by Rev-erbβ, which then results in the removal of Rev-erbβ–
induced inhibition. While Tip60α, a histone acetyltransferase, interacts with and 
acetylates an RxKK motif in the DBD of Rev-erbβ, ZNHIT-1 interacts via its FxLL motif 
with the LBD of Rev-erbβ and predicted to act via recruitment of a chromatin remodeling 
complex (61, 62). Sauve and colleagues have also shown in vitro interaction of Rev-erbs 
with a novel activator, CIA (NCOA5) in yeast two-hybrid assay. CIA interacts with 
nuclear receptors in an AF-2 independent manner and is predicted to act both as an 
activator and a repressor (52). 
 
Functions of Rev-erbα and Rev-erbβ are quite redundant and are required for rhythmic 
expression of Bmal1 and other target genes (35). Intriguingly, the role of individual Rev-
erbs and their preferential requirement in circadian regulation has not been well 
documented. A comparative study done by Yang and colleagues has demonstrated that 
peak expressions of rhythmic Rev-erbα and Rev-erbβ are at different Zeitgeber Times 
(ZT). They compared the expression profiles of Rev-erbα and Rev-erbβ in four different 
murine metabolic tissues (white adipose tissues, brown adipose tissue, liver and muscle). 
Expression of Rev-erbα  always peaked at ZT4, similar to most of the other nuclear 
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receptors in these tissues, while Rev-erbβ lagged 4 hrs behind and showed a peak 
expression at ZT8 (65).  
 
Rev-erbα and Rev-erbβ, both bind to same responsive element and thus should control 
expression of the same genes; however, only limited studies have examined the 
differential role(s), if any, of both Rev-erbs in gene regulation. Given that the expression 
levels of Rev-erbα and Rev-erbβ vary in most tissues (28) and that peak expression varies 
in different metabolic tissues (65), the requirement for Rev-erbα and Rev-erbβ could be 
spatial and time dependent. It will also be interesting to find out the intricate mechanisms 
by which Rev-erbs act as positive or negative regulators when bound to the same 
evolutionarily conserved DNA binding site.  For example Rev-erbβ, in general, acts as 
negative regulator of genes includingBmal1, however, acts as a positive activator of the  
srebp1c gene described in section 4.8. 
 
4.5.1 DNA binding properties 
Rev-erbs bind to two different but closely related promoter sequences, RORE (ROR-
responsive elements) and Rev-DR2 (Rev-erb direct repeat separated by two nucleotides).  
RORE is not strongly conserved and its consensus is PuAPuNTPuGGTCA. Thus, RORE 
is comprised of a classic hexanucleotide response element (bold letters, shown above),  
plus a 5׳ A/T rich extension (6, 27, 30). The C-terminal extension of the DBD of Rev-
erbα has been shown to interact with this A/T-rich 5׳ extension of a hexanucleotide half 
site (PuGGTCA) that is required for high affinity binding (73). In general, both the Rev-
erbα monomers bind independently to two relatively widely-spaced ROREs and recruit 
one NCoR. Rev-erbβ also requires two distant ROREs in order to suppress target genes 
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(62). Intriguingly, a monomeric Rev-erbα bound to a single RORE cannot recruit NCoR. 
(30, 69, 70) but can repress target genes by competing with RORs (23, 27, 28).  
 
Rev-erbs can also bind cooperatively as homodimers to RevDR2 (30, 70), which are 
composed of a RORE at the 5׳ end and a classic PuGGTCA element (a direct repeat of 
the hexanucleotide of RORE) at the 3׳ terminus, and these two elements are separated by 
two nucleotides (always CT) (30). Quantitative analyses have shown cooperative binding 
of DBD of Rev-erbβ to Rev-DR2 with a 50% fractional saturation at 270 nM (54) 
 
In both the above cases, the Rev-erb monomer binds to an extended hexanucleotide half-
site sequence via a PuGGTCA motif. Moreover, a recognition helix at the C-terminal part 
of the first Zn-finger interacts with the major groove of DNA and makes specific contacts 
with the PuGGTCA motif. The second Zn-finger stabilizes the interaction with DNA via 
a second helix and additionally, allows dimerization in the presence of a partner (6, 53).  
 
4.5.2 Ligand binding properties 
Rev-erbs were thought to be constitutive repressors until heme was discovered as an 
endogenous ligand for Rev-erbs in two parallel and independent studies (44, 68). Heme 
was shown via different spectroscopic methods to bind reversibly to the LBDs of Rev-
erbs. Moreover, heme binding increased the thermal stability of Rev-erbs, demonstrating 
the direct interaction of heme with Rev-erb. Dissociation constants (Kd) for heme were 
found between 2 to 6 μM for Rev-erbα and Rev-erbβ (44, 68). 
 
Less is known about heme binding to Rev-erbα than to Rev-erbβ. The H602F mutant of 
Rev-erbα was unable to bind heme or to recruit NCoR and HDAC3 and was unable to 
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repress the target gene (44, 68). Therefore, it is plausible that His602 is a heme ligand for 
Rev-erbα as is His568, the analogous residue in Rev-erbβ whose ligation, along with 
Cys384, was clearly revealed by crystallographic studies (42). However, no further 
studies were done to determine whether the Rev-erbα heme is a penta- or hexa-
coordinated. 
 
Cys384, which is one of the heme ligands in Rev-erbβ, also is a part of heme regulatory 
motif (HRM), present in many heme binding proteins. A cysteine residue flanked by a 
proline forms the core of HRM (also called CP motif) and has been shown to responsible 
for heme mediated activity and stability of proteins harboring them (71). The Cys384 CP 
motif in Rev-erbβ and analogus CP motif in Rev-erbα are conserved among most of 
species that harbor these proteins. Interestingly, Rev-erbα possesses several additional CP 
motives (2 in the LBD, 2 in the A/B domain and in the D domain), which are absent in 
Rev-erbβ (Figure 4.3). However, the role, if any, of these additional CP motif is not 
known.  
 
Further studies of heme ligation to Rev-erbβ have disclosed that the protein is capable of 
binding to both ferric and ferrous heme and that internal heme ligands can be replaced by 
other amino acids or diatomic gases (42). However, the physiological relevance of this 
ligand switching is not clear at this point. 
 
Many synthetic ligands have also been identified for Rev-erbs. The first synthetic ligand, 
{1,1-dimethylethylethylN-[(4-chlorophenyl)methyl]-N-[(5-nitro-thienyl)methyl]glycinate 
}, was found soon after the discovery of heme as an endogenous ligand. This synthetic 
ligand acted as an agonist and reset the circadian rhythm in a phasic manner (EC50=250 
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nM) in a cell-based assay (37). Recently, GSK4112/SR6452, a synthetic ligand, was also 
found as an agonist of heme and was shown to regulate NCoR binding (32). Furthermore, 
SR8278 was shown to behave as Rev-erbs antagonist (EC50=470 nM) and caused 
derepression of target genes of Rev-erbs (31). 
 
4.6 Regulation of expression and activity of Rev-erbs: 
 Expression of Rev-erbs is regulated at both transcriptional and post-translational levels 
(Figure 4.4).  Rev-erbs are clock genes and their expression is controlled by different 
clock genes as well. Expressions of Rev-erbs are enhanced by BMAL1/CLOCK 
heterodimers and are indirectly suppressed via PER and CRY. 
 
Figure 4.4: Regulation of expression/activity of Rev-erbs via different mechanisms. 
The figure is based either on the individual findings with Rev-erbα or Rev-erbβ and/or 
findings that applies to both of them (please refer to the text for detail). Promoter regions 
are represented by double helixes and names of the promoters are given beneath the 
helix. Proteins translated from the transcription products of genes under the influence of 
these promoters are shown in rectangles and indicated via arrow of the same color. 
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Rev-erbα is also able to modulate its own expression and activity via controlling the 
expression of PGC-1α (69). Rev-erbα downregulates the expression of PGC-1α, which is 
required for ROR-mediated induction of Rev-erbα expression. However, such an auto-
regulation of Rev-erbβ is not known. Moreover, PGC-1α is also required for expression 
of δ-ALAS1 (δ-amino levulinate synthase1), a rate-limiting enzyme in heme 
biosynthesis. Thus, Rev-erbα controls the biosynthesis of its own ligand and therefore 
modulates its own activity. 
 
At the post-translational level, Rev-erbα is stabilized via serine phosphorylation 
(FPPS55PTGS59LTQDPA) at its N-terminus by GSK3β, and this site is conserved in 
human, mouse and rat Rev-erbs (67). This is counterintuitive because GSK3β-mediated 
phosphorylation in general, targets proteins for proteasomal degradation (15). 
Phosphorylation via GSK3β stabilizes the Rev-erbα protein and inactivation of GSK3β 
results in ubiquitination leading to 26S proteasome-directed degradation of Rev-erbα. 
Interestingly, lithium, which is used for bipolar treatment, inhibits GSK3β and causes 
Rev-erbα protein level to diminish without affecting mRNA level (67). 
 
In addition to the aforementioned global regulation of Rev-erbα, limited studies have 
shown liver-specific regulation of Rev-erbα. PPARα directly induces the expression of 
Rev-erbα in the hepatic system in the presence of the PPARα agonist, fibrates (26). 
Glucocorticoid down regulates the expression of Rev-erbα in liver via glucocorticoid 
receptor (55). Moreover, liver X receptor (LXR) α also induces Rev-erbα expression 
directly in human macrophages (22). 
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4.7 Role of Rev-erbs in different cellular processes 
Rev-erbs regulate divergent cellular processes including circadian rhythm, metabolism, 
inflammation, growth and development (Table 1). The following two sections below 
describe genes regulated by either Rev-erbα or Rev-erbβ or both in different tissues and 
cellular processes. 
 
4.7.1 Role in Circadian rhythm 
Circadian rhythms are generated and sustained by transcriptional feedback loops 
contributed by clock genes (Figure 4.6). Brain and Muscle Arnt-Like protein 1 (BMAL1) 
and Circadian Locomoter Output Cycles Kaput (CLOCK) proteins form a heterodimeric 
complex and induce the expression of cryptrochrome (cry1, cry2) and period (per1, per2 
and, per3) genes. Once PER and CRY reach saturation levels, they inhibit BMAL1-
stimulated expression via binding to the BMAL1/CLOCK heterodimer in the nucleus. 
RORs upregulate the expression of BMAL1. On the other hand, Rev-erbs cause the 
transcriptional silencing of the bmal1 gene and are required for rhythmic expression of 
BMAL1 (10). Recent studies demonstrated that Rev-erbα also downregulates the 
expression of CLOCK and NPAS2 (CLOCK homolog in brain) (13, 14). Additionally, 
both Rev-erbα and Rev-erbβ can suppress the expression of Rev-erbα (1). Interestingly, 
expression of Rev-erbs is upregulated via RORα and the BMAL1/CLOCK heterodimer 
(Figure 4.6) (10). Hence, Rev-erbs form a negative feedback loop that connects the 
negative limb to the positive limb of the circadian rhythm. 
  
4.7.2 Role in Metabolism 
Rev-erbs are highly expressed in metabolic tissues, as mentioned above in sections 4.2.1. 
In these tissues, Rev-erbs control genes involved in glucose metabolism, fatty acid 
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metabolism, bile acid synthesis and heme biosynthesis. These target genes are described 
below in tissue specific manner. 
 
Gene Function/Pathways Rev-erbα Rev-erbβ Reference 
Bmal1 Clock gene √ √ (10, 66)  
Npas2 Clock gene √  (14)  
Clock Clock gene √  (13)  
Rev-erbα Clock gene √ √ (1)  
PGC-1α Heme biosynthesis and others √  (69)  
Glucose-6-
phosphatse Gluconeogenesis √  (68)  
mir-122 Cholesterol and fatty acid metabolism √   (25) 
apoCIII Fatty acid metabolism √ √  (12, 50) 
APOAI Fatty acid metabolism √  (59)  
Srebp1c Fatty acid synthesis  √ (46)  
Cyp7A1 Bile acid synthesis √ √ (40)  
SHP Bile acid synthesis √  (17, 34)  
E4BP4 Bile acid synthesis √  (17, 34)  
NF-кB Inflammation √  (38)  
N-myc Neural tumerogenesis √ √  (19) 
PAI-1 Fibrinolysis inhibition √  (63)  
α-fetoprotein Embryogenesis √  √  (7)  
 
Table 4.1: List of various genes under control of Rev-erbs. (√) indicates whether Rev-
erbα or Rev-erbβ is involved in regulation of the particular gene. 
 
 
4.7.2.1 Skeletal muscle metabolism: Rev-erbβ regulates numerous genes in skeletal 
muscles such as myostatin involved in myogenesis (45) or FAT/CD36 and FABP3/4, 
which facilitate uptake of long chain fatty acids and low-density lipoproteins (45). While, 
Rev-erbβ, in general, is a negative transcriptional regulator, it can induce expression of 
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the srebp1c gene that plays a role in lipogenesis (46). No gene target for Rev-erbα in 
skeletal muscle has been described so far. 
 
 
Figure 4.5: Molecular mechanism responsible for circadian oscillations. The figure is 
based either on the individual findings with Rev-erbα or with Rev-erbβ or findings that 
applies to both of them. The promoter regions are represented by double helixes and 
names of the promoters are given beneath the helix. The proteins translated from the 
transcription product of the genes under the influence of these promoters are shown in 
rectangles and are indicated by red arrows. This figure has been modified from Burris, T. 
P. Mol Endocrinol, 2008 (10). 
 
4.7.2.2 Adipose tissues metabolism: Rev-erbα induces adipogenesis, although   its exact 
target in adipose tissue is not known (60). The role of Rev-erbβ has not been well studied 
in adipogenesis. However, it is known that Rev-erbβ together with Rev-erbα is regulated 
in a biphasic manner upon induction of adipogenesis (47). 
 
4.7.2.3 Liver metabolism: Besides regulating clock genes (described in section 4.7.1), 
Rev-erbα along with Rev-erbβ suppresses the expression of apolipoprotein CIII (apoCIII) 
in liver (12, 49). Thus, mice lacking Rev-erbα exhibit elevated levels of apoCIII with an 
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increase in serum triglycerides and VLDL (48). Rev-erbα also regulates the expression of 
Apolioprotein A1, a component of high density lipoprotein (HDL); however this 
regulation is species-specific and is observed in rats but not in humans (59). Rev-erbα 
also plays a role in gluconeogenesis by regulating expression of glucose-6-phosphatase 
(68).  
 
 Rev-erbα and Rev-erbβ positively regulate bile acid metabolism by maintaining the 
robust and circadian expression of cholesterol 7α-hydoxylase, (CYP7A1), the first and 
rate limiting enzyme in the bile acid production pathway (40). Additionally, both Rev-
erbα and Rev-erbβ negatively regulate the expression of SHP and E4BP4, which are 
negative regulators of CYP7A1 (17, 34). 
 
Recently, Rev-erbα was shown to regulate the highly abundant liver-specific microRNA, 
mir-122 (25), which appears to regulate cholesterol and fatty- acid metabolism in adult 
mouse liver (21). Furthermore, Elovl3 (present in both liver and adipose tissue), which 
encodes a very long chain fatty acid elongase, has recently been identified as a Rev-erbα 
target (2). 
 
4.7.2.4 Heme biosynthesis: Biosynthesis of heme, which is a ligand for Rev-erbs, occurs 
in all cell types and therefore, has been described here separately. Interestingly, Rev-erbα 
regulates the synthesis of its own ligand. Heme biosynthesis, in general, is upregulated by 
NPAS2 and PGC-1α (coactivator). NPAS2 and PGC-1α induce the expression of 
ALAS1, a rate-limiting enzyme in heme biosynthesis. Rev-erbα, intriguingly, has been 
shown to down regulate both NPAS2 and PGC-1α and thus inhibit heme synthesis (14, 
69). 
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In addition to above mentioned roles, Rev-erbs are also involved in the inflammation 
cascade, fibrinolysis and embryogenesis. For example, Rev-erbα mediates expression of 
inflammatory cytokines such as IL-6 and COX-2 via NF-κB trans-activation in vascular 
smooth muscle cells (38). In addition to have a role in inflammation, Rev-erbα also 
interferes with the fibrinolysis cascade by inhibiting RORα-mediated induction of the 
plasminogen activator inhibitor (PAI)-1, and may support the development of 
atherothrombosis (58, 63). Furthermore, Rev-erbs also play a role in embryonic 
development by regulating the expression of α-fetoprotein, which is expressed in the yolk 
sack, fetal liver and intestine (7).  
 
Overall, Rev-erbs, which are clock genes, not only maintain the circadian rhythm of 
clock genes but also regulate huge numbers of metabolic genes and some genes involved 
in inflammation, growth and development. A causal relationship between altered 
circadian rhythm and metabolic disorders has already been observed.  For example, 
disruption of clock genes causes dyslipidemia, insulin resistance and obesity, all leading 
to atherosclerosis (16).  Therefore, Rev-erbs have been predicted to connect metabolism 
with circadian rhythm. Moreover, Rev-erbs might also be able to connect inflammatory 
responses, growth and development with circadian rhythm provided their widespread role 
in all these cellular processes. Therefore, study of regulation of Rev-erbs’ will open new 
opportunities for understanding the circadian control of many physiological events. 
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Chapter 5 
 
THIOL-DISULFIDE REDOX DEPENDENCE OF HEME BINDING AND HEME 
LIGAND SWITCHING IN THE NUCLEAR RECEPTOR, Rev-erbβ 
 
 
 
Results described in this chapter have been published (except the limited proteolysis 
experiment) and the reference is as follows: Gupta, N., and Ragsdale, SW. 2011. Thiol-
Disulfide Redox Dependence of Heme Binding and Heme Ligand Switching in the 
Nuclear Hormone Receptor, Rev-erbβ. J. Biol. Chem. 286(6):4392-403. Epub 2010 
Dec 1. 
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5.1 Abstract 
Rev-erbβ is a heme-binding nuclear hormone receptor that represses a broad spectrum of 
target genes involved in regulating metabolism, the circadian cycle and proinflammatory 
responses. Here, we demonstrate that a thiol-disulfide redox switch controls the 
interaction between heme and the ligand-binding domain of Rev-erbβ. The reduced 
dithiol state of Rev-erbβ binds heme five-fold more tightly than the oxidized disulfide 
state. By means of site-directed mutagenesis and by UV-visible and EPR spectroscopy, 
we also show that the ferric heme of reduced (dithiol) Rev-erbβ can undergo a redox-
triggered switch from imidazole/thiol ligation (via His568 and Cys384, based on a prior 
crystal structure) to His/ neutral residue ligation upon oxidation to the disulfide form.  On 
the other hand, we have found that a change in the redox state of iron has no effect on 
heme binding to the ligand-binding domain of the protein. The low dissociation constant 
for the complex between Fe3+- or Fe2+-heme and the reduced dithiol state of the protein 
(Kd ~ 20 nM) is in the range of the free intracellular  heme concentration. We suggest that 
this thiol-disulfide redox switch is one mechanism by which oxidative stress is linked to 
circadian and/or metabolic imbalance. Heme dissociation from Rev-erbβ derepresses the 
expression of target genes in response to changes in intracellular redox conditions. We 
propose that oxidative stress leads to oxidation of cysteine(s), thus releasing heme from 
Rev-erbβ and altering its transcriptional activity.  
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5.2 Introduction 
Rev-erbs are transcriptional repressors that are present in the nucleus and bind as a 
monomer to the Rev responsive element (RevRE) or as a dimer to a Rev-RE direct 
repeat, RevDR-2 (11, 57). Rev-erbs were considered to be the orphan nuclear receptors 
until recently, when the Drosophila ortholog of human Rev-erb (E75) (45) and then Rev-
erbα (43, 68) and Rev-erbβ (43) were demonstrated to bind heme at their LBDs. Heme 
binding to Reb-erbs promotes recruitment of nuclear corepressor (NCoR) and histone 
deacetylase (HDAC) (39, 43, 67). Rev-erbα recruits HDAC3, while Rev-erbβ recruits 
HDAC1 (10, 43, 68). In turn, the Rev-erb-NCoR-HDAC complex facilitates the 
repression of target genes involved in glucose, lipid and bile acid metabolism, as well as 
in regulating the circadian cycle and the proinflammatory response (10, 46, 67). 
Therefore, Rev-erbα and Rev-erbβ have been proposed to link metabolism and 
inflammation to the circadian clock (4, 11, 27, 44). Because heme controls the activity of 
Rev-erb, understanding regulation of heme binding is of special significance. 
 
Several recent studies have focused on the relationship between heme and Rev-erbs. 
Heme has long been implicated to play a key role in maintaining the circadian rhythm via 
binding to different circadian proteins such as NPAS2 and mPer2 (2, 63). 
Correspondingly, heme shows a circadian pattern of expression (24). Rev-erbβ has also 
been recently shown to bind heme and the X-ray crystal structure reveals Cys384 and 
His568 as axial ligands for the ferric heme (39), similar to the Drosophila homolog, E75 
(7). A ligand switch appears to occur upon reduction of the Fe3+-heme to Fe2+ with His 
568 proposed to remain as one of the Fe2+ ligands. Raman and MCD data indicated the 
presence of one or two neutral ligands in the Fe2+ state (34).  
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Here, we show that a thiol-disulfide redox switch regulates binding of heme to the ligand-
binding domain (LBD) of Rev-erbβ. Heme binds more tightly to the reduced dithiol state 
of Rev-erbβ, forming a complex with a dissociation constant that is similar to the low 
nanomolar intracellular concentration of free heme. Mass spectrometric and mutational 
analyses reveal that formation of the disulfide bond between Cys384 and Cys374 lowers 
the affinity for heme by ~5-fold. UV-visible and EPR spectroscopic studies with the 
purified protein and with E. coli cells expressing the Rev-erbβ LBD indicate that 
oxidation of Rev-erbβ also triggers a ligand switch converting His/Cys ligated heme to 
another six-coordinated heme ligated via His and an unknown neutral residue. Based on 
EPR spectra, the neutral ligand could be another His, Met or Lys. Increasing the pH 
above 10 also converts the His/neutral residue ligation state of the oxidized protein to 
His/Cys ligation. Our results indicate that the thiol/disulfide redox switch (but not the 
ligand switch) regulates heme affinity. Thus, the present study demonstrates a mechanism 
by which the redox status of Rev-erbβ can alter heme binding and may facilitate its 
ability to regulate the cyclic expression of metabolic and proinflammatory genes in 
response to changes in intracellular redox conditions. 
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5.3 Experimental Procedures 
5.3.1 Protein expression and purification: In all experiments, the LBD (residues 247-
579) of human Rev-erbβ was used. The wild-type Rev-erbβ LBD clone was generously 
provided by Thomas P. Burris (Scripps – Florida). The protein was expressed in a pET-
46Ek/LIC vector as an N-terminal 6X his-tagged protein. All the cysteines were kept 
intact in the protein unless otherwise specified. E. coli cells were grown without any 
heme supplement, unless otherwise stated. The protein was purified using a Ni-NTA 
column (Qiagen, Valencia, CA) and was then dialyzed against a buffer containing 20 mM 
Tris-HCl, 300 mM NaCl, and 10% glycerol, pH 8.0 (Buffer A). No significant amount of 
heme remained bound to the protein after overnight dialysis as was confirmed by the 
pyridine hemochrome assay (1).  
 
5.3.2 Site-directed mutagenesis of Rev-erbβ LBD: Site-directed mutagenesis was 
performed as described previously (16), and all clones were sequenced at the DNA 
Sequencing Core Facility (University of Michigan, Ann Arbor, MI). 
 
5.3.3 Reduction and oxidation of Rev-erbβ LBD: Throughout, we refer to the disulfide 
and dithiol states of the Rev-erbβ LBD when we describe the “oxidized” and “reduced” 
protein; the redox state of the heme, i.e., Fe3+ or Fe2+, is stated explicitly. To generate the 
fully reduced or fully oxidized form of the protein, the following methods were 
employed. To obtain the fully reduced protein, the Rev-erbβ LBD was first incubated 
with a 30-fold molar excess of TCEP (tris (2-carboxyethyl) phosphine) for 30 min on ice 
and then TCEP was removed on a Bio-Gel P-6 (Bio-Rad Laboratories Inc., Hercules, 
CA) column. Therefore no TECP was present while performing experiments with the 
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reduced protein. The number of free thiols in the reduced Rev-erbβ LBD was quantified 
by a 5, 5’-dithio-bis (2-nitrobenzoic acid) (DTNB) assay as described earlier (3, 13, 66). 
The TCEP treatment, incubation, chromatography, and assay were carried out inside an 
anaerobic chamber (Vacuum Atmospheres Co., Hawthorne, CA). Then, the protein was 
transferred to anaerobically closed vials/cuvettes or EPR tubes, thus, maintaining the 
reducing environment. To fully oxidize the protein, the reduced Rev-erbβ LBD was 
treated with 400 μM diamide; alternatively, the air-oxidized protein was used. Complete 
oxidation of thiols was verified by the DTNB assay before performing experiments with 
the oxidized protein. 
 
5.3.4 Heme binding analysis: Heme titrations were performed by difference 
spectroscopy in a double beam spectrometer using 0.2 to 0.5 μM protein, as described 
earlier (66), except that the buffer contained Buffer B (20 mM Tris-HCl, 300 mM NaCl, 
and 10% glycerol, 3% DMSO, pH 8.0). In these titrations, the blank cuvette contained 
buffer, the sample cuvette had both protein and buffer, and heme from a 50 μM stock 
solution was added to both cuvettes. Because heme solutions are prone to dimerization 
and oligomerization, special precautions, as described earlier (66), were taken in 
preparation of the stock heme solutions that were used in the titrations. Briefly, hemin 
(Fe3+-heme) stocks were prepared fresh for each use by dissolving  hemin (Sigma) in 0.1 
M NaOH and 5% DMSO, filtering with a 0.2 μm syringe filter (Amicon, Beverly, MA) 
and diluting to 50 μM by adding an aliquot into a solution of 20 mM Tris-HCl pH 8.0, 
300 mM NaCl, 5 % DMSO, and 10% glycerol. In order to prepare Fe2+-heme, the Fe3+ in 
the 50 μM hemin stock solution was reduced by adding 2.5 mM sodium dithionite in the 
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anaerobic chamber (Vacuum Atmospheres Co., Hawthorne, CA) and was handled 
anaerobically in vials and cuvettes that were sealed with rubber serum stoppers. 
To determine the binding parameters, the data obtained from the heme (7) titrations were 
plotted and fit to an equation describing a single binding site (Equation 1), which is 
quadratic and is used when the Kd value is similar to the concentration of protein, because 
it accounts for the amount of bound ligand in the solution (66). Here, ΔA refers to the 
absorbance difference at 416, 424 and 428 nm between the sample (containing protein 
and added heme) and reference (containing only protein) cuvettes; Δε is defined as the 
difference in extinction coefficient between free and bound heme; and EL is the 
concentration of the heme-protein complex. EL was calculated from equation 2, where E0 
refers to the total protein concentration, L0 to the total heme concentration, and Kd to the 
dissociation constant. Thus, the lines shown in the heme titrations are all theoretical fits 
of the data (the symbols) to these equations.  
 
EL= 0.5(E0+L0+Kd - ((E0+L0+Kd)2 - 4E0*L0)1/2)          [Equation 1] 
                                                      
ΔA=Δε*EL    [Equation 2]    
 
Surprisingly, for Rev-erbβ LBD, the apparent Kd value seemed to depend on the protein 
concentration. When the titration was performed at increasing concentrations of the 
oxidized protein (from 0.4 to 5 μM), the Kd value increased from 0.12 to 2 μM, similar to 
values reported earlier (see above). Likewise, variation in concentration of reduced 
protein from 0.3 to 5 μM resulted in an increase in the Kd from 23 nM to 0.9 μM. It is 
likely that aggregation of Rev-erbβ at higher protein concentrations is responsible for this 
non-ideal behavior in heme-binding experiments. Correspondingly, native gel 
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electrophoresis experiments with the oxidized LBD show high molecular weight species 
that are not present with the reduced protein or with reduced protein that has been freshly 
treated with diamide. When the concentration of the Rev-erbβ LBD was kept below 1 
μM, Kd values in the 0.20 μM range for the oxidized protein and in the 23 nM range for 
the reduced protein were consistently observed. Thus, the high Kd values in the 2-6 μM 
range are likely to be artifactual. Furthermore, free heme concentrations in the cell are 
below 0.1 μM (15, 31, 49) and free heme levels above 1 μM are toxic (49). Thus, we 
continued our experiments using protein concentrations below 1 μM.     
                                                                              
5.3.5 EPR spectroscopy: EPR spectra were recorded at 15 K on an X-band Bruker EMX 
spectrometer (Bruker Biospin Corp., Billerica, MA) containing an Oxford ITC4 
temperature controller, a Hewlett-Packard model 5340 automatic frequency counter, and 
a Bruker gaussmeter. All EPR samples were prepared in Buffer A (see above). Samples 
were frozen with liquid nitrogen before the experiment.  
 
5.3.6 Whole cell EPR spectroscopy: For in vivo detection of the Fe3+-heme complex 
with Rev-erb, whole cell EPR experiments were performed. E. coli cells expressing the 
Rev-erbβ LBD were grown overnight at 25 ºC after induction with 1 mM IPTG and 10 
ml of culture was centrifuged at 2977 x g for 10 min. The pellet obtained was 
resuspended in 100 μL of Buffer B, transferred to an EPR tube, and frozen in liquid 
nitrogen before obtaining the EPR spectrum.  
 
 5.3.7 Alkylation of cysteines: Samples of oxidized and reduced (with 10 mM TCEP) 
Rev-erbβ LBD (2 mg/ml) were subjected to a two-step alkylation protocol, as has been 
described previously (66). Briefly, samples were first treated with iodoacetamide (IAM) 
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in a denaturing buffer and then with 4-vinyl pyridine (VP) after reduction with 10 mM 
TCEP. 
 
5.3.8 Mass-spectrometric analysis: Alkylated Rev-erbβ LBD samples were digested 
with trypsin and analyzed by mass-spectrometry in the Protein Structure Facility at The 
University of Michigan, Ann Arbor. LC-MS/MS was performed on a NanoAqcuity/Qtof 
Premier Instrument (Waters Inc., Milford, MA). See supplementary method for detail. 
 
5.3.9 Quantification of redox states of the cysteines in Rev-erbβ LBD using the 
ICAT technique: OxICAT, a novel mass spectrometric method that couples thiol 
trapping with the ICAT technique to quantify oxidative thiol modifications, was 
performed. For trapping the redox states of purified Rev-erbβ LBD, 100 μg of oxidized 
Rev-erbβ LBD was applied to a two-step alkylation procedure with light/heavy ICAT 
reagents as described previously (30, 62). The alkylated protein was then digested with 
trypsin, and the cysteine-containing peptides, which are linked to biotin, were enriched 
on a cation-exchange cartridge followed by an avidin affinity cartridge (Applied 
Biosystems, Foster City, CA). The biotin tag, which was conjugated to the cysteine-
containing peptides, was removed afterwards and then samples were analyzed by nano-
liquid chromatography/tandem mass spectrometry at the Michigan Proteome Consortium 
to quantify the amounts of reduced (dithiol) protein containing the light ICAT and 
oxidized (disulfide) protein containing the heavy ICAT adduct. For determining the redox 
state of cysteines in Rev-erbβ LBD, different peptides were analyzed containing the 
cysteine(s) of interest. As expected, the high-resolution mass spectra consist of envelopes 
of multiple peaks reflecting the presence of 0.018% 2H, 1.11% 13C, 0.45% 15N, and 
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0.20% 18O in each peptide. The m/z ratios for the oxidized form of these peptides are 9 
(for peptides containing single cysteine) and 18 (for the peptide with two cysteines) mass 
units larger than those for the reduced protein (17). 
 
5.3.10 Protein preparation for spectroscopic analysis at different pHs: The protein 
was dialyzed in AMT (50 mM acetic acid, 50 mM MES and 100 mM triethanolamine, 
pH 8.0) buffer (12). Then heme-protein complex was prepared and UV-visible 
spectroscopy was performed. In these titrations, the blank cuvette contained buffer, the 
sample cuvette had both heme-protein complex and buffer, and NaOH from a 10 N stock 
solution was added to both cuvettes to obtain the spectra at different pHs. The EPR 
samples were prepared by adding 10 N NaOH to heme-protein complex in AMT buffer 
and frozen in liquid nitrogen before recording the spectra at 15K. 
 
5.3.11 Limited proteolysis: Limited proteolysis of Rev-erbβ LBD was carried out by 
trypsin digestion. 20 μg of oxidized or reduced (prepared as described section 5.3.3) Rev-
erbβ LBD in AMT buffer was modified by 2.2 mM iodoacetamide (Sigma) in 10 μl 
reaction in eppendorf tubes. Samples were incubated with iodoacetamide for 30 min in 
the dark. At the same time, trypsin was prepared in 50 mM acetic acid according to the 
manufacturer’s direction (Promega). Then, the desired amount of trypsin was added to 
each tube and tubes were incubated at RT for 5 minutes. The reaction was quenched by 
adding 5X non-reducing SDS-PAGE loading buffer and freezing immediately. A 12% 
SDS-PAGE was run later to analyze the differences in the digestion patterns of the 
oxidized and reduced protein. 
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5.4 Results 
5.4.1 Thiol-disulfide redox regulation of heme binding to Rev-erbβ 
Heme binding studies were performed with the oxidized and reduced forms (assessed by 
the DTNB assay as described in the Experimental Procedures section) of the purified 
LBD of Rev-erbβ and were monitored by difference UV-visible spectroscopy. All heme 
titrations were performed in Buffer A (see experimental procedures for details), unless 
stated otherwise.  
 
 
 
Figure 5.1: Redox-dependent binding of Fe3+-heme to Rev-erbβ LBD: Difference 
absorption spectra and titration curves for oxidized (0.4 µM) (A and B, respectively) and 
reduced (0.3 µM) (C and D, respectively) Rev-erbβ LBD.  Titration of reduced Rev-erbβ 
LBD with Fe3+-heme was performed anaerobically to avoid thioloxidation during the 
experiment.  
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When the oxidized Rev-erbβ LBD was titrated with Fe3+-heme, the difference spectra 
exhibited absorbance changes in the Soret region at 416 nm (Figure 5.1A) and in the 
alpha (567 nm) and beta (537 nm) bands. Titration of reduced Rev-erbβ LBD (after 
TCEP removal) with Fe3+-heme resulted in shifts in the Soret peak to 424 nm, and the 
alpha and beta peaks to 570 nm and 542 nm (Figure 5.1C), which is characteristic of 
His/Cys axial ligands (7, 19).  
 
 
Figure 5.2: UV-visible spectra of the Rev-erbβ LBD-heme complexes in different 
redox-states.  The spectra shown are of the complexes between oxidized LBD and Fe3+-
heme (Fe3+-Ox), reduced LBD and Fe3+-heme (Fe3+-Red), and reduced LBD and Fe2+-
heme (Fe2+-Red). The spectra were recorded in Buffer B with 10 μM protein and 9 μM 
heme. Inset: Five-fold vertical expansion of the spectral regions between 500-600 nm to 
better exhibit the alpha and beta peaks. 
 
The UV-visible spectra of the oxidized and reduced protein-heme complexes are shown 
in figure 5.2, and show similar peaks shifts as observed in the difference spectra (Figure 
5.1). The oxidized protein with bound Fe3+-heme has its Soret band at 415 nm, while two 
long-wavelength peaks are at 566 and 534 nm. However, the TCEP-reduced protein 
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containing bound Fe3+-heme exhibits a Soret peak at 424 nm and alpha and beta peaks at 
571 and 541 nm, respectively. These spectral changes between the oxidized and reduced 
protein in the Fe3+-heme state indicate that a ligand switch is associated with 
oxidation/reduction of the Rev-erbβ LBD (this conclusion is verified by the mutagenesis 
and EPR studies described below). By plotting the change in absorbance at 416 nm (for 
the oxidized LBD) or at 424 nm (for the reduced protein) versus the concentration of 
added Fe3+-heme, typical hyperbolic profiles were obtained, indicating saturation 
binding. When the data for the oxidized protein were fit to Equation 1, the Kd value was 
117 nM (Figure 5.1.B), significantly lower than the values of ~2 μM (43) or ~6 μM (39) 
reported earlier. Furthermore, the reduced protein binds Fe3+-heme even more tightly, 
with a Kd value of 23 nM (Figure 5.1.D). Because the crystal structure identified His568 
and Cys384 as heme ligands, we performed heme titrations of the H568R, H568A and 
C384A variants. The heme binding affinities of these variants, both in oxidized and 
reduced states, were significantly lower than those of the wild-type protein (Table 5.3). 
The Kd for the complex between heme and the H468R variant is about 20-fold higher 
than that for the H568A mutant, suggesting that this substitution may have an additional 
effect on the active site other than simply removal of the heme ligand. 
 
Because the heme binding assays demonstrated that oxidation of the protein weakens 
affinity for heme, we used LC-MS/MS analyses to determine if Cys384 forms a disulfide 
bond and (if so) which residue it is linked to, as well as to evaluate the redox-status of all 
seven cysteines present in the LBD. Initially, we performed the LC-MS/MS analysis of 
the trypsin-digested oxidized protein and searched for the peptides carrying disulfide 
bonds. The result of this analysis is described in Table 5.1, which compares the predicted 
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molecular mass of each peptide (based on sequence) to the experimentally determined 
mass. The intensity values given in the table do not measure the absolute quantity of a 
peptide, but quantify the relative abundance under similar LC-MS/MS conditions. Intact 
disulfide bonds were found between Cys337-Cys343, Cys374-Cys384, and Cys355-
Cys374 in their respective peptides. Two other disulfides, Cys301-Cys311 and Cys355-
Cys384 were also detected but with very low ionization intensity. The disulfide bonds 
between Cys301-Cys311 and Cys337-Cys343 were present in single peptides. Because 
there are trypsin cleavage sites between the interlinked cysteine residues, the other three 
disulfide bonds connected two peptides. Nevertheless, all the detected disulfides appear 
to be intra-molecular, because no dimeric form of the protein was observed in non-
reducing SDS-PAGE analyses of the oxidized protein. 
 
 
 
 
Table 5.1: Disulfide bonds analysis after mass-spectrometry of unmodified air-
oxidized Rev-erbβ LBD. a relative molecular mass based on the matched peptide 
sequence; b, observed m/z factored by z; c counts per second; **These peptides had very 
low ionization intensity. 
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LC-MS/MS was also performed on tryptic-digested products of the oxidized and reduced 
Rev-erbβ LBD that had been subjected to the two-step alkylation with iodoacetamide and 
vinyl pyridine, as previously described (41). This analysis further confirmed the 
involvement of all the above mentioned cysteines in disulfide bonds, in the oxidized state 
of the protein (Table 5.2). In the reduced protein, all Cys residues were modified by IAM, 
confirming that all Cys residues are in the thiol(ate) state in the reduced protein. In the 
oxidized protein, Cys301 and Cys311 from peptide 290-323 and Cys337 and Cys343 
from peptide 326-353 showed only 4-VP modifications, indicating that these cysteines 
were involved in disulfide bond in the oxidized protein. However, peptides containing the 
other three cysteine residues (Cys355, Cys374 and, Cys384) were detected with both 
IAM and 4-VP modifications in different fractions. This might result from incomplete 
oxidation of the cysteines. Regardless, the peptide containing 4-VP-modified Cys 384 
(peptide 380-388) was almost 50 times more abundant than that containing IAM 
modification. Moreover, the peptides containing Cys374-Cys384 was 1.6-fold more 
abundant than the peptides containing Cys355-Cys384. Thus, based on the above two 
mass-spectrometric analyses, we hypothesize that Cys384 may form a disulfide with 
either Cys374 or Cys355.  
 
To test the above hypothesis about Cys384, we used the oxICAT method to quantify the 
redox state of cysteines in the oxidized protein. As described under Experimental 
Procedures, we treated Rev-erbβ LBD with the light ICAT reagent, reduced all existing 
oxidative thiol modifications and alkylated all newly reduced thiols with the heavy ICAT. 
Thus, a peptide containing a free Cys thiol(ate) will have an m/z value that is 9 units 
smaller than one containing a Cys that is engaged in a disulfide bond (17). Mass spectral 
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analysis of the affinity-purified tryptic peptide harboring Cys384 (MHLVC384PMSK) 
reveals peaks at 1288.69 and 1297.65 (+9), with the major peak at 1297.65, resulting 
from labeling with one heavy ICAT molecule (Figure 5.3). Similarly, peptides containing 
Cys374 (NSYLC374NTGGR) and Cys355 (VC355DRVPIDGFSQNENK) showed major 
peaks at 1320.64 (+9) and 2057.02 (+9) from the addition of one heavy ICAT molecule 
(Figure 5.3). Thus, the majority of the oxidized protein contains oxidized forms of Cys 
384 (89%), Cys374 (87%) and Cys355 (92%). In fact, all of the LBD peptides containing 
Cys residues showed major peaks with an increase in their mass by 9 or 18 Da, indicating 
that all cysteines in the oxidized state of the LBD are in the oxidized form (not shown).  
 
 
Table 5.2: LC-MS/MS results of oxidized and reduced Rev-erbβ LBD after two-step 
alkylation. a number of cysteine residues modified; b relative molecular mass based on 
the matched peptide sequence; cobserved m/z factored by z; d cps, counts per second; ND, 
peptide not detected; IAM, idoacetamide; 4VP, 4-vinylpyridine. 
 
To determine which disulfides are involved in regulating heme binding, we generated 
C374S and C355S/C374S variants. Interestingly, mutation of Cys374 to Ser was 
sufficient for the loss of redox-dependent heme binding (Table 5.3). Both C374S and 
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C355S/C374S variants exhibited similar affinity for heme in both oxidized and reduced 
states. The C374S variant has binding constants of 12 nM and 13 nM for the oxidized and 
reduced states, respectively (Figure 5.4 top panel), while the C355S/C374S variant has 
binding constants of 13 nM and 24 nM for the oxidized and reduced proteins, 
respectively (Figure 5.4, bottom panels).  
 
Figure 5.3: Oxidation of cysteines in oxidized Rev-erbβ LBD: OxICAT analysis of the 
redox state of purified and oxidized Rev-erbβ LBD reveals incorporation of heavy ICAT 
(13C) in Cys384 (top panel), Cys374 (middle panel) and Cys355 (lower panel) in their 
respective peptides, which reflects that these cysteines are oxidized upon oxidation of the 
protein. 
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Table 5.3:  Redox-dependent heme binding properties of the wild-type and 
mutants.* Peaks from optical absorption spectra are given in nm. ** Ox = oxidized; Red 
= reduced 
 
Altogether, mass-spectrometric and heme binding analyses demonstrate that disulfide 
bond formation between Cys384 and Cys374 is responsible for lower heme affinity of the 
oxidized Rev-erbβ LBD as compared to the reduced Rev-erbβ LBD.  
 
 
Figure 5.4: Loss of redox-dependent binding of Fe3+-heme to the C374S variant: 
Fe3+-heme titration curves of the oxidized (ox) and the reduced (red) C374S (top panel) 
and C355S/C374S (lower panel) variants. The titrations were performed in Buffer B (see 
Experimental Procedures). Titration of reduced Rev-erbβ LBD variant with Fe3+-heme 
was performed anaerobically to avoid thiol-oxidation during the experiment. 
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5.4.2 A ligand switch occurs upon changing the thiol redox state 
 To further examine the nature of the ligand switch in the Rev-erbβ LBD predicted by the 
UV-visible absorption measurements, X-band EPR experiments were performed on the 
Fe3+-heme-bound oxidized and reduced proteins (Figure 5.5). The EPR spectrum of the 
anaerobically prepared complex of the reduced protein and Fe3+- heme manifests a 
rhombic spectrum with g-values of 2.49, 2.27, and 1.86. These g values are consistent 
with His and Cys axial ligation to a low-spin six-coordinate heme (Figure 5.5.A) (34). On 
the other hand, the predominant EPR spectrum of the complex between the oxidized 
protein and heme has g values (2.96, 2.27, and 1.52) that are characteristic of a low-spin 
six-coordinate Fe3+-heme that is ligated by His and a neutral residue. The minor 
component (~30 %) consists of His/Cys ligation (g values of 2.49, 2.27, and 1.87) (Figure 
5.5.A). The g values (2.96, 2.27, and 1.52) of the major species are fairly close to those 
assigned to a bis-His ligated heme (58); however, because the EPR spectra of His/Lys- or 
His/Met-coordinated heme are similar, the possibility of His/Met or His/Lys ligation can 
not be excluded (5). When Cys384 was mutated to Ala, as expected, the EPR spectrum of 
the oxidized C384A-heme complex exhibited pure His/neutral residue ligation (g values 
at 2.96, 2.27, 1.52), with no detectible g = 2.48 peak. On the other hand, EPR 
experiments of the reduced C384A-heme complex (Figure 5.5.C) did reveal low amounts 
of a low-spin EPR spectrum characteristic of His/Cys ligation (which might be provided 
from another unknown Cys) along with a g = 2.0 species of unknown origin.  
 
Assuming that the EPR spectrum with g values at 2.96, 2.27, and 1.52 originates from 
bis/His ligation, we assessed whether His381, which is near Cys384, might be the ligand 
that replaces Cys384 in this ligand switch. However, as shown in Figure 5.6, the EPR 
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spectrum of the H381A variant is nearly identical to that of the wild-type protein, with no 
diminution in the g = 2.96 peak. To ensure that this His/neutral residue ligation is not due 
to an artifact resulting from the binding of one of the His residues in the His-tag, we 
removed this tag by proteolytic cleavage with enterokinase and performed EPR 
experiments on the oxidized protein. The EPR spectrum of the oxidized tagless variant is 
identical to that of the wild-type protein (Figure 5.6), demonstrating that the His-tag does 
not affect the ligation state of the heme.  
 
 
Figure 5.5: Ligand switching associated with a change in redox-state of Rev-erbβ 
LBD: A. EPR spectroscopic analysis of heme complexes with the reduced and oxidized 
proteins (complexes were prepared at a ratio of 1:1.5 of Fe3+-heme: LBD). B. EPR 
analysis of E. coli over-expressing Rev-erbβ LBD (without or with oxidation by 30 mM 
diamide (DA) for 4 and 8 hours). Inset: Western blot analysis of the EPR samples from 
the diamide treatment at 0, 4 and 8 hrs using anti-penta His antibody. C. EPR analysis of 
C384A-heme and C374S-heme complexes as in panel A. Note: The in vitro experiments 
were performed in Buffer B. The minor peaks at g-values of 2.0 and 1.99 are from the 
buffer. 
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Figure 5.6: EPR analysis of oxidized Rev-erbβ LBDs: EPR spectra of the oxidized 
wild-type protein, the oxidized H381A variant and the tag less oxidized wild-type protein 
are nearly identical. 
 
To further examine whether the LBD binds heme in vivo and whether the Cys-to-
unknown neutral residue ligand switch occurs in growing cells, we performed whole-cell 
EPR analyses on E. coli cells overexpressing the Rev-erbβ LBD. One might criticize the 
use of a bacterial system for these studies; however, use of the oxICAT methodology 
revealed that the redox state of human heme oxygenase-2 under normoxic growth 
conditions, as well as the response to oxidative and reductive conditions, was similar 
whether the protein was expressed in E. coli or in the human embryonic kidney cell line 
(HEK293) (64). Even though the E. coli cells were grown without a heme precursor, the 
cells were amber colored (Figure 5.7.C), indicating that overexpression of the human 
Rev-erbβ LBD induces heightened production of heme in E. coli. The whole-cell EPR 
spectrum exhibited a single rhombic species with identical g-values (g = 2.48, 2.27, 1.86) 
to those obtained for the purified reduced LBD–Fe3+-heme complex (Figure 5.5.B, 0 h), 
confirming that heme binds to the LBD through His/Cys ligation. This spectrum is absent 
when cells lacking the overexpression construct are similarly treated. When cells were 
treated with 30 mM diamide, a partial switch from His/Cys to His/neutral residue ligation 
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was observed. Initially, only the set of g values (2.48, 2.27, 1.86) characteristic of 
His/Cys ligation was detected; then, after 30 min, the spectrum of a His/neutral residue-
ligated species appeared (g = 2.96, 2.27, 1.52). By 8 hrs, there was an equal mixture of 
the EPR spectra from the His/Cys- and His/neutral residue-ligated species (Figure 5.5.B). 
The amount of Rev-erbβ LBD was unchanged throughout the experiment (Figure 5.5.B 
inset). Thus, treatment of the cells with oxidants caused a Cys-to-neutral residue ligand 
switch, as observed for the purified protein. For control experiments, when either the 
H568R, H568A or C384A variants were overexpressed, the cells did not turn red (Figure 
5.7.C) and the whole-cell EPR spectra revealed a pronounced g=4.3 spectrum, without 
detectible amounts of low-spin Fe3+- heme (Figure 5.7.A), even when the growth medium 
was supplemented with δ-ALA (data not shown). Control E. coli cells, not expressing 
Rev-erbβ, also had the same peak (g=4.3), although with lower intensity. The g=4.3 EPR 
spectrum, which is characteristic of “extraneous” iron, probably derives from other iron 
proteins in the cell. Expression levels of the variants are similar to those of the wild-type 
Rev-erbβ LBD (Figure 5.7.B). 
 
Because the mass-spectrometric results (above) demonstrated a disulfide linkage between 
Cys384 and Cys374, we hypothesized that mutating Cys374 would enable free Cys384 to 
ligate heme in the oxidized state of the protein. Thus, EPR experiments of the heme-
bound C374S variant were performed. To our surprise, the variant showed an EPR 
spectrum that was similar to that of the wild-type protein, both in the reduced and 
oxidized states, although, the oxidized C374S variant exhibits slightly more Cys/His 
ligation (43%) than  the corresponding wild-type protein (29%) (Figure 5.5.C). The EPR 
spectra of the C355S/C374S variant are similar to those of C374S (data not shown).  
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Figure 5.7: Whole cell EPR studies of heme binding to the His568R and C384A 
variants: Whole cell EPR analysis of E. coli cells overexpressing WT Rev-erbβ LBD, 
H568R, H568A and C384A variants, without any heme precursor (A) were performed as 
described in Experimental procedures. Expression levels of wild-type Rev-erbβ LBD and 
variants were similar, based on western blot analysis (B). The color of the pellet fraction 
from E. coli cells overexpressing Rev-erbβ LBD was deep red, while mutation of C384 to 
Ala produced a dark green pellet and mutation of H568 to Arg/Ala resulted in a cell paste 
that appears similar in color to that of E. coli cells lacking the expression plasmid (C).  
 
 
Figure 5.8: Absorption spectra of the oxidized Rev-erbβ LBD and variants: The 
absorption (A) and difference (B) absorption spectra of the oxidized Rev-erbβ LBD, 
C384A, C374S, and C355S/C374S variants. The spectral measurements were taken in 
Buffer B with 10 μM protein and 9 μM heme. 
 
Overall, mutation of Cys374 resulted in the loss of the redox-dependence of heme 
binding, but not redox-dependent ligand switching. This indicates that oxidation of 
Cys384 (resulting in a disulfide bond with Cys374) is not solely responsible for the 
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ligand switch. Perhaps, oxidation of Cys384 induces a conformational shift that moves 
Cys384 away from the heme. This hypothesis is supported by the electronic absorption 
spectra (Figure 5.8.) of the oxidized wild-type, C384A, C374S and C355S/C374S 
proteins. Similar absorption spectra of wild-type and cysteine variants indicate similar 
heme ligation states (i.e., His/neutral residue) in the oxidized forms of these variants and 
the wild-type protein (Figure 5.8).  
 
However, unlike the wild-type protein, the oxidized and reduced states of the C374S 
variant bind heme with similar affinities. Therefore, it is the redox switch (oxidation of 
Cys384), not the ligand switch (replacement of Cys384 with other neutral residue) that 
alters the heme binding affinity. It is plausible that a conformational change in the LBD, 
resulting from oxidation of Cys384, might block the heme binding site, thus, decreasing 
the affinity of the oxidized protein for heme. On the other hand, a conformational change 
induced by formation of the disulfide in the Rev-erbβ LBD might cause the ligand 
switching in the protein. The conformational change hypothesis was tested by limited 
proteolysis of the oxidized and reduced Rev-erbβ LBDs (Figure 5.9). The oxidized and 
reduced Rev-erbβ LBDs have markedly different digestion patterns indicating that they 
are in different conformational states. Initially with a lower amount of trypsin (reaction 
2), the reduced state appears to undergo cleavage to form 4 major cleavage products 
along with some minor products. Subsequently, with the use of higher amount of typsin 
(reactions 3 to 5), these bands are ultimately degraded to two main cleavage products 
around 25 and 20 kDa. On the other hand, the oxidized protein shows only one major 
cleavage products with some minor products at the lowest trypsin (reaction 2) 
concentration unlike the reduced protein. The cleavage products between 25 to 37 kDa 
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regions are more stable in the oxidized protein as compared to the reduced protein at 
various trypsin concentrations used (reactions 1 to 5). When a very high concentration of 
trypsin was used (reaction 5), all cleavage products in the oxidized protein also  
accumulated in two main cleavage products at 25 and 20 kDa similar to the reduced 
protein with a minor cleavage product below the band at 25 kDa.  Theses data show that 
the oxidized state of the protein is much more resistant to degradation as compared to the 
reduced protein. Non-overlapping digestion patterns of the oxidized and reduced proteins 
indicate dissimilar accessibility of trypsin to these two forms and thus predict their 
different conformation, at least, around trypsin digestion sites. 
 
 
Figure 5.9: Limited proteolysis of oxidized and reduced Rev-erbβ LBD: SDS-PAGE 
analysis of products of trypsin mediated limited proteolysis of the reduced (R) and 
oxidized (O) Rev-erbβ LBDs. Conditions for limited proteolysis are specified in 
experimental procedures. Different ratios between the protein and trypsin used are given 
below the gel; M = molecular weight marker.  
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5.4.3 pH dependent ligand switch in the oxidized Rev-erbβ LBD 
 Apart from the redox-dependent ligand switch, the oxidized protein shows a pH-
dependent switch from His/neutral residue to His/Cys ligation. At increasing pH values, 
the Soret peak of the wild-type oxidized protein showed a red-shift from 416 nm to 424 
nm along with a significant decrease in intensity from pH 8 to pH 10 (Figure 5.10.A) and 
the color of the complex changed from dark red to green over the pH range from pH 8 to 
pH 10. The titrations could not be performed at lower pH values, because the protein 
precipitated below pH 7. Similar observations were made for the C374S variant (Figure 
5.10.C). Similarly, EPR spectroscopic results indicate a ligand switch from His/neutral 
residue to His/Cys ligation above pH 10 for wild-type LBD (Figure 5.10.B) and for the 
C374S (Figure 5.10.D) variant. It is plausible that a base-induced cleavage of the 
Cys374-Cys384 disulfide bond occurs at pH 10, which releases Cys384 for ligation to the 
heme.   
 
As the pH is increased, a minor amount of high-spin heme (g~6.2) is observed, as seen 
earlier with cytochrome b561 (58). In addition, a small amount of a low-spin species with 
a g value at 2.68 appears which could result from His /water ligation (66). Furthermore, a 
peak at g=4.3 is observed which is likely to reflect heme decomposition. Nevertheless, 
the physiological relevance of this pH-dependent ligand switching is not clear at this 
point. 
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Figure 5.10: pH dependent ligand switching of oxidized Rev-erbβ LBD: Titration of 
the oxidized wild-type Rev-erbβ LBD (A) and the C374S variant (C) with NaOH shifts 
the Soret peak from 416 nm to 424 nm, indicating a ligand switch from His/neutral 
residue to His/Cys B. EPR analysis of the oxidized wild-type protein-heme (B) and the 
oxidized C374S mutant-heme (D) complexes also show ligand switching from 
His/neutral residue (2.96, 2.27 and 1.52) to His/Cys (2.48, 2.27 and 1.88) upon increasing 
the pH from 8 to 10. Note: AMT buffer was used in both the above analyses in order to 
provide higher stability to the protein at pH values above 8 (see experimental procedure).  
 
 
5.4.4 No effect of change in iron redox state on heme binding affinity 
 Pardee et al. (39) recently showed that Rev-erbβ is capable of binding both Fe3+- and 
Fe2+-heme. We performed Fe2+-heme titrations to determine if the reduced protein prefers 
Fe3+- versus Fe2+-heme. All titrations with Fe2+-heme were performed in anaerobically 
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closed vials in the presence of 2.5 mM sodium dithionite to prevent oxidation of the Fe2+-
heme to Fe3+. The absorption spectrum of Fe2+-heme–reduced Rev-erbβ LBD complex is 
shown in figure 5.2. The spectrum has a Soret band at 428 nm and alpha and beta bands 
at 560 and 530 nm, respectively, indicating that the Cys ligand is released from the Fe2+-
heme (22, 26). Similarly, the difference spectrum of the complex between the reduced 
Rev-erbβ LBD and Fe2+-heme exhibited a Soret peak at 428 nm along with the alpha 
(560 nm) and beta (530 nm) bands (Figure 5.11.A). Titration of the reduced Rev-erbβ 
LBD with Fe2+-heme resulted in a sharply saturating binding isotherm (Figure 5.11.B), 
which, when fit to the quadratic equation (Eq 1) gave a Kd value in the low nM range (Kd 
= 15.8 ± 4.1 nM). This Kd value is similar to that obtained in the titration of the reduced 
form of the Rev-erbβ LBD with Fe3+-heme (above). Thus, the reduced protein exhibits 
similar high affinity for Fe2+- and Fe3+-heme. Because dithionite, which is used to reduce 
the heme, also reduces the disulfide groups in the LBD, it is not possible to determine the 
Kd of the oxidized protein for Fe2+-heme. 
 
Figure 5.11: Similar affinity of reduced Rev-erbβ LBD towards Fe3+- and Fe2+-
heme: The Rev-erbβ LBD (0.3 µM) was anaerobically titrated with Fe2+-heme in Buffer 
B, in the presence of 2.5 mM dithionite. The Soret peak for Fe2+-heme is at 428 nm and 
exhibits sharp alpha and beta peaks at 560 and 530 nm, respectively (A). The Kd values 
of the complexes of Fe3+- and Fe2+-heme with reduced Rev-erbβ LBD are 23 ± 2.7 nM 
(Figure 5.1.D) and 15.8 ± 4.1 nM (B), respectively.  
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Magnetic circular dichroism and resonance Raman spectroscopic experiments have 
revealed that the Fe2+-heme bound to Rev-erbβ can exist in a five-coordinate environment 
with a single neutral ligand as well as a six-coordinate state with two neutral ligands (34). 
His568 has been postulated to remain as an axial ligand in the Fe2+-state. To further 
examine the ligand environment of Fe2+-heme, we determined the affinity of the H568R 
variant for Fe2+-heme. Substitution of His568 by  Arg severely diminished the affinity of 
the Rev-erbβ LBD for Fe2+ heme (Kd = 1.52 ± 0.49 μM). On the other hand, mutation of 
C384 to Ala had a more modest effect on the affinity (Kd = 210 ± 30 nM) for Fe2+-heme 
(Table 5.3). These observations lend further support for the conclusion that in the Fe2+ 
state, His568 remains as an axial ligand, while Cys384 ligation might be lost. 
Dissociation of a thiolate anionic ligand upon reduction of Fe3+-heme is a fairly common 
phenomenon (40).   
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5.5 Discussion 
Rev-erbα and Rev-erbβ are heme-binding nuclear receptors that are highly expressed in 
the brain, liver, adipose tissue and skeletal muscle. The Rev-erbs exhibit circadian 
patterns of expression and play important roles in controlling the expression of genes 
constituting the primary transcriptional-translational feed back loop that regulates the 
vertebrate circadian clock (48, 54). This primary negative feedback loop involves a 
highly conserved suite of proteins (CLOCK, the CLOCK paralog NPAS2, BMAL1, Per1, 
Per2, Cry1 and Cry2) that are expressed within the suprachiasmatic nucleus (SCN) of the 
hypothalamus, the central circadian pacemaker in humans, as well as in peripheral tissues 
that are subject to circadian modulation. In this primary feed back loop, the CLOCK-
BMAL1 heterodimer serves as a positive acting transcription factor that activates 
expression of the Cry and Per proteins, which feedback to repress the expression of 
BMAL1. In a secondary negative feedback loop, Rev-erb represses the expression of 
BMAL1 by binding to two ROR response elements in the BMAL1 promoter; yet 
expression of Rev-erb is activated by the CLOCK-BMAL1 heterodimer, which binds to 
E-boxes within the Rev-erb promoter (4, 29, 42). Transcriptional regulation through the 
primary and secondary circadian loops, coupled to post-translational modification and 
degradation of circadian clock proteins (29, 52), synchronizes to the daily light–dark 
cycle a wide range of metabolic and behavioral processes, including the sleep–wake 
cycle, feeding behavior, body temperature, and blood hormone levels (54). 
 
Besides serving as a prosthetic group in enzymes, heme can act as a signaling molecule 
that regulates biochemical and physiological processes as diverse as enzyme and ion 
channel activity, DNA binding, signal transduction and protein complex assembly (36); 
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thus, heme is linked to the circadian cycle at several levels. Like Rev-erb, heme exhibits 
circadian patterns of expression, due at least in part to circadian regulation of ALA 
synthase, the rate-limiting enzyme in heme synthesis (24). Heme also modulates the 
activity of multiple nuclear receptors such as Hap1, HRI kinase, elF2α (36) and several 
key players involved in the circadian rhythm, including Rev-erbα and Rev-erbβ (8, 43, 
63, 67). Heme binding to Rev-erb is required for efficient NCoR recruitment; thus, 
alterations in intracellular heme levels modulate the expression of BMAL1 in a manner 
suggesting that heme stabilizes the Rev-erb-NCoR complex (4). 
 
The intracellular redox state has also been proposed to entrain the circadian oscillator by 
modulating the ability of the CLOCK:BMAL1 and NPAS2:BMAL1 heterodimers to bind 
DNA (48). One mechanism of redox-regulation of gene expression is by thiol-based 
redox modification of nuclear receptors (55). For example, upon treatment with thiol-
oxidizing reagents, the ligand binding activity of the glucocorticoid receptor is severely 
impaired, but is restored by overexpression of thioredoxin (32, 55).  
 
One mechanism by which proteins link redox- and heme-dependent regulation is by thiol-
disulfide regulation of heme binding. For example, human heme oxygenase-2 and the BK 
channel contain redox switches that undergo reversible thiol-disulfide interconversion, 
with different heme binding affinities in the oxidized disulfide state and the reduced state 
(64-66). The HRM consists of a conserved Cys-Pro core sequence that is usually flanked 
at the N-terminus by basic amino acids and at the C terminus by a hydrophobic residue 
(35, 53, 69). Given that the LBD of Rev-erbβ contains an HRM motif (HLVC384PMSK), 
in which Cys384 is a heme ligand (39), we hypothesized that Cys384 may be involved in 
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a ligand switch in which oxidation of this residue would abolish (or reduce) binding of 
Fe3+-heme. Because heme binding to Rev-erb regulates the expression of target genes 
(39, 43, 67), such a redox and/or ligand switch could help explain how intracellular redox 
state and heme metabolism can control the circadian cycle.  Furthermore, since the Cys 
residue appears to dissociate upon conversion to the Fe2+ state (39), we expected that the 
redox state of Cys384 would not affect binding of Fe2+ heme.  
 
Our combined mutagenesis, spectroscopic (EPR and UV-visible) and mass spectrometric 
experiments provide novel insights into redox- and ligand-based changes in the LBD and 
lend support to the conclusions based on previous resonance Raman and crystallographic 
experiments that Cys384 and His568 can serve as the axial ligands to the heme in Rev-
erbβ (34, 39). Based on heme titrations, the reduced state of the Rev-erbβ LBD binds 
Fe3+-heme (Kd = 23 nM) with ~5-fold greater affinity than does the oxidized protein (Kd 
= 117 nM). This change in heme affinity appears to be associated with the reduction of 
the disulfide state of Cys384 (linked to Cys374) to the free thiolate state. With such a 
redox-coupled ligand switch, the Cys residue would only be available for heme ligation 
under reducing conditions within the cell. Mutagenesis studies further indicate that 
Cys384 is redox active, because the EPR spectra of the oxidized C384A variant, which 
has only His/neutral residue ligation to the heme, are similar to those of the diamide-
oxidized wild-type Rev-erb β LBD. It is likely that His568 remains as one of the heme 
ligands in the oxidized protein, because mutation of His568 to either Ala or Arg 
markedly lowered heme binding affinity (Table 5.3). In an attempt to identify the other 
neutral residue that binds heme in the oxidized state, we performed EPR studies on 
mutants of  the residue that seemed most likely to be involved in the ligand switch, e.g., 
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His381, based on the crystal structure of the protein (39). However, the H381A variant 
exhibits an EPR spectrum that superimposes with that of the wild-type protein. Thus, the 
identity of the other neutral residue that can bind heme in the oxidized state of the protein 
is unknown.  
 
The heme titrations quantitatively demonstrate that the reduced state of the purified LBD 
tightly binds heme at the low nanomolar concentrations of free heme present within the 
cell and the in vivo EPR and mutagenesis experiments confirm that the LBD tightly binds 
heme within growing cells. We used E. coli cells for this expression because obtaining 
sufficient numbers of mammalian cells for such an experiment is prohibitive and, at least 
from a redox perspective, the intracellular redox potential of E. coli is ~ -250 mV (38, 
56), which is within the range of the ambient redox potential of mammalian cells, from -
170 to -325 mV (9, 23). Furthermore, when heme oxygenase-2 was expressed in 
mammalian cells grown under different redox conditions, the measured ratios of 
oxidized/reduced thiols were similar to those observed when the protein was expressed in 
E. coli cells that had been treated under similar conditions (64). Therefore, we submit that 
this ex vivo EPR experiment is relevant and likely reflects the redox state of Rev-erbβ in 
mammalian tissues.  
 
That the LBD binds heme with high affinity is also indicated by observation of the 
amber-color of E. coli cells that are overexpressing the LBD in the absence or presence of 
the heme precursor, δ-ALA.  Similarly, when cytochrome b and NPAS2 are 
overexpressed, the bacterial cells exhibit the characteristic amber color of heme (8, 47). 
Earlier studies on heme binding to the Rev-erbβ LBD have yielded Kd values of 2 and 6 
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μM (39, 43), which are problematic because these values are much higher than the 
physiological concentration of free heme (< 100 nM) (37). Based on a 2 μM Kd value, at 
100 nM free heme, ~95% of the Rev-erb population would be in the apo form. However, 
based on the published UV-visible spectra (including Soret peaks for the Fe3+-heme-
bound 415-420 nm) (34, 39, 43, 68), the previous studies were performed with a mixture 
of oxidized and reduced LBD. Our results also indicate that, besides the potential 
problems associated with working with mixed redox states of the LBD, the very high Kd 
values reported in prior studies result from protein aggregation at the high concentrations 
used in those experiments. Here, we show heme binding to the Rev-erbβ LBD at 
physiologically relevant heme concentrations and that heme affinity is redox regulated.  
 
The EPR spectrum of the LBD-bound heme is easily observed in E. coli cells and the g-
values, which are fingerprints for the heme ligation state, can be readily assigned. Thus, 
the mutagenesis and in vivo EPR experiments demonstrate that the switch between 
His/neutral residue and His/Cys coordination environments observed for the purified 
oxidized and reduced proteins also occurs within cells. It appears likely that the 
coordination environment is governed by the ambient intracellular redox potential.  
 
The studies described here also explain the discrepancy noted by De Rosny et al.(6), i.e., 
that, although His/Cys ligation was observed in the crystal structure of Rev-erbβ LBD, 
the Soret peak was unexpectedly at 415 nm. Our results show that the fully oxidized Fe3+-
protein exhibits a Soret peak at 416 nm, while this band for the reduced ferric protein is 
observed at 424 nm, which is characteristic of His/Cys ligation (6, 33). Therefore, the 
crystal structure of the TCEP-incubated protein seems to have trapped one of the two 
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stable states of the protein, i.e., the reduced state, while the His/neutral residue liganded 
state is responsible for the 415 nm band.  
 
A novel aspect of the ligand switch between the His/neutral residue and His/Cys states of 
the Fe3+-heme is that it is regulated by the change in redox state of thiols in Rev-erbβ. 
This ligand switch in Rev-erbβ also can be brought about by changes in the redox state of 
the heme (34), a property that is commonly observed when the iron undergoes redox 
changes between the Fe3+and Fe2+ states (20, 21, 28, 33). In Rev-erbβ, the reduced LBD 
binds Fe2+- and Fe3+-heme with similar affinity (16 nM and 23 nM, respectively). 
Generally the anionic thiolate ligand is replaced upon reduction of the ferric ion (40). 
Based on the earlier experiments (39), it is possible that Fe2+-heme is ligated via His 
only; however, the UV-visible spectrum cannot rule out the possibility of His/Met or 
His/Lys ligation (22, 26). Although the physiological relevance of Fe2+-heme binding is 
not very well established (19), it is clear that replacement of a strong ligand (like thiolate) 
by a weak ligand facilitates reduction of the iron and promotes binding of extrinsic axial 
ligands, like CO, NO or H2S as has been described in chapter 6 (Figure 5.12).  
 
Redox-mediated ligand switching allows adjustment of the activity of heme proteins, in 
response to changes in the ambient redox potential within the cell, which occur during 
oxidative stress or conversely, hypoxia. Oxidative stress, a factor in many important 
diseases (14, 51, 60, 61), is correlated with disruptions in the circadian rhythm (18, 50). 
Oxidative stress may also play a role in different diseases, originating from imbalance in 
circadian rhythm such as shift work sleep disorder (50). Because Rev-erbβ is considered 
to link the circadian cycle and metabolism (44), we consider that under more reducing 
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intracellular redox conditions, Rev-erbβ (containing the reduced thiolate form of Cys384) 
is in its heme-bound state, which is optimal for recruitment of nuclear corepressor and 
repression of target genes. When subjected to oxidative stress conditions, Cys384 of Rev-
erbβ undergoes oxidation to form a disulfide bridge with Cys374. This disulfide and a 
conformational change upon oxidation of the protein, as observed in the limited 
proteolysis experiment, may trigger a ligand switch of heme from Cys/His to His/neutral 
residue. Due to low heme affinity of the oxidized state of the protein, as measured in the 
binding analysis, it might further result in release of bound heme and derepression of 
target genes. These redox- and ligand-dependent changes could then trigger alterations in 
circadian patterns and, if not reversed, result in circadian and/or metabolic disorders 
(Figure 5.12). The effects of heme, redox, and intrinsic ligands on RevErb would likely 
be complemented by those on other heme proteins with key roles in the circadian cycle, 
such as NPAS2 and Per2 (25, 59).  
 
Thus, based on the results described here and with heme oxygenase-2, the redox state of 
the thiol groups in heme proteins may markedly influence their properties, including their 
affinity for heme and their Fe-coordination environment. 
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Figure 5.12: Model for redox modulation of heme binding and heme ligand 
switching in Rev-erbβ. Ferric heme is ligated via Cys384 and His568 in the ligand 
binding domain of the thiol-reduced form of Rev-erbβ (1). Disulfides, formed after the 
oxidation of the protein, change the conformation of the protein, which results in His/NR 
(neutral residue) ligation (His/His or His/Met or His/Lys) of the heme (2). Formation of 
the disulfide bond between Cys374 and Cys384 interferes with heme binding and lowers 
the heme affinity of the protein. This might cause heme release from Rev-erbβ (3) and 
ultimately may result in untimely derepression of target genes and thus circdain and/or 
metabolic imbalance, The LBD can bind ferrous heme with similar affinity to the ferric 
heme (4). In this state, Cys384 appears to be replaced by a neutral ligand, suggested to be 
Met (22, 26). This neutral ligand can replaced by any of the gaseous ligands (5), 
described in the next chapter. The effect of gas binding on the function of the protein is 
either not yet confirmed or has not yet been tested. Note: The part of the figure shown in 
gray box is based on our hypothesis and not on experimental results shown in this chapter 
or anywhere else. 
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Chapter 6 
 
REDOX-SPECIFIC GAS BINDING TO THE LIGAND BINDING DOMAIN OF A 
THIOL-BASED REDOX REGULATED HEME SENSOR; Rev-erbβ 
 
 
 
The CO binding analysis described in this chapter is published and the reference is as 
follows: Gupta, N., and Ragsdale, SW. 2011. Thiol-Disulfide Redox Dependence of 
Heme Binding and Heme Ligand Switching in the Nuclear Hormone Receptor, Rev-erbβ. 
J. Biol. Chem. 286(6):4392-403. Epub 2010 Dec 1. 
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6.1 Abstract 
Reb-erbβ is a heme responsive nuclear receptor that is expressed in various organs and 
tissues, such as brain, heart, liver, spleen, lung, skeletal muscle, adipose tissues, testes, 
and ovaries. In these tissues, Reb-erbβ regulates multiple metabolic genes in addition to 
the clock genes and thus has been predicted to connect metabolism with the circadian 
rhythm. CO and NO are predicted to modulate the activity of Reb-erbβ by binding to its 
heme center. In this study, we have measured CO, NO and H2S binding to the ligand 
binding domain of Reb-erbβ (Reb-erbβ LBD).  We have determined that the Fe2+-heme 
bound to the reduced protein has a high affinity for CO (Kd = 60 nM) but lower affinity 
for NO (Kd ~300 μM) and negligible affinity for H2S.  The reduced (dithiol) form of the 
Reb-erbβ LBD containing Fe3+-heme, on the other hand, lacked affinity for  NO, but 
exhibited moderate affinity for  H2S   (Kd = 1 μM). Further, the oxidized (disulfide) state 
of the Reb-erbβ LBD containing Fe3+-heme showed very low affinity for NO (Kd ~ 9 
μM) and negligible affinity for H2S. The dissociation constants for the complexes 
between the LBD and gaseous signaling molecules are in the physiological range, except 
for NO, which appears to have a much lower physiological concentration (up to 5 nM).  
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6.2 Introduction  
Heme is a prosthetic group in several hemoproteins that include gas sensors, P450 
enzymes, cytochromes, catalases, peroxidases, nitric oxide synthases (NOS), guanylyl 
cyclases and several transcriptional factors (30).  An important attribute of heme-
dependent proteins is their ability to bind gaseous signaling molecules; CO, NO, and H2S 
(10, 26). Diverse functions of these gaseous autocrine/paracrine messengers or 
gasotransmitters are critical to vertebrate physiology and probably to the physiology of 
all living organisms. Gasotransmitters are functionally analogous to hormones but are 
lipid soluble and are not constrained by cellular membranes.  Because gasotransmitters 
are unconstrained and they diffuse down a partial pressure gradient, precise uptake or 
metabolizing processes are not required for signal termination. Signal termination easily 
occurs with the falling concentration of gasotransmitters (17). 
 
In addition to exogenous gas uptake, CO is mainly produced in cells and tissues as an 
elimination product of heme degradation, catalyzed by heme oxygense (HO) (18, 29). 
The biosynthesis of NO, on the other hand, takes place during the conversion of L-
arginine to L-citrulline, and this process is catalyzed by nitric oxide synthase (NOS) (28). 
At a molecular level, CO binds to ferrous heme, whilst NO can bind to both ferrous and 
ferric heme (13). CO has vasoregulatory, anti-inflammatory, anti-proliferative and anti-
apoptotic effects that are largely mediated by guanylyl cyclase and mitogen-activated 
protein kinase (MAPK) signaling pathways (28). Apart from its role in normal 
physiology, the role of CO has also been linked to abnormalities in metabolism in a 
variety of diseases; including neurodegeneration, hypertension, heart failure, and 
inflammation (34). NO also plays a role as a neurotransmitter, vasorelaxant, and has an 
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additional role in immune cells during macrophage-mediated killing of microbes and 
tumor cells (6). Guanyl cyclase and cytochrome c-oxidase have been proposed as major 
physiological targets for NO (11). Furthermore, NO has been implicated in various 
pathophysiological states such as septic shock, hypertension, stroke, and 
neurodegenerative diseases (6).  
 
While NO is the most studied gasotransmitter, H2S is the newest addition to the family of 
gasotransmitters. H2S is generated in mammalian cells by the action of cystathionine β-
synthase (in liver and neuronal tissue) and cystathionine γ-lyase (in cardiovascular 
systems) and by 3-mercaptopyruvate sulfurtransferase (in vascular endothelium, vascular 
smooth muscle and brain) (14, 17, 24). Mechanisms for H2S generation by these enzymes 
using different substrates (5, 14) and H2S generation by numerous other pathways in 
invertebrates have been reported (14, 24). At the molecular level, H2S binds to ferric 
heme and converts it to ferrous heme in Lucina pectinata (26). However, its preference 
either towards ferric or ferrous heme has not been documented yet. Similar to the 
functions of CO and NO, H2S is also suggested to act as a neuroprotector, 
neuromodulator and smooth muscle relaxant/contractor (26). Pathophysiologies 
associated with malfunction of H2S-producing enzymes have been observed and include 
homocytinuria, cystathioninuria and others (14).  
 
 Like some other heme-dependent transcriptional regulators, Rev-erbβ appears to bind 
diatomic (CO/NO) gases (25); however, the affinities have not been measured. Based on 
Raman and MCD studies, it has been proposed that NO/CO replaces Cys384 as an axial 
ligand and that a neutral ligand binds to the sixth coordination site in the (CO/NO)-bound 
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form of Rev-erbβ (19, 25). To ascertain the potential physiological relevance of gas 
binding, we have quantitatively measured the binding affinities of CO NO, and H2S to the 
Reb-erbβ LBD in vitro. CO binding is restricted to Fe2+-heme bound protein. However, 
both NO and H2S show preferential binding towards specific redox states of thiols in 
Rev-erbβ and/or its bound heme, as described in the  Results section. 
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6.3 Experimental procedures 
6.3.1 Protein expression and purification: Expression and purification of the Rev-erbβ 
LBD is described in section 5.3.1. 
 
6.3.2 Reduction and oxidation of Rev-erbβ LBD: Reduction and oxidation of the Rev-
erbβ LBD is mentioned in section 5.3.3. Throughout, we refer to the disulfide and dithiol 
states of the Rev-erbβ LBD when we describe the “oxidized” and “reduced” protein; the 
redox state of the heme, i.e., Fe3+ or Fe2+, is stated explicitly. 
 
6.3.3 Reconstitution of the protein with heme for binding assays:  For the gas binding 
assays, the heme-protein complex was formed first and then passed through two Bio-Gel 
P-6 (Bio-Rad., Hercules, CA) columns to remove any free heme. This heme-protein 
complex was used for gas titrations and binding was detected by UV-visible 
spectroscopy. 
 
6.3.4 CO binding assay: Rev-erbβ LBD-heme complexes were prepared anaerobically 
as described above. For experiments with the Fe2+ form of the LBD, the heme-protein 
complex was treated with sodium dithionite (2.5 mM, final), and transferred 
anaerobically to the reaction cuvette. Aliquots of CO were added to the assay mixture 
from an anaerobic stock solution consisting of Buffer A (see section 5.3.1) that had been 
bubbled with a gas mixture of N2/CO (75%/25%, providing a stock CO concentration of 
0.25 mM). Gas mixes (25% CO) were purchased from Metro Welding Supply 
Corporation (Detroit, MI). The final concentration of CO in the CO-saturated buffer was 
confirmed by titration with myoglobin, whose concentration was determined based on its 
published extinction coefficient (121 mM-1 cm-1 at 435 nm) (15). 
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6.3.5 NO binding assay: Reduced and oxidized Rev-erbβ LBD-heme complexes were 
prepared anaerobically and were transferred anaerobically to a reaction cuvette. NO-
saturated buffer was prepared by bubbling Buffer A (see section 5.3.1) with 99.9 % pure 
NO from NO cylinders (Metheson, Garden city, MI). An NO gas assembly set up in Dr. 
Mark Meyerhoff’s lab was used. Aliquots of this buffer were added anaerobically to the 
reaction mixture and UV-visible spectra were recorded. When studying the ferrous heme 
complex, 2.5 mM dithionite was added to the reaction cuvette. All assays with NO, 
regardless of the redox-state of Rev-erbβ LBD or heme, were performed anaerobically to 
prevent any free radical generation via exposure to oxygen. 
 
6.3.6 H2S binding assay: NaHS (Sigma-Aldrich) was utilized as an H2S donor in order 
to investigate H2S binding to the heme-Rev-erbβ LBD complex. NaHS dissociates into 
Na+ and HS- in solution and then HS- re-associates with H+ to produce H2S. However, at 
pH 7, only 33.3% is present as H2S and 66.7% exists as HS- (8). This equilibrium was 
taken into account while calculating the final concentration of H2S in the binding 
experiments. 
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6.4 Results 
6.4.1 Tight CO binding to Rev-erbβ LBD 
 CO is an important signaling molecule and is shown to interact in vitro with the Fe2+ 
heme-Rev-erbβ complex, probably by replacing Cys as an axial ligand. In order to 
quantify the interaction between CO and the LBD, we performed CO titrations. Addition 
of CO to the Rev-erbβ LBD resulted in a blue-shift in the Soret band from 428 to 422 nm. 
The UV-visible spectra and difference spectra are shown in figure 6.1A & B respectively.  
The spectral features of CO bound Rev-erbβ LBD is indicative of a 6-coordinate heme. 
Moreover, MCD and Resonance Raman studies also support a 6-coordinate heme with 
neutral ligand or histidine trans to CO (19).  
 
Data obtained from the titration were subjected to quadratic analysis (section 5.3.4), 
which showed very high affinity (Figure 6.1.C) of the LBD for CO (Kd = 60 ± 15 nM). 
Therefore, re-examination of in vivo CO binding is required and its strategy is discussed 
in section 6.5. 
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Figure 6.1: High affinity of CO towards Fe2+ heme-reduced Rev-erbβ LBD complex.  
UV-visible spectra (A) and difference spectra (B) following titration of Rev-erbβ LBD 
with CO. C. Fitting the binding isotherm for the CO titration yielded a Kd value of 60 ± 
15 nM. The CO titration was performed anaerobically in Buffer B, in the presence of 2.5 
mM dithionite with 2 μM Fe2+-heme-LBD complex, as described in experimental 
procedures. 
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6.4.2 Redox-dependent NO binding to Rev-erbβ LBD 
 NO, as reported earlier, is capable of binding both the Fe2+ and Fe3+ forms of 
hemoproteins (13). Thus, NO binding was assessed with both the Fe2+- and Fe3+- heme-
Rev-erbβ LBD complexes (Figure 6.2 and 6.3). Titration of NO with the Fe2+-heme-
reduced Rev-erbβ LBD complex resulted in a Soret peak shift from 427 nm to a less 
intense Soret band at 422 nm accompanied by a decrease in the α and β band intensities 
(Figure 6.2.A). Similar changes in the spectrum of the NO-bound Rev-erbβ LBD were 
observed by Marvin and others (19). Characteristics of the difference spectra are given in 
figure 6.2.B. Proteins in which one neutral endogenous ligand is retained opposite to NO, 
in general, exhibit sharp Soret bands between 415 nm – 425 nm (19). Moreover, EPR and 
Resonance Raman spectra of the NO bound Fe2+ heme-reduced Rev-erbβ LBD complex 
also confirmed a 6-coordinate NO-heme adduct (19). This binding assay gave a binding 
constant of ~300 nM when the data was fitted to equation 1 (see experimental procedures 
in chapter 5).  
 
Titration of NO with the Fe3+ heme-reduced Rev-erbβ LBD complex did not show any 
changes in the spectrum, which reflected negligible binding. Titration of NO with Fe3+-
heme-oxidized Rev-erbβ LBD complex, however, did show changes in the spectrum, but 
exhibited no peak shift of the Soret band (Figure 6.3). Isosbestic points and peaks that 
shifted upon NO binding are labeled in figure 6.3A & 3B.  The dissociation constant 
obtained from this analysis is 7 μM ± 1.4 μM (Figure 6.3C). This value is not only higher 
than the Kd values reported for other NO binding proteins, but is also well above the 
physiological concentrations of NO in the cell (up to 5 nM) (12). The high dissociation 
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constants (Kd) indicates that NO binding to Rev-erbβ is not relevant in vivo, except, under 
acute conditions, for example during infections, as discussed below in section 6.5.  
 
Figure 6.2: NO binding with the Fe2+ heme- reduced Rev-erbβ LBD complex.  UV-
visible spectra (A) and difference spectra (B) following titration of Fe2+ heme- Rev-erbβ 
LBD complex with NO. C. Fitting the binding isotherm for the NO titration yielded a Kd 
value of 305 ± 30 nM. The NO titration was performed anaerobically in Buffer B, in the 
presence of 2.5 mM dithionite with 2 μM Fe2+-heme-LBD complex, as described in 
experimental procedures. 
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Figure 6.3: NO binding with the Fe3+heme-oxidized Rev-erbβ LBD complex.  UV-
visible spectra (A) and difference spectra (B) following titration of Fe3+ heme-Rev-erbβ 
LBD complex with NO. C. Fitting the binding isotherm for the NO titration yielded a Kd 
value of 7 ± 1 μM. The NO titration was performed anaerobically in Buffer B with 3.5 
μM Fe2+-heme-LBD complex, as described in experimental procedures.  
 
7.3 ± 1.4 μM 
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6.4.3 Redox-specific H2S binding to Rev-erbβ LBD 
H2S is a newly recognized gasotransmitter and its affinities for different redox-states of 
Rev-erbβ LBD and its bound heme were also analyzed. Titration of NaHS with the Fe3+ 
heme-reduced Rev-erbβ LBD complex resulted in a blue-shifted Soret band from 424 to 
420 nm with a reduction in peak intensity (Figure 6.4). UV-visible and difference UV-
visible spectra are shown in Figures 6.4A & B, respectively. H2S can ligate to heme 
either as H2S or in HS- form. Quadratic analysis (equation 1 in chapter 6) of NaHS 
titration curve yielded a binding constant of ~2 μM  for HS- (Figure 6.4C) and ~1 μM for 
H2S binding to the Fe3+ heme-reduced Rev-erbβ LBD complex. To distinguish between 
HS- and H2S binding to Rev-erbβ EPR analysis of NaHS saturated Fe3+ heme-reduced 
Rev-erbβ LBD complex was done. EPR spectra of H2S bound to the Fe3+ heme-reduced 
Rev-erbβ LBD complex (data not shown) was not different from the spectrum of the Fe3+ 
heme-reduced Rev-erbβ LBD complex itself (Figure 5.5 A). Therefore, H2S might be 
binding to the heme center of reduced Rev-erbβ LBD complex by replacing an internal 
Cys ligand in HS- form similar to thiolate of the cysteine. Moreover,  features of the EPR 
spectrum of NaHS saturated Fe3+ heme-reduced Rev-erbβ LBD complex are identical to 
what has been observed for HS--ligated myoglobin (2). Therefore, it is plausible to 
predict HS- ligation to the heme center of Rev-erbβ.  However, further confirmation via 
other methods is needed as discussed in section 6.5. 
 
Titration of NaHS with the Fe3+ heme-oxidized Rev-erbβ LBD complex gave a saturation 
curve after a long lag phase. This phase could be due to reduction of oxidized Rev-erbβ 
LBD by NaHS. In fact, the DTNB assay (refer section 5.3.3) confirmed that NaHS is able 
to reduce the oxidized Rev-erbβ LBD (data not shown). Therefore, H2S appears to only 
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bind to the Fe3+ heme center of the protein in the reduced state. No binding was observed 
when NaHS was titrated against the Fe2+ heme-reduced Rev-erbβ LBD complex. 
 
Figure 6.4: H2S binding to the Fe3+heme-reduced Rev-erbβ LBD complex. UV-
visible spectra (A) and difference spectra (B) following titration of Fe3+ heme-Rev-erbβ 
LBD complex with NaHS. C. Fitting of the binding isotherm for the H2S titration 
provided a Kd value of 2.37 ± 0.31 μM. The H2S titration was performed anaerobically 
with 2 μM Fe2+-heme-LBD complex, as described in experimental procedures. 
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6.5 Discussion 
Gaseous signal mediators such as NO, CO and H2S modulate cellular activity either via 
signaling or directly via binding to their targets (21, 23, 32, 33). The role of 
gasotransmitters has been established in modulation of the circadian rhythm. CO and NO 
both have been shown to play a role in cholinergic signaling to the suprachiasmatic 
nucleus (SCN) clock via binding to soluble guanylyl cyclase (sGC). In cholinergic 
signaling to circadian clock, NO provides tonic stimulation of a discrete sGC/cGMP pool, 
which is later required for CO-mediated clock resetting. Additionally, NO also shows a 
circadian pattern of expression (20). Moreover, H2S mediated rhythmic expression of 
proteins in the rat retinal ganglion was shown in a study done by Nevalennaya and others 
(22). 
 
In addition to sGC, many targets have been described for CO and NO, including proteins 
involved in the circadian rhythm. NPAS2, which directs transcription of the Per and Cry 
proteins after forming a heterodimer with Bmal1, has been found to be under  regulation 
of CO. Dioum and colleagues have revealed that CO binds to the heme center of NPAS2 
and inhibits the DNA binding capacity of NPAS2-Bmal1 heterodimer in vitro (7).  
Expression of Per1 has also been shown to be regulated by NO. Kunieda and colleagues 
have discovered that NO mediated S-nitrosylation of Bmal1 stabilizes the protein, which 
in turn stably induces Per1 expression via an E-box (16). 
 
Similarly, Rev-erbβ LBD was shown to interact with CO and NO in vitro. In combination 
with previous studies showing that CO can interact with Rev-erbβ LBD (19, 25), the high 
affinity (Kd = 60 nM) suggests a potential role for CO in regulating the functional 
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properties of Rev-erbβ. In comparison, NPAS2 (Kd = 1 μM) and a bacterial CO sensor 
(CooA) (Kd = 11 μM) bind CO with significantly lower affinity (7, 35). Thus, such tight 
binding of CO to Rev-erbβ might indicate CO as a preferred ligand for the heme center in 
Rev-erbβ in the cell. Therefore, the conclusion that Rev-erbβ cannot respond to CO in 
vivo (25) needs to be reexamined carefully with a wider range of physiological assays.  
 
Our studies indicate that NO has a poor affinity for the ferrous heme center. The 
dissociation constant (Kd) for NO is ~300 nM for the Fe2+ heme-reduced Rev-erbβ LBD 
complex and 7 μM for the Fe3+ heme-oxidized Rev-erbβ LBD complex. These Kd values 
are higher than the known physiological concentration of NO (100 pM - 5 nM) (12), thus 
casting doubt on a potential functional role for in vivo NO binding to Rev-erbβ under 
physiological conditions. However, NO has been shown to cause de-repression via Rev-
erbβ on Bmal1 promoter in a luciferase assay.  In this assay, cells were treated with NO 
producing compounds and therefore unphysiologically high NO levels might have been 
reached during this experiment (25). Thus, neither these nor our results confirm the 
physiological relevance of NO binding to Rev-erbβ.  
 
However, NO concentrations may reach the μM range in macrophages during infection 
(31).  Interestingly, the role of Rev-erbs has been implicated in inflammation (27). 
Therefore, binding of NO to the Rev-erbβ complex may become relevant in macrophages 
during infection and might play a role in regulating an antimicrobial inflammatory 
response of this key transcriptional regulator.  
 
Interaction of H2S with hemeoproteins has been recognized and studied for many years.  
H2S-responsive proteins include hemoglobin1 from Lucina pectinata (26), mitochondrial 
  153 
 
cytochrome c oxidase (3) and human neuroglobin (4). However, no circadian target of 
H2S has been found so far. Identification of H2S binding to Rev-erbβ is remarkable, 
because it might be the first known circadian target of H2S. H2S concentration in cells has 
been determined by different groups and results vary over a wide range from ~ 15 nM to 
300 μM (9, 23). Kabil and Banerjee have discussed these variations in concentration 
measurements and have pointed out that most of the physiological effects of H2S 
observed so far are in hundreds of μM range.  Therefore, H2S might exist in μM range in 
microenvironment of the cell (14). We have found that binding constant for H2S is about 
2 μM, which might be physiologically relevant. However, this needs to be confirmed in 
an in vivo set up as described below. 
 
Studies described above have been done with the ligand binding domain of Rev-erbβ, and 
they all need to be extended to the full length Rev-erbβ. In fact, we have recently been 
successful in purifying full-length hRev-erbβ, which is described in chapter 7. We plan to 
do spectroscopic evaluation of gas binding by EPR, MCD and resonance Raman with 
full-length hRev-erbβ, which will shed further light on the importance of gas binding to 
the heme center of the protein. Furthermore, the physiological relevance of these gaseous 
interactions with Rev-erbβ needs to be assessed in detail with the full-length protein. A 
luciferase reporter assay system has been developed for this and has been described in 
chapter 7. This will help identify the effect of gas binding on the function of   Rev-erbβ. 
Gas binding not only offers another possible layer of regulating Rev-erb activity, but 
might also expand our knowledge about the signaling role of gasotransmitters in the 
circadian clock (1) and merits testing.  
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Chapter 7 
 
ONGOING WORK AND FUTURE DIRECTIONS 
 
7.1 Collateral redox modulation of ligand and DNA binding by Rev-erbβ 
The nuclear hormone receptor Rev-erbβ was first discovered in 1994 in three parallel and 
independent studies. Dumas and others, while searching for nuclear receptors, isolated a 
Rev-erbβ clone from a cDNA library of human lymphocytes (4). Bonnelye and 
colleagues isolated a chicken Rev-erbβ, and reported its expression in the central and 
peripheral nervous system, spleen, mandibullar and maxillar processes and in blood 
islands during embryonic development (1). Another study, where Enmark and others 
searched for nuclear receptors in the adult rat brain, reported high expressions of Rev-
erbβ in the cerebellum, dentate gyrus of the hippocampus and pituitary gland (5). The 
role of Rev-erbβ was initially proposed in neuronal differentiation (1). However, due to 
the presence of Rev-erbβ in a wide variety of tissues, its role in different processes of 
cellular physiology was postulated. Over the almost two decades since its discovery, Rev-
erbβ has been identified to have several targets. These targets are mostly present in 
metabolically active tissues including those described above and in chapter 4.  
 
The mRNA transcript of Rev-erbβ is robustly induced in the presence of planar aromatic 
antioxidants, which indicates a role for this nuclear receptor in cellular redox processes 
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(4). These results are likely to be related to the recent demonstration that the ligand 
binding domain of Rev-erbβ is subject to redox modulation (8). Rev-erbβ binds heme 
tightly, (2). We have shown that Rev-erbβ has similar affinities for ferrous and ferric 
heme. On the other hand, changes in the redox state of specific cysteines in Rev-erbβ 
markedly affect the affinity for heme, which might ultimately influence the function of 
the protein (8). 
 
We have recently cloned and expressed full-length human Rev-erbβ (FL hRev-erbβ) in E. 
coli. Preliminary results indicate that the full-length protein shows redox-dependent heme 
binding and redox-dependent heme ligand switching, similar to what has been observed 
with Rev-erbβ LBD (8). In addition, our recent results indicate that changes in redox 
poise affect DNA binding ability of the full-length protein. As shown by the 
electrophoretic mobility gel-shift assay (EMSA), oxidation of FL hRev-erbβ by diamide 
results in decreased productive protein-DNA complex formation. Moreover, when heme 
was present along with diamide, it enhanced the loss of productive protein-DNA 
complex.  
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7.2 Experimental procedures 
7.2.1 Cloning, Expression, and Purification of full length hRev-erbβ 
A FL hRev-erbβ cDNA clone was purchased from the mammalian genome collection via 
ATCC (Manassas, Virginia); catalogue no.10435076. This construct contained the FL 
hRev-erbβ cDNA sequence in a pBluscriptR plasmid inserted between SalI-XhoI (5’) and 
BamHI (3’) sites. For overexpression in E. coli, the FL hRev-erbβ sequence was excised 
and cloned into a pGB1 vector, which contained an N-terminal 6XHis-GB1 tag and was a 
generous gift from William Clay Brown (University of Michigan, Ann Arbor). Ligase 
independent cloning (LIC) was performed using the following PCR primers that contain 
LIC regions, highlighted in gray (3): Forward primer 5׳tacttccaatccaatgct gaggtgaatg 
caggaggtgt 3׳; Reverse primer 3׳ct tggcct ttaaagttca ccct taa cattggaagtggataa 5׳. These 
LIC regions correspond to an SspI restriction site, which is also present in the pGB1 
vectors thus allowing for LIC of the FL hRev-erbβ into the pGB1 vector. After the 
ligation reaction, plasmid (pGB1::FL hRev-erbβ) was transformed into Top10 competent 
cells (Invitrogen) and plasmid DNA from the selected colonies were sent for sequencing 
to the DNA sequencing core (University of Michigan, Ann Arbor). 
 
Later, to overexpress the protein, pGB1::FL hRev-erbβ was transfected in BL21 cells 
(Invitrogen). To overexpress the 6XHis-GB1-hRev-erbβ fusion protein, E. coli cells were 
induced at OD600 ~ 0.8 with 1 mM IPTG and grown overnight at 25 ºC. The cell pellet 
was collected by centrifugation and frozen at -80 ºC. Purification of the protein was 
carried out at 4 ºC on a Ni-NTA column as directed by the manufacturer (Qiagen, 
Valencia, CA). The purified protein was dialyzed and stored in 20 mM Tris-HCl (pH 
8.0), 300 mM NaCl and 10 % glycerol. 
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7.2.2 Reduction and oxidation of FL hRev-erbβ:  Please refer to section 5.3.3. 
 
7.2.3 Heme binding analysis: Please refer to section 5.3.4.  
 
7.2.4 EPR spectroscopy: Please refer to section 5.3.5.  
 
7.2.5 Whole cell EPR spectroscopy: Please refer to section 5.3.6. 
 
7.2.6 Electrophoretic mobility gel-shift assay (EMSA) 
A 25 bp double-stranded Rev-DR2 promoter sequence (7) that was labeled with 6-
carboxy fluorescein (FAM) at the 3׳ end of the forward oligonucleotide was used for the 
EMSA. The forward (labeled with FAM at 3׳ end) and reverse oligonucleotides were 
purchased from TriLink biotechnologies (San Diego, CA) and their duplex DNA was 
prepared by heating the oligonucleotides at 94 ºC in a water bath and then by slow 
cooling to room temperature. Rev-erbβ and DNA complexes were prepared in binding 
buffer containing 20% glycerol, 5 mM MgCl2, 2.5 mM EDTA, 250 mM NaCl, 50 mM 
Tris-HCl, pH 7.5 and 0.25 mg/ml poly(dI-dC)-poly(dI-dC) (final concentrations are 
given). Heme and diamide (Sigma–Aldrich, St. Louis, MO), when required, were also 
added to the assay mixture. The reaction mixture was incubated for 20 min at room 
temperature. Nondenaturing acrylamide gels (8%) were used to analyze the retardation of 
the protein-DNA complex. Gels were prepared according to a standard Promega protocol 
(Promega, Madison, WI). The oligonucleotide duplex was visualized in the gel using a 
Typhoon 7000 fluorescence gel imager (GE healthcare). 
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7.2.7 Mammalian cell culture and in vivo assay 
7.2.7.1 Plasmids 
For reporter assays, five plasmids were used and are as follows: 1: The Bmal1 promoter 
upstream of the luciferase gene in the pGL3 plasmid (pGL3Basic:P(Bmal(s))-dLuc) was a 
generous gift from Dr. Vivek Kumar (University of Texas). 2: Constitutively expressed 
full-length Rev-erbβ, a negative regulator of the bmal1 promoter, in the pEZ-M12-
3XFlag::hrev-erbβ plasmid (purchased from gene copeia). 3: The same vector lacking 
rev-erbβ was used as a negative control as well as to make up the total tranfectant volume 
equal when lower amounts of the rev-erbβ plasmid were used. 4: A plasmid carrying the 
rorα gene (pCMV-SPORT6:rorα), a positive activator of the bmal1 promoter, was 
purchased from ATCC (MGC-5892). 5. The pCMV:lacZ plasmid and was used later to 
normalize the transfection efficiency via β-galactosidase assay. This plasmid was kindly 
provided by Dr. Daniel Bochar (University of Michigan). 
 
7.2.7.2 Reporter assays 
HEK293 cells were maintained in DMEM medium supplemented with 2 mM glutamine, 
10 % FBS and 1x penicillin/streptomycin (Invitrogen) at 37 ºC /5 % CO2 incubator. The 
cells were seeded as 3 x 105 cells/well/ml in 12-well plates and were grown up to 70 % 
confluency. Co-transfection of the above described 5 plasmids was performed using the 
TransIT-2020 transfection reagent (Mirus Bio LLC) as directed by the manufacturer. 
Amounts of plasmids transfected during the experiment are given below in section 7.3.4. 
At 24 hrs post transfection, cells were harvested and stored as per the protocol provided 
by Promega. The next day, the luciferase reporter assay and the β-galactosidase assay 
were performed using kits as directed by the manufacturer (Promega).  
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7.3 Results, discussion and future directions 
7.3.1 Expression and purification of FL hRev-erbβ 
The 6XHis-GB1-hRev-erbβ fusion protein was overexpressed in E. coli as described in 
section 7.2.1. Overexpression of FL hRev-erbβ resulted in amber colored E. coli cells, an 
indication that the protein is able to bind heme in vivo, similar to what was observed 
during Rev-erbβ LBD expression in E. coli (8). Purification of the 6XHis-GB1-hRev-
erbβ fusion protein was performed on a Ni-NTA column and a representative of SDS-
PAGE gel with fractions of eluted protein is shown in Figure 7.1. Elution fractions from 
E6 to E12 were collected and concentrated for further use. The protein eluted with some 
other unknown contaminants and I am in the process of further purifying the protein by 
ion-exchange chromatography.  The preliminary results shown in this section are 
obtained with the protein purified from the Ni-NTA column only. 
 
 
Figure 7.1: SDS-PAGE analysis of the 6XHis-GB1-hRev-erbβ fusion protein. A one 
–step purification of FL hRev-erbβ was performed on a Ni-NTA column and 10 μl of 
eluted fractions were run on a 10% SDS-PAGE. M=molecular weight marker, L= lysate, 
W= wash, E= eluent. 
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7.3.2 Redox-dependent heme binding in FL hRev-erbβ 
To determine the affinity of the oxidized and reduced FL hRev-erbβ proteins for heme, a 
quantitative heme binding analysis was conducted by UV-visible spectroscopy. 
Absorption spectra and difference absorption spectra of the FL hRev-erbβ-heme 
complexes in different redox states are shown in figure 7.2 and figure 7.3, respectively. 
Throughout, we refer to the disulfide and dithiol states of FL hRev-erbβ when we 
describe the “oxidized” and “reduced” protein; the redox state of the heme, i.e., Fe3+ or 
Fe2+, is stated explicitly. The oxidized and reduced proteins and complexes were prepared 
as described in section 5.3.3. When the oxidized GB1-FL hRev-erbβ fusion protein was 
incubated with Fe3+-heme, the UV visible spectrum showed a Soret band at 416 nm, α 
peak at 569 nm and β peak at 539 nm. The spectrum of the complex between Fe3+-heme 
and reduced Rev-erbβ (prepared anaerobically), showed a Soret band at 424 nm, α peak 
at 574 nm and β peak at 548 nm. The complex between Fe2+-heme and reduced Rev-erbβ 
was prepared in the presence of 2.5 mM dithionite in an anaerobic chamber. The 
spectrum of the Fe2+-heme- reduced Rev-erbβ complex exhibited a Soret band at 427 nm, 
α peak at 560 nm and β peak at 530 nm. The spectra of these three states of the protein 
are in concordance with those observed for the Rev-erbβ LBD-heme complexes (Table 
7.1), suggesting that the heme coordination environments in the LBD and full-length 
Rev-erbβ are identical (described later in this chapter). 
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Figure 7.2: Absorption spectra of FL hRev-erbβ-heme complexes. Absorption spectra 
of FL hRev-erbβ-heme complexes in different redox-states are shown. FL hRev-erbβ (5 
μM) and heme (4 μM) were used to record the spectra of the complexes. Dithionite (2.5 
mM) was also added in the reaction in order to record the spectrum of Fe2+-heme-FL 
hRev-erbβ complex.  Spectra of the Fe3+heme-reduced protein complex and the 
Fe2+heme-reduced protein complex were recorded anaerobically. 
 
 
Table 7.1: Comparison of redox-dependent heme binding properties of FL hRev-
erbβ and Rev-erbβ LBD. The spectral peaks provided here are taken from the UV-
visible spectra of respective complexes for the FL hRev-erbβ (Figure 7.2 and 7.3) and 
Rev-erbβ LBD (Section 5.4.1). Details of the dissociation constants are provided in text 
and also in figure 7.2. Ox = oxidized, Red= reduced, FL= full-length protein, LBD= 
ligand binding domain. Note: The Rev-erbβ LBD data provided here are taken from 
Gupta et al. 2008 (8). 
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To determine the affinity of FL hRev-erbβ for heme, 0.3 μM of the fusion protein was 
titrated with varying concentrations of Fe3+-heme and the UV-visible spectra were 
recorded. Because the dissociation constants obtained from hyperbolic fits were lower 
than the concentration of the protein used during titrations, the data obtained from the 
heme titration of FL hRev-erbβ (Figure 7.3) were fit to the quadratic equation 1 (see 
section 5.3.4). Titration of the reduced protein with Fe2+-heme (Figure 7.3 A and B) gave 
a Kd value of 226 nM, and 97 nM with Fe3+-heme. (Figure 7.3 C and D). The affinity of 
the oxidized FL hRev-erbβ for Fe3+-heme was markedly lower (Kd ~ 1 μM) (Figure 7.3 E 
and F). In spite of the fact that the preliminary dissociation constants obtained for the 
full-length protein are higher than the values determined for Rev-erbβ LBD (Table 7.1) 
(8), the general characteristics are the same, i.e., the affinity of the oxidized protein for 
Fe3+- heme is markedly lower than that of the reduced protein. Thus, binding of Fe3+-
heme by full-length Rev-erbβ is controlled by a redox switch, just as observed with the 
LBD. On the other hand, the higher dissociation constants of FL hRev-erbβ might be due 
to impurities present in the protein after the Ni-NTA column (Figure 7.1). Therefore, 
binding analysis need to be repeated after obtaining a more homogeneous protein. 
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Figure 7.3: Redox dependent heme binding in  FL hRev-erbβ. Difference absorption 
spectra and titration curves of reduced Rev-erbβ with Fe2+-heme (A and B, respectively), 
oxidized Rev-erbβ with Fe3+heme (C and D, respectively) and reduced Rev-erbβ with 
Fe3+heme (E and F, respectively). The titrations were performed with 0.3 μM protein in 
Buffer B (see experimental procedure in chapter 5). Titrations of reduced Rev-erbβ with 
Fe3+-heme or with Fe2+-heme were performed anaerobically to avoid thiol and heme-
oxidation during the experiment. 
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7.3.3 Redox-dependent heme ligand switching in FL hRev-erbβ 
The marked differences in the UV-visible absorption spectra (Figure 7.2) between the 
oxidized versus reduced forms of heme-bound FL hRev-erbβ indicated that oxidation of 
FL hRev-erbβ induces a ligand switch, as observed with the isolated LBD (8). The ligand 
switching in the full-length protein was confirmed by EPR in vitro (Figure 7.4) and in 
vivo (Figure 7.5) analyses. The analyses indicated some differences in the spectra 
between the full-length and Rev-erbβ LBD proteins (8). A rhombic EPR spectrum was 
observed for the reduced FL hRev-erbβ -Fe3+- heme complex (Figure 7.4, upper panel), 
with g-values of 2.49 2.27 and 1.88, which are indicative of Cys/His heme ligation. 
Oxidation of the protein resulted in mixed heme ligation including Cys/His (g-values 
2.49, 2.27 and 1.86) and His/His (or Met or Lys) (g-values 2.94, 2.27 and 1.54), akin to 
Rev-erbβ LBD (8). Interestingly, the intensity of the low-spin (g ~2) Fe3+- heme complex 
with the oxidized protein was much less than that observed with the reduced protein 
(Figure 7.4, upper panel). Moreover, the oxidized protein exhibited a new peak in the 
high spin region (g ~ 6) (Figure 7.4, red traces). Thus, we hypothesized that most of the 
heme in the oxidized protein was either loosely bound or free and was concentrated in the 
g ~ 6 regions in the spectrum. An estimate of the total spin number in g=6 peak of the 
oxidized protein-Fe3+-heme complex by comparing its peak height with the peak height 
of free heme of the same concentration (Figure 7.4), lower panel indicated that almost 80 
% heme was present in the high spin state.  This peak (g~6) was most probably due to 
loosely bound heme with His/OH- ligation (6) as was observed in the in vivo EPR 
spectrum of Rev-erbβ described below. Thus, oxidation of the full-length protein appears 
to lead to significant release of heme.  
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Figure 7.4: In vitro redox-dependent ligand switching in FL hRev-erbβ. EPR analysis 
of heme complexes with the full-length reduced and oxidized proteins. Complexes were 
prepared at a ratio of 250 μM: 300 μM of Fe3+-heme: protein. Free heme spectrum in 
lower panel was run under similar condition to heme-protein complex (see experimental 
procedures) and had the same concentration as used for heme-protein complex. 
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Figure 7.5: Ex vivo redox-dependent ligand switching in FL hRev-erbβ. EPR analysis 
of E. coli cells over-expressing Rev-erbβ and exposed to none or 30 mM diamide (DA) 
for 1, 4 and 12 hours 
 
 
Ex vivo whole-cell EPR analysis of E. coli overexpressing FL  hRev-erbβ depicted a 
rhombic spectrum with g-values of 2.49, 2.27 and 1.88 (Figure 7.5), which is similar to 
the EPR spectrum obtained for the purified protein-heme complex, as described above. 
Diamide treatment of growing E. coli cells resulted in a mixed ligation state of the bound 
Fe3+-heme (Figure 7.5). The mixed ligation state included a low-spin component with g-
values of 2.49, 2.27 and 1.88 (as observed for the reduced protein- Fe3+heme complex) 
and a high-spin component with g values of 5.9 and 2 indicating His and water as heme 
ligands (6). As observed with the purified protein, the low-spin component is assigned to 
a His/Cys ligated heme, while the high-spin component appears to derive from His/water 
ligation.  A third but minor species with g-values of 2.95, 2.27 and 1.54, indicative of 
His/neutral residue ligation was also observed (Figure 7.5). This ligation state was also 
observed in the EPR spectrum of the oxidized Rev-erbβ LBD-heme complex that 
represented almost 50 % of the ligation state of heme in the Rev-erbβ LBD (8). Thus, the 
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other domains of the full-length protein appear to affect heme binding to the LBD and 
might be causing the differential ligand switching between the FL hRev-erbβ (i.e. 
Cys/His to His/Water) and Rev-erbβ LBD (Cys/His to His/neutral residue), upon 
oxidation of proteins.  
 
7.3.4 Redox and heme dependent binding of FL hRev-erbβ to DNA 
To analyze the effect of oxidative stress on DNA binding activity of FL hRev-erbβ, a gel-
shift assay was performed (Figure 7.6). No shift in DNA mobility was observed in the 
absence of the protein (lane 1). When reduced with 5 mM TCEP, the protein formed a 
Rev-erbβ dimer-DNA complex that resulted in retarded DNA mobility in the gel (lane 3). 
However, results with the air-oxidized protein are difficult to interpret.  As shown in lane 
2, free DNA was not observed in the absence of the Rev-erbβ dimer-DNA complex. 
However, a faint band was observed on top of the lane, which indicated that some of the 
DNA, remained in the well and didn’t enter the gel. When TCEP was used either below 5 
mM (i.e., 3 mM, lane 4) or in the presence of 0.5 to 2.5 mM diamide (lanes 5 -7), similar 
results were observed. Very faint and smeared bands appeared at the expected place of 
Rev-erbβ dimer-DNA complex and no free DNA was observed (lanes 4-7). Similar to 
lane 2, a band was observed on top of each lane (lanes 4-7), which is indicative of DNA 
in the well that didn’t enter in the gel. When higher concentrations of diamide (5 and 10 
mM) were used in the presence of 5 mM TCEP (lanes 8 & 9), the Rev-erbβ dimer-DNA 
complex was not observed at all. Some of the free DNA appeared at the bottom of lanes 8 
& 9 this time, with the rest of the DNA remaining in the well as before. The oxidation of 
Rev-erbβ seems to abrogate the protein dimer-DNA complex formation; however, 
because of the absence of the free DNA, these results are ambiguous at present. 
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Figure 7.6: Decreased Rev-erbβ dimer-DNA complex formation upon oxidation of 
the protein. For binding reactions 22 μM of FL hRev-erbβ was incubated with 60 nM 
Rev-DR2 duplex (lanes 2-9) in the presence of absence of TCEP or diamide (DA). Lane 
1 is a control where no protein was used. 
 
 It might be possible that the oxidation causes aggregation of protein that is still bound to 
DNA, causing this complex to remain in the well. Moreover,  22 μM protein was  used to 
achieve an complete shift with 60 nM DNA for the  EMSA. This protein concentration is 
more then 300 times the DNA concentration and indicates that the protein is not fully 
active, nor it is very pure. It could be due to some non-specific DNA which may remain 
bound to the protein during purification of FL hRev-erbβ. This is common when DNA 
binding proteins are expressed in heterologous organisms. . Therefore, we are working to 
obtain more active and homogeneous full-length protein from E. coli and to understand 
the modulation of DNA binding properties of the protein upon oxidation. 
  
Rev-erbβ is constitutively bound to its promoter in cells.  Suppression of the target genes 
occurs when heme binds to the LBD of the protein. We have earlier shown that oxidation 
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of FL hRev-erbβ not only results in lower heme binding affinity (Figure 7.3), but also 
interferes with the proper DNA binding of the protein (Figure 7.6) similar to what has 
been proposed for  glucocorticoid receptor (10).  To assess whether these two 
phenomena, are linked or independent, EMSA in the presence of heme and diamide was 
performed (Figure 7.7). 
 
Binding reactions were performed in the presence of 0.3 mM diamide (lower 
concentration of diamide was used in order to be able to see some protein-DNA complex) 
and varying concentrations of heme (Figure 7.7; lanes 6-9). As a control experiment, 
varying concentrations of heme in the absence of diamide were also used (Figure 7.7; 
lanes 2-5). Sample without protein reveals mobility of free DNA (lane 1), while in the 
presence of TCEP, FL hRev-erbβ showed a band-shift due the formation of Rev-erbβ 
dimer-DNA complex (lane 2). This protein-DNA complex moved faster in the presence 
of 1X heme (equivalent heme and Rev-erbβ) (lane3), whereas it is lost in the presence of 
higher concentration of heme lane 4 & 5).  As expected, the presence of low 
concentrations of diamide did not have a significant effect on  protein binding to DNA 
(compare lane 6 to 2)  However, a synergistic effect of heme and diamide on the loss of 
DNA binding was observed, which was dependent on the concentration of heme (lane 7-
9).  It is unclear if the excess heme interfered with the protein-DNA complex formation 
via binding to the protein or to the DNA. Flurescence anisotropy experiments are being 
planned in order to quantitatively analyze the affinity of FL hRev-erbβ towards its 
promoter DNA in the presence of diamide and/or heme and, to validate the above 
findings. 
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Figure 7.7: Decreased Rev-erbβ dimer-DNA complex formations in the presence of 
excessive heme and diamide. For binding reactions 22 μM of FL hRev-erbβ was 
incubated with 60 nM Rev-DR2 duplex (lanes 2-9) in the presence or absence of TCEP, 
diamide (DA) or hemin as indicated in the figure. Lane 1 is a control where no protein 
was used.  
 
The results described in this section are controversial because heme is a ligand for Rev-
erbβ and should not cause its dissociation from the promoter. However, ligand dependent 
degradation of Rev-erbα has been proposed during adipogenesis, where overproduction 
of heme was associated with decreased protein levels of Rev-erbα with no change in 
mRNA levels. Further, proteosome-mediated degradation of Rev-erbα was observed and 
no role of heme in the degradation was identified (9). Intriguingly, combining our results 
with theirs, it is possible that the overproduction of heme in the cell may cause the 
protein to dissociate from the promoter, which may then be targeted for proteosomal 
degradation. Nonetheless, this hypothesis needs to be tested and its experimental design 
has been described later in this chapter. 
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In addition to in vitro studies, it is imperative to study the effect of redox-status on 
transcriptional activity of Rev-erbβ in the cell. To examine this, a luciferase based 
reporter assay has been set up in HEK293 cells. Constitutively expressed full-length 
3XFlag::hRev-erbβ gene under CMV promoter in one plasmid and Bmal1 promoter in 
front of luciferase gene in pGL3 plasmid were co-transfected in HEK293 cells. Co-
transfection of these two plasmids should result in repression of the Bmal1 promoter via 
Rev-erbβ and thus decreased expression of luciferase, as observed in Figure 7.8.  
 
 
Figure 7.8: hRev-erbβ mediated repression of Bmal1 promoter activity in HEK293 
cells. Transfection of RORα resulted in upregulation on Bmal1 promoter- mediated 
higher expression of luciferase gene. Overexpression of hRev-erbβ exerted repression on 
Bmal1 promoter in a dose dependent manner. The concentration of plasmid used for the 
transfection as given below the graph. A control plasmid carrying the lacZ gene was also 
co-transfected, which was used as efficiency of transfection control. 
 
To elucidate the redox-regulation of Rev-erbβ function, cells will be treated with diamide 
and hydrogen peroxide to generate oxidative stress and then the transcriptional activity of 
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Rev-erbβ will be observed via luciferase assay. Simultaneously, cells can be treated with 
succinyl acetone and δ-ALA which will down-regulate and upregulate the heme-
biosynthesis, respectively. The effect of altered cellular heme concentrations on DNA 
binding by Rev-erbβ will also be examined by the luciferase assay in HEK293 cells. 
Furthermore, the cells can be treated by both diamide and δ-ALA to observe their 
combined effect on the transcriptional activity of Rev-erbβ via the luciferase assay. In 
addition to the luciferase assay, ChIP can also be performed under the conditions 
described above, to further confirm the results obtained from the luciferase assay.  
 
After confirmation of redox-modulation of FL hRev-erbβ, the cellular redox-partner 
needs to be identified. To identify the redox-partner of Rev-erbβ in cells, thioredoxin will 
be overexpressed or cells will be treated with glutathione mono ethyl ester. If either of 
these redox-protein/molecules is a redox partner of Rev-erbβ in cells, then their 
overproduction should reverse the function of oxidized Rev-erbβ and can be analyzed by 
the luciferase and ChIP assays.  
 
Furthermore, crystallization of Rev-erbβ in presence of heme, DNA or both will shed 
additional light on its structure and function. Additionally, crystallization of oxidized and 
reduced Rev-erbβ with heme would enable us to identify the structural changes 
responsible for reduced heme binding upon oxidation of Rev-erbβ. Adding DNA during 
crystallization will also enhance our understanding of effects of oxidation on the DNA 
binding activity of Rev-erbβ. 
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